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1.1 Tumor Immunity 
 
The first trial of cancer immunotherapy can be dated back to the 19th century, when William 
Coley, a New York surgeon, used extracts of pyogenic bacteria to treat tumors (Coley, 1893). 
Coley was able to show that this nonspecific activation of the immune system could result in 
recovery or even in tumor regression and cure of some patients. Some decades later, it was 
demonstrated that tumors could be induced in mice after treatment with chemical carcinogens. 
These findings together with the discovery of MHC and the development of inbred mouse 
strains by Gorer and Snell (Gorer, 1956) made it possible to undertake the first 
immunological experiments with transplantable tumors. Transplanted tumors in mice exhibit 
a variable pattern of growth when injected into syngenic animals: Some are rejected when 
transplanted into syngenic hosts (regressive growth), but most tumors grow progressively and 
eventually kill the host. 
 
The first demonstration that inbred mice could be immunized against transplanted tumors was 
in 1943. Gross and colleagues showed that intradermal immunization of mice against sarcoma 
protects the animals from outgrowth of the same tumor (Gross, 1943). Some years later, it 
was demonstrated in more detailed experiments that normal tissue of the mouse of tumor 
origin did not immunize against the transplanted tumor, nor did the tumor cells immunize 
against normal skin grafts from this mouse (Prehn and Main, 1957; Foley, 1953; Baldwin, 
1955; Klein et al., 1960; Old et al., 1962). These first transplantation experiments revealed 
that this immunological protection against challenge with tumor cells was individually tumor 
specific. The unique specificity indicated that each tumor had a unique transplantation antigen 
and/or expressed a unique combination of shared antigens. This could not only be shown for 
transplanted tumors originally induced by chemical carcinogens, but also by physically 
carcinogens or by spontaneous tumors (Globerson and Feldman, 1964; Pasternak et al., 1964; 
Kripke, 1974) (Basombrio, 1970; Basombrio and Prehn, 1972). Since these protective effects 
cannot be shown in T cell deficient mice but can be compensated by adoptive transfer of T 
cells from immunized mice, it was suggested that tumors express antigenic peptides that can 
be recognized by tumor-specific T cells.  
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1.1.1 Tumor immunosurveillance 
 
The notion that the immune system could protect the host from neoplastic disease was 
initially proposed by (Ehrlich, 1909) and formally introduced as the cancer 
immunosurveillance hypothesis nearly 50 years later by Thomas and Burnet (Thomas, 1959; 
Burnet, 1970): They claimed that tumors arise with similar frequency to infection with 
pathogens and that the immune system constantly recognizes and eliminates these tumors 
based on their expression of tumor antigens. During the last decades, this hypothesis has 
evoked strong criticism, but today more and more studies in animal models as well as in 
certain human diseases support the view of Thomas and Burnet that the immune system 
monitors and modulates tumor growth (Dunn et al., 2002; Darnell and Posner, 2003). For 
instance, studies using gene-targeted mice that lack the recombinase activating gene (RAG)-1 
or (RAG)-2 (Shinkai et al., 1992) showed that these immunodeficient mice, which cannot 
rearrange lymphocyte antigen receptors and thus lack T, B and NKT cells, have enhanced 
susceptibility to chemically (e.g. methylencholanthrene [MCA]) induced and spontaneous 
tumors (Shankaran et al., 2001; Smyth et al., 2001a). Results of relevant studies on different 
mouse models were reviewed by Dunn et al. (Dunn et al., 2002; Dunn et al., 2004) and are 
summarized in Table 1.1. Taken together, these observations demonstrate that tumor 
development in mice is controlled by components of the immune system. The induction of 
tumor-specific immune responses results from complex interactions of antigen presenting 
cells (APCs), cytotoxic T cells (CTLs), T helper cells and antibody-producing B cells as well 
as effector cells of the innate immune system like natural killer cells (NK cells) and NKT 
cells which can recognize transformed cells and eradicate them. 
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Phenotype 
or depletion 
Immune deficiency Tumor susceptibility Reference 
RAG2-/- 
RAG1-/- 
Lacks T, B and NKT cells MCA-induced sarcomas 
Spontaneous intestinal neoplasia  
(Shankaran et al., 
2001; Smyth et 
al., 2001a) 
αβ T cell-/- Lacks αβ T cells MCA-induced sarcomas 
 
(Girardi et al., 
2001; Gao et al., 
2003) 
γδ T cell-/- Lacks γδ T cells MCA-induced sarcomas 
 
(Girardi et al., 
2003; Gao et al., 
2003; Girardi et 
al., 2001) 
Anti-NK1.1 
antibody 
 
Lacks NK and NKT cells MCA-induced sarcomas 
 
(Smyth et al., 
2000; Smyth et 
al., 2001a) 
Anti-asialo-GM1 
antibody 
 
Lacks NK cells,  
monocytes, macrophages 
MCA-induced sarcomas 
 
(Smyth et al., 
2001a) 
IFN-γ-/- Lacks IFN-γ MCA-induced sarcomas 
B6:spontaneous disseminated  
lymphomas 
BALB/c : spontaneous lung  
adenocarcinomas 
(Street et al., 
2001; Street et 
al., 2002) 
 
Table 1.1: Evidence supporting the tumor immunosurveillance hypothesis: Enhanced susceptibility of 
immunodeficient (genetically engineered or in vivo depleted) mice to formation of spontaneous and chemically 
induced tumors (adapted from Dunn 2002) 
 
 
1.1.2 Tumor antigens recognized by T cells 
 
Any protein in the tumors cell is a potential tumor antigen (also called tumor rejection 
antigens, tumor-associated antigens or in the mouse system tumor-specific transplantation 
antigens). Peptides derived from tumor antigens can become the targets of a tumor-specific T 
cell response, because they are not displayed on the surface of normal cells, at least not at 
levels sufficient to be recognized by T cells.  
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Most of the murine and human tumor antigens now known have been identified by screening 
tumor derived cDNA libraries using tumor-reactive T cell lines and clones from cancer 
patients, thus identifying the gene encoding the target epitope (De Plaen et al., 1988; Lurquin 
et al., 1989; van der Bruggen et al., 1991; Boon, 1993; Rosenberg, 1996, summarized in van 
der Bruggen et al., 2002). Several other antigenic peptides have been found by peptide elution 
followed by mass spectrometry analysis (Cox et al., 1994; Mandelboim et al., 1994; Huang et 
al., 1996). An alternate technique for the identification of tumor antigens, which is not 
dependent on T cell recognition, is the serological analysis of recombinant cDNA expression 
libraries (SEREX). In this approach, diluted sera of cancer patients are used to identify 
circulating Immunoglobulin (Ig)G that are specific for tumor antigens (Sahin et al., 1997; 
Chen et al., 1997; Jäger et al., 1998; Krackhardt et al., 2002). The first antigens identified 
with this method were two melanoma antigens (melanoma antigen 1 [MAGE-1] and 
tyrosinase) and the esophageal cancer-associated antigen NY-ESO-1. MAGE-1 and tyrosinase 
were originally identified by cloning the epitopes recognized by T cells, and NY-ESO was 
subsequently shown to be reactive with T cells. (summarized in Greten and Jaffee, 1999 and 
Rosenberg, 1999). 
In addition, potential target antigens have been defined by gene expression profiling searching 
for overexpressed gene products in neoplastic cells compared with normal tissues. 
Microarray-based studies of gene expression in a large number of tumor types have 
repeatedly revealed novel features of human cancer and have led to the identification of a very 
large number of potential tumor antigens (summarized in Mohr et al., 2002).  
 
Different categories of tumor antigens can be distinguished and examples of each of these are 
given in Table 1.2. The first category consists of antigens that are strictly tumor-specific. 
These antigens are the result of point mutations or gene-rearrangements, which often arise as 
part of the process of oncogenesis. The best example for this might the cyclin-dependent 
kinase 4 (CDK4)-R24C antigen, the result of a mutation in CDK4. The mutation occurs 
within the antigenic epitope recognized by CD8+ T cells. In addition, this mutation prevents 
binding of a CDK4 inhibitor, thereby disrupting cell-cycle regulation (Wolfel et al., 1995). 
Another example is the mutated tumor suppressors genes p53 (Theobald et al., 1995). 
Mutations of p53 are found in 60-70% of all human cancers (Greenblatt et al., 1994). 
 
The second category includes tumor specific antigens such as MAGE or NY-ESO. Tumor 
specific antigens are silent in all normal adult tissues except for male germ cells, which do not 
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express major histocompatibility complex (MHC) molecules and therefore cannot present 
peptides from these molecules to T cells. These genes are expressed in a significant 
proportion of tumors, including melanomas, lung tumors, head and neck tumors, and bladder 
carcinomas. 
 
Tissue-specific differentiation antigens belong to the third category of tumor antigens. These 
antigens are encoded by genes that are only expressed in particular types of tissues. For 
example, tyrosinase (Brichard et al., 1993; Robbins et al., 1994; Wolfel et al., 1994; Kittlesen 
et al., 1998), MART-1/Melan-A (Coulie et al., 1994; Kawakami et al., 1994a; Kawakami et 
al., 1994b) and gp100 (Cox et al., 1994; Bakker et al., 1994) are presented on normal 
melanocytes as well as on melanomas. 
 
The fourth category is comprised of antigens that are strongly overexpressed in tumor cells 
compared with their normal counterparts. A typical example for this is HER/2-neu, which is a 
receptor tyrosine kinase homologous to the epidermal growth factor receptor (Fisk et al., 
1995). This receptor is overexpressed in many adenocarcinomas, including breast and ovarian 
cancer.  
 
The fifth category of tumor antigens includes molecules that display abnormal tumor-specific 
posttranscriptional modifications. An example is the aberrant glycosylated mucin, MUC1, 
which is expressed by a number of tumors, including breast and pancreatic cancers (Girling et 
al., 1989; Finn et al., 1995). 
 
Antigens derived from oncogenic viruses represent the sixth category of potential tumor 
antigens. These viral antigens play a critical role in the oncogenic process and, because they 
are foreign, can induce T cell responses. Examples are the oncoproteins E6 and E7 of human 
papilloma virus 16 (HPV16), which is present in most cervical carcinomas (Wu, 1994).  
(summarized in Boon et al., 1997; Greten and Jaffee, 1999; Rosenberg, 1999; Janeway and 
Travers, 2001) 
 
While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, 
there is more and more evidence that CD4+ cells also play an important role in tumor 
immunity (Pardoll and Topalian, 1998; Toes et al., 1999; Wang, 2001). CD4+ cells can 
promote cellular and humoral immune responses and are essential for the priming and 
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persistance of CD8+ T cell responses. Tyrosinase was the first MHC class II restricted antigen 
that was detected in some melanoma patients (Topalian et al., 1994; Topalian et al., 1996). So 
far, only few CD4+ epitopes have been identified for several other tumor antigens such as 
MART-1/ Melan-A (Zarour et al., 2000a), MAGE-1 (Chaux et al., 2001), MAGE-3 (Manici 
et al., 1999; Chaux et al., 1999) or NY-ESO (Jager et al., 2000; Zeng et al., 2000; Zeng et al., 
2001; Zarour et al., 2000b; Zarour et al., 2002) due to the lack of effective methods for 
identifiying MHC class II restricted tumor antigens.  
 
 
Category of antigen Antigen 
Tumor-specific mutated oncogene or 
tumor suppressor  
CDK-4 
β-Catenin 
CASP-8 
p53 
K-ras 
Germ cell MAGE-1 
MAGE-3 
NY-ESO 
CEA 
Differentiation Tyrosinase 
MART-1/Melan-A
gp100 
Overexpressed antigens HER-2/neu 
Abnormal post-translational 
modification 
MUC1 
Oncoviral protein E6 and E7  
(HPV16) 
 
Tabel 1.2. Potential origins of tumor antigens 
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1.1.3 Effector mechanisms in cancer immunity 
 
1.1.3.1 Adapted effector mechanisms in cancer immunity 
 
Several preclinical and clinical studies have demonstrated that activation of both CD4+ and 
CD8+ T cells is critical for generating the most potent antitumor immune responses 
(Marchand et al., 1995; Rosenberg et al., 1998; Jager et al., 1999). CD8+ CTL cells are able to 
lyse tumor cells directly upon recognition of peptide-MHC-class I complexes expressed by 
the tumor. “Professional” APCs like dendritic cells (DCs) can initiate antigen-specific T and 
B cell responses by capturing the antigens that are secreted or shed by tumor cells or after cell 
lysis. As professional APCs, DCs are the most powerful stimulators of naïve T cells. 
Immature DCs take up and process antigens (Ridge et al., 1996; Schoenberger et al., 1998; 
Bennett et al., 1998). Encountering inflammatory mediators or interaction with CD4+ cells via 
CD40 ligand (CD40L)-CD40 interaction leads to DC maturation. Mature DCs down-regulate 
their antigen uptake and processing machinery, express CD83 and up-regulate MHC and 
costimulatory molecules such as CD80 and CD86 (B7.1 and B7.2) (Banchereau and 
Steinman, 1998; Fong and Engleman, 2000; Schuler et al., 2003). Processing and presentation 
of tumor antigens by major histocompatibility complex (MHC) class I and class II molecules 
on a single DC can enable priming and activation of both CD4+ and CD8+ T cells. The ability 
of APCs to present endocytosed tumor antigens not only to CD4+, but also to CD8+ T cells is 
called “cross priming” (Huang et al., 1994; Albert et al., 1998). CD4+ cells can be divided into 
T Helper (TH)1 and TH2 cells based on their cytokine secretion profile (Morel and Oriss, 
1998). CD4+ TH1 and TH2 cells promote cellular and humoral immune responses, 
respectively. CD4 TH1 cells are essential in the maintenance of CD8+ CTL effector functions. 
Costimulation occurs via CD4+ T cell derived cytokines (e.g. classical TH1 cytokines such as 
Interleukin (IL)-2 and Interferon (IFN)-γ or classical TH2 cytokines such as IL-4) and also 
through the APC itself via CD40-CD40L or B7-CD28 interactions. In addition, memory 
CD4+ T cells and CD8+ T cells play a critical role in maintaining the protective immunity 
(Swain et al., 1991; Mackay, 1993). (summarized in Greten and Jaffee, 1999 and in Smyth et 
al., 2001b and shown in Figure 1.1). 
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Figure 1.1: Adaptive immune response to tumor-derived antigens. The capture and presentation of tumor 
antigens (TAAS) by “professional” APCs like DCs is one of the earliest steps towards mounting an adaptive 
immune response against tumors. APCs are additionally activated by tumor cell derived signals like certain 
cytokines. In combination with costimulation (e.g. B7-CD28 interaction), activated APCs carry tumor antigens 
to the lymph node where the tumor antigen-derived peptides are presented via MHC class II molecules to CD4+ 
and MHC class I molecules to CD8+ lymphocytes. Activated CD4+ cells can subsequently express CD40L, 
which, in turn, further stimulates CD40-expressing APCs. B cells (not shown here) are also involved in anti-
tumor immune response. Tumor antigen-specific lymphocytes develop into activated effector cells – CD4+ 
helper T cells and CD8+ CTLs – which possess now the ability to migrate into the tissue to mount together with 
local APCs an effective response against the developing tumor (adapted from Smyth 2001). 
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1.1.3.2 Innate effector mechanisms in cancer immunity 
 
NK cells can spontaneously kill MHC class I deficient tumor cells (Hoglund et al., 1988; 
Whiteside and Herberman, 1995). They mediate cytotoxicity via perforin and produce a 
variety of cytokines like IFN-γ and are highly responsive to many cytokines, including IL-2, 
IL-12, IL-15 and IFNs. NK cells express a set of functionally diverse receptors on their 
surface: As an important actor in antibody-dependent cell mediated cytotoxicity (ADCC), NK 
cells recognize via their FcγRIII receptor IgG antibody coated cells (Ravetch and Perussia, 
1989; Lanier et al., 1989; Perussia et al., 1984). NK cells also display a subset of inhibitory 
receptors (e.g. KIR and Ly49) (Colonna and Samaridis, 1995; Mason et al., 1995; Stoneman 
et al., 1995), which are specific for MHC class I. NKG2D has been defined as an activating 
receptor for NK cells (Vivier et al., 2002; Jamieson et al., 2002). This receptor binds to the so 
called MHC class I chain related (MIC) glycoproteins, which are low or not expressed on 
normal adult tissue but are induced by cellular stress (Diefenbach et al., 2000; Cerwenka et 
al., 2000). NKG2D plays a key role in immune responses, including those against tumors 
(Diefenbach et al., 2001; Cerwenka et al., 2001) and has been demonstrated as a primary 
cytotoxicity receptor on mouse NK cells (Hayakawa et al., 2002). 
 
NKT cells, a subset of T cells that express NK cell markers such as NK1.1 (Godfrey et al., 
2000) have shown to exhibit the capacity to regulate both CTL and NK cell anti tumor 
activity (Smyth et al., 2000). NKT cells have a restricted TCR repertoire and recognize the 
nonclassical MHC class I protein CD1d in the context of glycolipids. Several studies have 
demonstrated the importance of NKT cells in immune regulation and in the prevention of 
autoimmune diseases in mice (Hong et al., 2001; Sharif et al., 2001; Miyamoto et al., 2001), 
which supports the idea that NKT cells can act as suppressor cells. Unlike other regulatory T 
cells, NKT have also been implicated as effectors in immune responses to some pathogens. 
NKT cells express a variety of cell-death-inducing effector molecules and have been 
demonstrated to kill tumor target cells in vitro. In addition, NKT cells rapidly secrete large 
amounts of both pro-inflammatory T helper 1 (TH1) cytokines such as IFN-γ, and anti-
inflammatory TH2 cytokines, such as IL-4 and IL-10, bridging the innate and adaptive 
immune system (summarized in Smyth et al., 2002). 
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1.2 Mechanisms of tumor escape 
 
Despite an active and apparently normal immune response by a healthy immune system, 
tumor cells can grow, invade and metastasize in the host (Pardoll, 2003). Tumor cells can 
escape or fail to elicit anti-tumor immune responses by various mechanisms. They are 
phenotypically and genetically less stable than normal cells and can rapidly change to escape 
immune destruction.  
 
1.2.1 Changes in expression of MHC class I molecules 
 
Some tumors lose or down-regulate the expression of MHC class I molecules, perhaps 
through immunoselection by T cells specific for a peptide presented by that MHC class I 
molecule. Tumor cells can use multiple mechanisms to partially or completely down-regulate 
the expression of MHC class I antigens. A variety of altered Human Leukocyte antigen 
(HLA) phenotypes have been defined in human tumors, including HLA total loss, HLA 
haplotype loss, HLA-specific locus down-regulation, HLA allelic losses, and a combination 
of these phenotypes . Decreased or absent MHC class I expression has shown to be associated 
with invasive and metastatic lesions (Garrido et al., 1997; Garrido and Algarra, 2001). Total 
loss of MHC class I expression is not uncommon in many tumors, including melanomas, 
colorectal and breast carcinoma and prostate adenocarcinoma (Algarra et al., 1997; Cabrera et 
al., 1996). In other cancers, such changes may be due to mutations in the gene coding for β2-
microglobulin (Wang et al., 1993; Hicklin et al., 1998).When a tumor loses expression of its 
MHC class I molecules, it can no longer be recognized by cytotoxic T cells, but it might 
become susceptible to NK cell lysis (Porgador et al., 1997). One explanation why MHC class 
I negative tumor cell variants continue to grow and are not destroyed by NK cells might be 
the concomitant loss or down-regulation of the expression of ligands (e.g. MIC) for NK cell 
activation receptors (Garrido and Algarra, 2001). These mechanisms for tumor escape from 
host immunity may occur especially in cancer cells that cannot lose their tumor specific 
antigen because its expression is required for the maintenance of the malignant phenotype of 
the tumor cell. 
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1.2.2 Antigenic loss or down-regulation  
 
Another tumor escape mechanism is the loss or down-regulation of the expression of a CTL-
recognized target antigen (Urban et al., 1982; Uyttenhove et al., 1983; Ward et al., 1990), 
which can occur independently of MHC class I down-regulation. In the mouse system it was 
already demonstrated in the 1960s that loss of immunogenicity of tumors can be the result of 
successive transplantations, and that tumors isolated from mice originally transplanted with 
immunogenic tumors frequently grow with increased malignancy (Pasternak et al., 1964; 
Graffi et al., 1964). Also in human cancers decreased expression of melanoma-melanocyte 
differentiation antigens such as gp100, MART-1 and tyrosinase have been described to be 
associated with disease progression (de Vries et al., 1997). The mechanisms that control the 
down-regulation of tumor antigens might be explained by a suggested epitope 
immunodominance: Antigen-loss variants within a tumor are protected from immune 
pressure, because the parental tumor cells carry the immunodominant epitope and are 
therefore the ones that are noticed and eliminated by the immune system of the host 
(Schreiber et al., 2002).  
 
1.2.3 Production of inhibitory cytokines by the tumor 
 
Another way by which tumors evade rejection is the secretion of immunosuppressive 
cytokines. Transforming growth factor (TGF)-β and IL-10, which have been shown to be 
produced by a number of tumors of different tissues origins, can suppress inflammatory T 
cells and cell-mediated immunity and can compromise development and activity of DCs, 
respectively (Chen et al., 1994; Chen et al., 2001; Tada et al., 1991; Inge et al., 1992; Elgert et 
al., 1998; Gorelik and Flavell, 2001). 
 
1.2.4 Suppression of anti-tumor immunity by immunoregulatory T cells 
 
The presence of regulatory CD4+CD25+T cells within the tumor has also been shown to play a 
role in dampening tumor-specific immune responses (Liyanage et al., 2002; Woo et al., 2002; 
Woo et al., 2001). Depletion of CD4+CD25+T cells, which have been shown to be crucially 
involved in the prevention of autoimmune diseases (Shevach, 2000; Sakaguchi et al., 2001), 
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can abrogate immunological unresponsiveness to syngenic tumors in vivo, resulting in 
spontaneous tumor-specific CTL and NK cell cytotoxicity (Shimizu et al., 1999; Onizuka et 
al., 1999). In addition to CD4+CD25+T cells, IL-13-secreting NKT cells can exert inhibitory 
effects on tumor immunity.  
 
1.2.5 Defective death receptor signaling 
 
Death receptor ligands such as Fas ligand and TRAIL play also a role in tumor 
immunosurveillance. Defective death receptor signaling at multiple sites represents a 
mechanism that may contribute to the survival and proliferation of tumor cells, on the one 
hand, by rendering tumor cells resistant to death receptor-mediated apoptosis (i.e. 
programmed cell death) (Davidson et al., 1998; Takeda et al., 2002; Takeda et al., 2001; 
Straus et al., 2001) and on the other hand, by inducing activation-induced cell death (AICD) 
of tumor-reactive T cells (Strand et al., 1996; Walker et al., 1998; Gastman et al., 1999). 
 
1.2.6 Tumor stroma and other local factors 
 
Another factor that may contribute to tumor development and progression may result from the 
localization of a tumor; thus, the inability of the circulating T cells to reach the tumor site 
leads to ignorance to the presence of the tumor (Ochsenbein et al., 1999; Ochsenbein et al., 
2001). For instance, the so called stromal barrier may prevent the immunological destruction 
of tumor cell. Tumor cells become embedded in a matirx non-malignant tissue consisting of 
vessels, sessile and migratory cells, and extracellular matrix, which together are termed 
“tumor stroma”. This stroma seems to play a complex role in tumor growth (Singh et al., 
1992; Ibe et al., 2001). Furthermore, most tumors seem to grow in a non-inflammatory 
microenvironment. This lack of costimulatory molecules (e.g. B7.1-CD80, B7.2-CD86 and 
CD40 ligand) by tumor cells may lead to suboptimal activation of NK cells and T cell anergy 
(Schwartz, 1990). 
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1.3 Cancer Vaccines  
 
Different vaccination approaches are being evaluated in clinical trials in efforts to induce host 
immune responses against a variety of solid tumors. 
 
1.3.1 Whole cell vaccines 
  
One vaccination approach is the application of whole cell vaccines. Cell-based vaccines 
consisting of irradiated melanoma cell lines administered with adjuvants such as Bacillus 
Calmette-Guerin (BCG) have been tested since the 1970s with small but significant success 
against melanoma (Hsueh et al., 1998; Mitchell, 2002; Sondak et al., 2002). Furthermore, 
genes encoding costimulatory molecules, like the B7 family or genes encoding cytokines 
(Golumbek et al., 1991; Gansbacher et al., 1990b; Gansbacher et al., 1990a; Asher et al., 
1991; Hock et al., 1991; Porgador et al., 1992; Blankenstein et al., 1991), which can be 
further enhanced by the combination of both, cytokine and B7 expression (Azuma et al., 
1993; Chen et al., 1992; Baskar et al., 1993; Townsend and Allison, 1993; Cayeux et al., 
1995) were transferred into tumor cell vaccines to enhance the immunogenicitiy of tumor 
cells. Compared to other cytokines, Granulocyte–Macrophage-Colony-Stimulating Factor 
(GM-CSF) appears most effective. GM-CSF has the ability to recruit granulocytes, 
macrophages and APCs such as DCs, which could enhance cross-presentation of tumor 
antigens. Moreover, GM-CSF has also been shown to upregulate CD1 on APCs, suggesting a 
possible interaction with NKT cells (Sato et al., 1999; Dranoff, 2002). Tumor-cell vaccination 
using tumor cells transfected with GM-CSF have led to promising results not only in 
experiments with rodents (Dranoff et al., 1993; Disis et al., 1996; Chiodoni et al., 1999), but 
also in clinical studies (Jaffee et al., 2001; Jaffee et al., 1998; Simons et al., 1999; Salgia et 
al., 2003). A number of other tumor cell vaccines expressing IL-2, IL-4 and B-7.1 are 
currently being tested in clinical trials (Maio et al., 2002; Antonia et al., 2002).  
 
 
1.3.2 Peptide based vaccines 
  
The identification of tumor antigens provided the basis for the establishment of peptide based 
vaccines. The best-studied clinical model of peptide vaccination is malignant melanoma. It 
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was shown that the use of native peptides for immunization is often insufficient to generate 
reactive T cells and clinical responses in most patients. Rosenberg and colleagues for instance 
evaluated vaccination with native gp100 peptide and found that it produced only low levels of 
T cell reactivity in immunized patients, whereas an epitope-enhanced gp100 peptide 
(modified amino acid sequence to enhance e.g. MHC molecule binding) generated strong T 
cell reactivity. However, only one single objective clinical response was reported. 
Combination of the epitope-enhanced gp100 with high-dose IL-2 treatment resulted in an 
anti-tumor response in nearly half of all patients (Rosenberg et al., 1998). Further clinical 
approaches (Smith et al., 2003; Lee et al., 2001; Schaed et al., 2002; Marchand et al., 2003) 
used adjuvants such as incomplete Freund`s adjuvant (IFA), cytokines and costimulatory 
molecules to enhance immunogenicity of the peptide vaccination. In a new trial, blockade of 
CTL-associated antigen (CTLA)-4 in combination with epitope-enhanced gp100 showed 
promising results in melanoma patients (Phan et al., 2003). Although vaccines based on tumor 
antigens are, in principle, the ideal approach to T cell-mediated cancer immunotherapy, the 
disadvantage of a peptide vaccine is that its immunogenecity is restricted. Including a range 
of tumor antigens in a tumor vaccine might be an effective approach. 
 
 
1.3.3 Heat-shock proteins 
 
The use of heat-shock proteins (HSPs) isolated from tumor cells represents a novel 
experimental approach to tumor vaccination. HSPs are found in most cells where they act as 
intracellular chaperones of antigenic peptides. There is evidence for receptors on professional 
APCs that take up certain HSPs together with any bound peptide. It is postulated that HSPs 
induce a specific CTL response by introducing antigens into the MHC class I pathway. 
Immunizations with tumor-derived HSPs such as the HSP96, generated tumor-specific 
immunity in mice (Tamura et al., 1997; Blachere et al., 1997). HSP96 has already been tested 
successful in clinical trials (Belli et al., 2002; Marchand et al., 1995). 
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1.3.4 Adoptive transfer of cytotoxic T cells 
 
Another approach of immunotherapy for cancer is the isolation of antigen-specific cells, their 
ex vivo expansion and generation, and subsequent autologous administration. The generation 
of T cell clones specific for tumor antigens such as MART1/Melan-A and gp100 and their 
effective transfer have been shown in several recent studies. The obvious disadvantage of this 
approach is again the required presence of defined tumor antigens (Sing et al., 1997; 
Rosenberg et al., 1994; Yee et al., 2002; Dudley et al., 2002; Overwijk et al., 2003) and 
furthermore that the ex vivo generation of such T cell populations is labor-intensive and time 
consuming.  
 
 
1.3.5 CpG Oligonucelotides 
 
Nonspecific immune adjuvant strategies such as incorporating bacterial unmethylated ssDNA 
sequences, so called cytosine-phosphorothioate-guanine (CpG) containing oligodeoxy-
nucleotides (ODN), in the vaccine formulation have been shown to be potent in inducing anti-
tumor immune response in several studies. CpGs are the ligands to toll-like receptor (TLR)-9. 
Signaling through TLRs can produce effects in DCs similar to CD40 ligation (Krieg, 2002; 
Krieg, 2003). CpGs are quite effective in the induction on an anti-tumor T cell response in a 
variety of mouse models (Sandler et al., 2003; Hartmann et al., 2000; Brunner et al., 2000; 
Weiner et al., 1997; Kawarada et al., 2001; Davila et al., 2003; Garbi et al., 2004), but so far, 
only one clinical trial of treating melanoma with CpGs has been reported (van Ojik et al., 
2002). 
 
 
1.3.6 Recombinant viral vectors and DNA Vaccines 
 
Another approach is using recombinant viruses such as vaccinia, adenovirus, fowlpox and 
avipox virus to express tumor antigens. Several trials reported the induction of weak cellular 
immune responses against the particular tumor antigen but also the induction of antiviral 
neutralizing antibodies (Marshall et al., 2000) (Zhu et al., 2000; Restifo et al., 1995; McCabe 
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et al., 1995; Irvine et al., 1995). The problem of the immunodominance of viral antigens over 
tumor antigens still remains to be solved. 
DNA-based vaccines, which were successfully used to induce antibody and cellular immune 
responses in mice (Tang et al., 1992; Ulmer et al., 1993; Condon et al., 1996), represent 
another approach, but have not yet shown much promise for antitumor vaccination in clinical 
trials (Timmerman et al., 2002; Conry et al., 2002). To enhance the efficacy of DNA-
vaccines, so-called prime-boost vaccination strategies were established (Ramshaw and 
Ramsay, 2000). It seems that priming with naked DNA, followed by boosting with the same 
antigen delivered through a viral vector, is particularly effective in amplifying immune 
responses. Especially against infectious diseases these heterologous prime-boost 
immunization approaches led to promising results (McConkey et al., 2003; Hanke et al., 
2002) and have therefore clear relevance for cancer (Duenas-Carrera, 2004).  
 
 
1.3.7 Dendritic-cell-based vaccines  
 
As professional APCs, dendritic cells (DCs) are the most powerful stimulators of naïve T 
cells. The use of antigen-pulsed autologous DCs to stimulate therapeutically useful cytotoxic 
T cell responses has been developed in experimental models. In these experiments, DCs were 
loaded in vitro with protein (Paglia et al., 1996), peptide (Zitvogel et al., 1996; Mayordomo et 
al., 1996) or tumor cell extracts (Ashley et al., 1997), were fused with whole tumor cells 
(Gong et al., 1997), or were transduced ex vivo with viral vectors or transfected with tumor 
cell mRNA (Specht et al., 1997; Song et al., 1997). In the first clinical trial patients with B 
cell lymphoma were treated with protein-pulsed DCs (Hsu et al., 1996). Further human 
studies with promising results were carried out with melanoma (Nestle et al., 2001; Nestle et 
al., 1998; Mackensen et al., 2000; Banchereau et al., 2001; Schuler-Thurner et al., 2002) 
gastrointestinal malignancies (Sadanaga et al., 2001; Stift et al., 2003), renal (Su et al., 2003) 
and prostate cancer (Fong et al., 2001).  
 
 
In summary, there are three steps that are required for an effective immunotherapy for cancer: 
There must be sufficient numbers of tumor-reactive lymphocytes in the host, these 
lymphocytes must home and survive at the site of cancer, and once there, they must be able to 
destroy the tumor cells (Rosenberg, 2004). 
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1.4 Mouse models for cancer 
 
 
Experiments in mice are in most cases performed by injecting fast growing tumors that have 
already been analyzed in transplantation experiments several times. This allows performing 
experiments under well standardized conditions concerning the minimal lethal dose, the 
latency and the growth in syngenic recipients. However, these transplantation experiments do 
not recapitulate the human disease in any way. Typically, transplanted tumors are inoculated 
subcutaneously or intravenously and therefore do not grow in the anatomically appropriate 
site. As a consequence, the mouse model does not mimic the organ-specific physiology 
characteristics of the tumor and the immune system of the mouse is not exposed to the tumor 
in a manner comparable to that of naturally occurring tumors in patients. Spontaneous human 
tumors usually develop through a gradual series of cellular changes from pre-malignant to 
malignant pathologies, whereas transplantable tumors generally progress very rapidly upon 
inoculation and the immune system of the mouse is therefore abruptly confronted with the 
tumor. Furthermore, vaccination against “artificial” tumor antigens only expressed by the 
transplanted tumor may be totally foreign for the mouse. In this case, the induction of a 
protective immunity against the transplanted tumor does not have to overcome tolerance. 
Most human cancer antigens are normal, non-mutated differentiation molecules or non-
mutated proteins found only in tumor or germ cells and because of that, the human immune 
system seems to be more tolerant of these tumor antigens than the mouse system is of 
allogens. Human cancer can be imitated in the mouse by overexpressing a tumor antigen in 
transplanted tumors that is also expressed at low levels by a few normal tissues. In this 
situation the vaccine has to break tolerance, but again the short duration of the experiment is 
not mimicking the natural situation in a cancer patient and vaccination consequences like 
induction of autoimmunity can not be evaluated. Another disadvantage of transplantable 
murine tumors is that they are normally not spontaneously metastatic, so that vaccine 
strategies developed using these mouse models are not particularly relevant for human 
cancers, whereupon disseminating metastatic disease is frequently the predominant cause of 
death in most patients (summarized in Lollini and Forni, 2002; Ostrand-Rosenberg, 2004; 
Rosenberg, 2004). 
 
Mice transgenic for the tumor antigen provide more accurate indication of vaccine efficacy 
and the risk of autoimmunity. There are several transgenic mouse models for spontaneous 
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adenocarcinoma (Gendler and Mukherjee, 2001), however most of these mice develop breast 
and prostate carcinoma and only a few gastrointestinal cancer. Most of these mouse models 
express well characterized human tumor antigens, such as the human epidermal growth factor 
receptor HER-2/neu (HER2 or c-erb-B2), mucin (MUC)-1, the carcinoembryonic antigen 
(CEA) or the adenomatous polyposis coli (Apc) gene, that are known to be overexpressed in a 
variety of human cancers as ovarian and breast cancers, pancreatic adenocarcinomas and 
colorectal cancers. 
 
The RIP-Tag mouse model, which expresses the large T-antigen (Hanahan, 1985) of simian 
virus 40 (SV-40) under the control of the rat insulin promotor in the beta-cells of the 
endocrine pancreas, represents a model of spontaneous multistep tumorgenesis for pancreatic 
islet carcinoma. Several studies using RIP-Tag mice demonstrated that the induction of Tag-
specific lymphocytes and costimulation are not sufficient for tumor rejection (Adams et al., 
1987; Ganss and Hanahan, 1998; Onrust et al., 1996). However, irradiation as an 
inflammatory stimulus rendered solid tumors accessible for infiltration by adoptively 
transferred effector cells and resulted in tumor eradication (Ganss et al., 2002). 
 
Based on the work of Leder and Muller (Muller et al., 1988), there are several models of 
transgenic mice that overexpress the rat (r) epithelial growth factor receptor Her-2/neu or its 
transformed mutated form under the control of the mouse mammary tumor virus (MMTV) 
promoter at a distinct period of their life and therefore develop mammary carcinoma at 
different ages. Vaccination-induced antibodies appear to block carcinogenesis by inhibiting 
receptor function and down-regulating its membrane expression in preneoplastic cells, but in 
most of the studied mouse lines, vaccination fails to elicit a strong, effective CTL response, 
probably due to the difficulty of fully breaking tolerance (Reilly et al., 2001; Foy et al., 2001; 
Nanni et al., 2001; Rovero et al., 2000; De Giovanni et al., 2004). 
 
Vaccination studies on transgenic mice expressing human MUC1 under its own promotor 
revealed that tolerance to vaccination against MUC1 could only be broken by increasing the 
immunogenicity of vaccine preparation (Rowse et al., 1998; Acres et al., 2000; Koido et al., 
2000; Soares et al., 2001; Carr-Brendel et al., 2000). The so called double transgenic MET 
mouse that is transgenic for MUC1 and in addition expresses SV-40 Tag under the control of 
the rat elastase promoter spontaneously develops MUC1-expressing acinar carcinoma of the 
pancreas. Concurrent with tumor development these mice spontaneously develop MUC1-
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specific CTLs that do not stop the growth of the pancreatic tumors (Mukherjee et al., 2000). 
In a MUC1 transgenic mouse model for spontaneous mammary carcinoma MTT mice express 
the polyoma virus middle T (PyMT) oncogene under the control of the MMTV promotor and 
MUC1 in a tissue-specific fashion. In contrast to MET mice, no MUC1-specific CTLs can be 
detected in naive MTT mice, but vaccination of these mice with DC/tumor fusion cells 
doubles the latency period of mammary carcinoma (Xia et al., 2003). 
 
Studies using CEA transgenic mice (Eades-Perner et al., 1994) have shown that vaccines can 
break tolerance to CEA and protect mice against subsequent tumor challenge by tumor cells 
expressing CEA without inducing any autoimmune reactions against CEA expressing tissues 
(Kass et al., 1999; Xiang et al., 2001; Zhou et al., 2004). Crossbreeding these mice to APCmin 
(mouse homologue of the human APC gene) mice (Moser et al., 1990; Su et al., 1992) results 
in the development of numerous intestinal neoplasms in adult mice with strong CEA 
expression in all tumor cells, as well as CEA expression in normal gastrointestinal tissue 
(Thompson et al., 1997; Wilkinson et al., 2001). 
Only a very intense immunotherapeutic protocol induced anti-CEA host immune response 
that significantly suppresses intestinal tumor load and improved long-term survival of 
CEA.Tg/MIN mice (Greiner et al., 2002). In a recently published study, vaccination with DCs 
fused to tumor cells resulted in a reduced tumor growth in APC gene mutant mouse models 
(Iinuma et al., 2004). 
 
 
 
1.5 Pancreatic Cancer 
 
Pancreatic cancer is one of the most lethal human cancers and continues to be a major 
unsolved health problem at the start of the 21st century. Pancreatic cancer represents the fourth 
leading cause of cancer death in both men and woman; this number has been quite steady over 
the past 3-5 years (Jemal et al., 2003). Over 90% of pancratic cancers are adenocarcinomas 
arising from pancreatic ductal cells (Cubilla and Fitzgerald, 1976; Hruban et al., 2001; 
Meszoely et al., 2001); anatomy of the pancreas shown in Figure 1.2 (Bardeesy and DePinho, 
2002). The overall 5-year survival rate is only 3-5%, and with a median survival of less than 6 
months, a diagnosis of pancreatic adenocarcinoma carries one of the most dismal prognoses in 
all of medicine. Due to the lack of specific symptoms and limitations of diagnostic methods, 
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the disease often eludes detection during its formative stages. Whipple and colleagues 
reported the first “pancreaticoduodenectomy” in 1935 and surgery has since offered the only 
possibility of cure, although surgical intervention alone rarely achieves a curative end point 
(Warshaw and Fernandez-del Castillo, 1992; Baumel et al., 1994). For the 15-20% of patients 
who undergo potential curative resection, the 5-year survival is only 20% (Ahrendt and Pitt, 
2002; Yeo et al., 1995). Some improvements in surgical outcome occur in patients who 
receive adjuvant treatment like chemotherapy and/or radiotherapy, although the impact on 
long term survival has been minimal (summarized in Bardeesy and DePinho, 2002; Li et al., 
2004). 
Like many other malignant diseases, pancreatic ductal carcinoma results from the 
accumulation of acquired mutations. In pancreatic ductal cancers oncogene (e.g. K-ras) 
activation, tumor suppressor gene (e.g. Trp53, p16) inactivation, and growth factor (e.g. TGF-
α) and receptor (e.g EGFR, HER-2/neu) overexpression have been reported (Digiuseppe et 
al., 1994b; Digiuseppe et al., 1994a; Day et al., 1996; Sohn and Yeo, 2000; Sakorafas et al., 
2000). A progression model has been developed that describes pancreatic ductal 
carcinogenesis: the pancreatic ductal epithelium progresses from normal to increasing grades 
of pancreatic intraepithelial neoplasia, to invasive cancer. By definition, the different stages of 
tumor development are termed pancreatic intraepithelial neoplasia (PanINs) and diagnostic 
criteria for each grade were established, summarizing histological and genetic changes (Fig. 
1.3, (Hruban et al., 2000; Hruban et al., 2001)). The prevalence of these genetic alterations 
increases as the degree of cytological and architectural atypia in the duct lesions increases 
(Wilentz et al., 1998; Wilentz et al., 2000; Moskaluk et al., 1997; Goggins et al., 2000). 
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Figure 1.2: Anatomy of the pancreas. Two major physiological processes are regulated by two separate 
functional units of the pancreas: digestion and glucose metabolism (Githens 1993). The exocrine pancreas 
consists of acinar and duct cells (b and c). The acinar cells that are organized in grape-like clusters, which are the 
smallest termini of the branching duct system, produce digestive enzymes and constitute the bulk of pancreatic 
tissue. The ducts, which add mucous and bicarbonate to the enzyme mixture, form a network  and empty into the 
duodenum (a). The endocrine pancreas that consists of four different cell types (shown in different colors) 
organized into the Langerhans Islet and embedded within acinar tissue (d), sectretes hormones (insulin and 
glucagon) into the bloodstream (adapted from Bardeesy 2002). 
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Fig 1.3. Progression model for pancreatic cancer. The pancreatic ductal epithelium progresses from normal to 
increasing grades of pancreatic epithelial neoplasia, to invasive cancer through a series of histological defined 
precursos (PanINs = pancreatic intraepithelial neoplasia) (adapted from Hruban 2000). 
 
 
 
1.5.1 Immunotherapy for pancreatic cancer 
 
Despite efforts in the past 50 years, conventional treatment approaches, such as surgery, 
radiation, chemotherapy, or combinations of these, have had little impact on the course of 
adenocarcinoma of the exocrine pancreas and five-year survival rates remain below 5 % (Li et 
al., 2004). One promising alternative therapy is immunotherapy (Greten and Jaffee, 1999) that 
can be integrated with surgery, radiation therapy and chemotherapy. Recently, an allogeneic 
granulocyte macrophage colony-stimulating factor-secreting tumor vaccine was tested in 
patients who underwent a Whipple procedure. The vaccine was demonstrated to be safe and to 
induce tumor-specific immunity (Jaffee et al., 2001). Immunization with heat shock proteins 
(HSP) isolated from pancreatic tumor cells is another important approach that is undergoing 
clinical testing (Janetzki et al., 2000). Antibody approaches targeting pancreatic cancer-
associated tumor antigens such as CEA, MUC-1, and mutated KRAS have also undergone 
clinical testing. These antibodies have been employed in two ways for treatment: The first is 
treatment with antibodies conjugated to immunotoxins or radionucleotids that are upon 
binding of the antibody directly delivered to the cancer cell. Second, treatment with 
antibodies alone can result in the antibody acting as growth factor inhibitor, thereby 
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decreasing cellular signaling after receptor engagement. Antibodies alone as treatment can 
also induce antibody dependent cell cytotoxicity via activation of the complement pathway. 
(Nishihara et al., 2000; Bruns et al., 2000; Nielsen et al., 2000; Staib et al., 2001; Fan and 
Mendelsohn, 1998). Active immunization with peptide- and protein-based vaccines for 
MUC1, KRAS as well as immunization with recombinant virus encoding the antigens such as 
CEA and with loaded or transfected dendritc cells are also clinical trials that are in progress 
(Gjertsen et al., 2001; Gjertsen et al., 1995; Goydos et al., 1996; Marshall et al., 2000; Pecher 
et al., 2002). (summarized in Laheru et al., 2001, Kawakami et al., 2004). In a recently 
published study, a pancreatic tumor-associated antigen mesothelin was identified as a relevant 
target for vaccine-induced T cell responses. In this approach, the correlation of in vitro T cell 
responses with immunological responses in vaccinated pancreatic cancer patients was 
validated and it was suggested that cross-presentation of mesothelin may have clinical 
relevance (Thomas et al., 2004). However until today immunotherapeutic approaches have 
not been tested in a murine model of pancreatic adenocarcinoma due to the lack of an 
appropriate model. 
 
 
1.5.2 Transforming growth factor -α 
 
Transforming growth factor alpha (TGF-α) is a member of the epidermal growth factor (EGF) 
family of proteins. It shares structural and functional characteristics with EGF and is a ligand 
of the EGF receptor (EGFR), a protein tyrosine kinase that is involved in the mitogenic signal 
transduction pathway of cells. TGF-α is synthesized as a 160 amino acid glycosilated and 
palmitoylated transmembrane precursor, termed proTGF-α (Lee et al., 1985; Blasband et al., 
1990). The mature 50 amino acid TGF-α is released from the extracellular domain by 
proteolytic cleavage. Larger soluble forms of TGF-α representing incomplete processed 
intermediates have also been identified. This heterogeneity appears to be due to both the type 
of degree of ectoglycosylation and the preference for different sites of proteolytic cleavage of 
the precursor. Mutant forms of the integral membrane pro-TGF-α, which cannot be processed 
to mature peptide, can still initiate signal transduction through EGFR on the surface of 
contiguous cells in vitro (Wong et al., 1989; Bringman et al., 1987). Elevated expression of 
TGF-α has been found in neoplastic tissues or cell lines derived from spontaneous human 
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tumors or induced animal tumors, suggesting that TGF-α contributes to neoplastic growth 
through autocrine and paracrine mechanisms (Maruvada and Levine, 1999; Derynck, 1988).  
 
In fact, increased expression of the precursor for TGF-α in transgenic mice causes hyperplasia 
of several tissues and even neoplastic transformation (Jhappan et al., 1990; Matsui et al., 
1990; Sandgren et al., 1990). 
 
 
1.5.3  The tumor suppressor gene Trp53 
 
The wild type p53 gene is a tumor suppressor gene which encodes a protein that regulates a 
cell cycle checkpoint and the induction of programmed cell death (apoptosis). In normal cells, 
the p53 protein levels are low. DNA damage, cell stress or the aberrant expression of some 
oncogenes trigger the increase of the p53 protein (Yonish-Rouach et al., 1991). As a potent 
transcription factor p53 serves as the “guardian of the genome” (Lane, 1992). Expression of 
high levels of wild-type p53 has three major outcomes: growth arrest, DNA repair and 
apoptosis. Growth arrest stops the progression of the cell cycle, preventing replication of 
damaged DNA. During this growth arrest, p53 may activate the transcription of proteins 
involved in DNA repair. Apoptosis is the “last resort” to avoid proliferation of cells 
containing abnormal DNA (Marx, 1994; Ko and Prives, 1996). The cellular concentrations of 
p53 must be tightly regulated. In cells, p53 can associate with MDM2, which is the major 
regulator of p53. Binding to MDM2 keeps p53 levels low and holds apoptosis in check 
(Alarcon-Vargas and Ronai, 2002). Mutations of the p53 gene disable this “emergency brake” 
on cell proliferation and lead to genetic instability. Missense mutations in the p53 gene 
(generally alterations of the DNA-binding domain), which inactivate its growth suppressing 
activities, have been observed in more than 50% of pancreatic adenocarcinomas (Rozenblum 
et al., 1997) and in over 60% of all human tumors (Hollstein et al., 1991; Chang et al., 1995). 
 
Mice that are homozygous null for the Trp53 gene, although developmentally competent, are 
highly predisposed to cancer and develop tumors in multiple tissues (Jacks et al., 1994; 
Donehower et al., 1992). The loss of p53 does not alter lymphopoiesis or significantly impairs 
immune responses (Donehower et al., 1992; Wen et al., 2001; Grayson et al., 2001; Bachelier 
et al., 2003). 
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1.5.4 Mouse models for exocrine pancreatic cancer 
 
Spontaneously or following carcinogen administration, pancreatic cancer is rarely observed in 
mice. Genetic engineering has allowed the generation of mouse strains that harbour germline 
oncogenic lesions that are found in human adenocarcinomas. Most of these mouse models of 
exocrine pancreatic tumor development do not reproduce the ductal phenotype of human 
pancreatic adenocarcinoma but display predominantly acinar characteristics, mixed acinar-
ductal tumors, or cystic tumors (Quaife et al., 1987; Ornitz et al., 1987; Sandgren et al., 1991; 
Glasner et al., 1992; Mukherjee et al., 2000; Tevethia et al., 1997; Bardeesy et al., 2002; 
Grippo et al., 2003). In a new a transgenic mouse model activated mutant Kras and tumor 
suppressor gene Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal 
adenocarcinoma with striking resemblance to the human disease (Aguirre et al., 2003). 
 
 
1.5.4.1 TGF-α p53-/- mice 
 
Transgenic mice overexpressing transforming growth factor alpha (TGF-α) under the control 
of the rat elastase promotor (EL-TGF-a-hGH, Fig. 1.4) show a transdifferentiation of acinar 
cells to duct-like cells, which represent premalignant lesions (Sandgren et al., 1990; Wagner 
et al., 1998), accompanied by an induction of the EGFR expression in the resulting 
metaplastic ducts that proliferate due to an autocrine loop. About 30% of TGF-α transgenic 
mice develop malignant pancreatic tumors with a mean tumor-free survival of 410 days, 
similar to the human disease regarding cellular differentiation, growth characteristics, and 
genetic alterations. Crossbreeding TGF-α transgenic mice to p53 deficient mice results in 
increased incidence of pancreatic tumors (Fig. 1.5, (Wagner et al., 2001)). Heterozygous loss 
of p53 resulted in an increased incidence of pancreatic tumors (77%) and a decreased tumor-
free survival to 220 days in TGF-α p53+/- animals. 100% of TGF-α p53-/- mice developed 
pancreatic tumors within 120 days after birth. Some pancreatic tumors form ductal structures 
in dense connective tissues, others show frequent mitotic figures surrounded by sparse 
fibrosis. Malignant ascites, local invasive growth with duodenal obstruction, and metastasis to 
the liver and lung is also observed in TGF-α transgenic mice crossbred to p53-null mice 
(Wagner et al., 2001). The tumor spectrum of p53 deficient mice is dominated by lymphomas 
and sarcomas (Jacks et al., 1994). This spectrum shifted to ductal pancreatic cancer in 
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crossbred animals. Only 3 of 90 mice developed pancreatic tumors and sarcomas. The 
pancreatic tumors bear similar genetic changes, as were observed in human pancreatic cancer, 
including loss of the wild-type allele of p53 and inactivation of the putative tumor suppressor 
p16ink4A (Serrano et al., 1996) in TGF-a Trp53+/- mice (Wagner et al., 2001). Thus, TGF-α 
p53 deficient mice represent a murine pancreatic cancer model that recapitulates several 
pathomorphological features and genetic alterations of the human disease. 
 
 
 
Figure 1.4. EL-TGF-α-hGH fusion gene contruct for the generation TGF-α transgenic mice. Solid 
rectangle represents TGF-α cDNA sequences, stippling represents hGH exon sequences, and open rectangles 
represent introns (adapted from Sandgren 1990). 
 
 
 
Figure 1.5: Cumulative incidence of tumors in TGF-α, p53+/-, TGF-α p53+/-, p53-/- and TGF-α p53-/- mice 
(adapted from Wagner 2001)  
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1.6 Aims of the study 
 
TGF-α Trp53-/- mice have been decribed as the first murine model for the development of 
ductal adenocarcinoma of the pancreas with pathomorphological features and genetic 
alterations similar to the human disease (Wagner et al., 2001). To perform immunological 
studies on pancreatic adenocarcinoma in a murine mouse model, TGF-α Trp53-/- mice were 
bred on C57Bl/6 background. In order to see if these mice are a suitable model for the 
development of immunotherapy approaches, extensive morphological and immunological 
analysis of TGF-α Trp53-/- mice should be performed. The aims of this study were: 
 
• Monitoring of the development of spontaneous pancreatic tumors in TGF-α Trp53-/- mice 
on C57Bl/6 background. Morphological and immunohistological examination of the 
pancreatic tumors to define the degree of tumor development and to analyze tumors for 
infiltrating lymphocytes.  
 
• Generation and characterization of cell lines derived from pancreatic adenocarcinoma of 
TGF-α Trp53-/- mice. Comparison of in vivo growth kinetics of these cell lines in immune 
competent and in immune deficient mice. 
 
• Vaccination studies with pancreatic cell lines. Definition of the role of TGF-α as potential 
tumor antigen. 
 
• Analysis of tumor specific cellular and humoral immune responses in TGF-α Trp53-/- 
mice with premalignant and malignant lesions.  
 
• Investigation of possible tumor escape mechanisms of solid tumors. 
 
• Finally, suitable immune therapy approaches against pancreatic adenocarcinoma in TGF-
α Trp53-/- mice should be evaluated. 
  
 
 
 
 
 
 
 
 
 
 
 
2 MATERIALS AND METHODS 
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2.1 Mice 
 
The p53-deficient mice and the transforming growth factor-α (TGF-α) transgenic mice that 
express a TGF-α-human growth hormone (hGH) fusion gene under the control of the elastase 
(EL) promotor (EL-TGF-α-hGH transgenic mice, line no. 2261-3) have been previously 
described (Jacks et al., 1994; Sandgren et al., 1990). TGF-α transgenic mice were kindly 
provided by Dr. Roland Schmid, TU München. TGF-α+/-Trp53-/- mice were obtained by 
crossing TGF-α transgenic mice with Trp53-/- mice. IFN-γ-deficient mice (B6.129S7-
Ifnγtm1Ts) were kindly provided by Dr. Siegfried Weiss, GBF, Braunschweig. TGF-α 
transgenic, p53-deficient, IFN-γ-deficient and nu/nu mice were bred in the animal facilities of 
the Medizinische Hochschule Hannover. Mice were backcrossed for a minimum of 10 
generations on C57Bl/6 background. 
RAG1-/- mice were kindly provided by Dr. Jan Buer, GBF, Braunschweig. CD1-/- mice were 
kindly provided by Dr. Stefan Kaufmann, MPI for Infection Biology, Berlin. C57Bl/6 mice 
were obtained from Charles River (Sulzfeld, Germany). SCID.beige mice were purchased 
from Jackson Laboratories (Bar Harbor, ME, USA). All mice were kept under specific 
pathogen-free conditions, and all experiments were conducted according to the German 
animal protection law. 
 
 
2.1.1 PCR screening 
 
Genotype of mice used in this study was determined by genomic PCR of tail biopsies. PCRs 
were performed using Hot Star Taq (Qiagen, Hilden, Deutschland) and were initiated at 95°C 
for 15 min. The status of p53 was assessed by a multiplex PCR using the following primers: 
5`p53 (5`-CCCGAGTATCTGGAAGACAG-3`) and 3`p53 (5`-ATAGGTCGGCGGTTCAT-
3`), 5`neo (5`-CTTGGGTGGAGAGGCTATTC-3`) and 3`neo (5`-AAGTGAGATGAC 
AGGAGATC-3`). A 600 bp fragment of wt p53 and a 280 bp fragment of neomycin were 
amplified by PCR as follows: 94°C for 30 s, 58°C for 1 min, 72°C for 1 min. PCR was carried 
out for 30 cycles. The presence of TGF-α transgene was determined using hGH gene specific 
primers: 5`hGH (5`-GGCTTTTTGACAACGCTATG-3`) and 3`hGH (5`-TAGGAGGTC 
ATAGACGTTGC-3`) (600 bp). The PCR was performed for 40 cycles according to the 
following program: 94°C for 30 s, 58°C for 1 min, 72°C for 1 min. IFN-γ -/- mice were 
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identified using multiplex PCR with 3 different primers: G-IFN725 (5`-TCAGCGCAGGGG 
CGCCCGGTTCTTTT-3`) and G-IFN482 (5`-AGAAGTAAGTGGAAGGGCCCAGAAG-3`) 
for wt IFN-γ (260 bp) and G-IFN484 (5`-AGGGAAACTGGGAGAGGAGAAATAT-3`) and 
G-IFN484 for neo-disrupted IFN-γ (1 Kb). Conditions were: 94°C for 30 s, 58°C for 1 min 
and 72°C for 1 min; 35 cycles.  
 
 
2.2 Tumor cell lines 
 
Tumor cell lines were generated from pancreatic tumors of 6 TGF-α/p53-/- mice by fine 
needle aspiration or homogenization. Fibroblast overgrowth was controlled by differential 
trypsinization. Established primary cultures were passaged by trypsinization when each 
culture formed an 80% to 100% monolayer. Established mPAC (murine pancreatic 
adenocarcinoma cell lines) 1-25 derived from TGF-α/p53-/- mice were used for further in vitro 
and in vivo characterization and analysis. The main in vivo experiments of this study were 
performed with mPAC-6 and the once in vivo passaged (ivp) variant mPAC-2ivp. 
 
B78H1KbDb, a derivative of B78H1, a MHC class I-negative variant of B16 melanoma of a 
C57Bl/6 mouse (Graf, Jr. et al., 1984), was transduced with the KbDb gene (Levitsky et al., 
1994). Hepa1-6 is a murine hepatom derived from C57L/J mouse (Darlington et al., 1986). 
RMA is a mouse T cell lymphoma of C57Bl/6 origin (Karre et al., 1986). NIH3T3 is a murine 
fibroblast cell line. All cell lines were grown in DMEM complete medium (10% FCS, 100 
U/ml Penicillin, 100 µg/ml Streptomycin, 2 mM L-Glutamin, 1% NEEA and 1 mM 
Sodiumpyruvat under standard culture conditions (37°C, 5% CO2). mPAC were tested for 
mycoplasma contamination using nested PCR. Two consecutive PCR runs were performed to 
increase the sensitivity of the PCR, employing a nested set of general, mycoplasma specific 
primers (Wirth et al., 1994; Hopert et al., 1993). As few as 1-2 mycoplasma genome copies 
are detectable using this nested PCR. Some cells were subjected to 2-weeks treatment with 40 
µg/ml ciprofloxacin (Ciprobay 200; Bayer, Leverkusen, Germany) (Uphoff et al., 2002). 
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2.2.1 Cloning of cell lines 
 
Established mPAC were plated in 96-well-plates under limiting dilution conditions and only 
wells bearing single colonies were expanded for further experiments. 
 
 
2.3 Transfection and Retroviral Transduction 
 
To construct pSecTagTGF-α, rat cDNA of TGF-α was cloned out of TGF-α pGEM-4Z 
(kindly provided by David Lee) into pSecTag2A/Hygro vector (Invitrogen, Karlsruhe, 
Germany). Cells used as target cells in cytotoxicity assays (B78H1kbDb and Hepa1-6) were 
transiently transfected with pSecTagTGF-α using Lipofectamine (Invitrogen). TGF-α 
expression of the transfected cells was verified by Western Blot using anti-TGF-α or anti-myc 
antibody for detection (see below for detailed protocol). For retroviral transduction, 
supernatant of GM-CSF-retrovirus (CMMP GM-CSF/IRES/GFP) producing cells (kindly 
provided by Dr. Christoph Klein, MHH) was applied at different ratios to mPAC in the 
presence of 8 µg/ml Polybrene . After overnight (o.n.) incubation, the infection supernatant 
was discarded and fresh medium was added to the cells. After another 48-72 hours of culture, 
cells were analyzed by fluorescence microscopy and FACS analysis for Green Fluorescent 
Protein (GFP) expression. For detection of GM-CSF expression, mPAC were seeded at a 
defined density in a defined volume of cell culture medium and the supernatant of the 
transduced mPAC was analysed after o.n. culture for GM-CSF by ELISA (Quantikine kit, 
R&D, Wiesbaden, Germany) according to manufacturer`s recommendations. 
 
 
2.4 Western Blot  
 
To detect protein expression, pancreata, mPAC, control cell lines or cell lines expressing 
recombinant proteins were homogenized in ice cold lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 7,2, 2 mM EDTA and 1% NP40). The buffer was supplemented with a protease 
inhibitor cocktail (Complete Mini, Roche Diagnostics, Mannheim, Germany). Protein 
concentrations were measured using the Bradford method (Bradford reagent, BioRad, 
München, Germany). Equal amounts of total protein were separated on 10-15% SDS gels and 
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analysed by Western Blot for Cytokeratin 8/18 or TGF-α expression using a polyclonal 
guinea pig anti-Cytokeratin 8/18 (GP11, Progen, Heidelberg, Germany) or monoclonal anti-
TGF-α antibodies (134A-2B3, Oncogene, Cambridge, MA, USA or MF9, Neomarkers, 
Fiemont, CA, USA). Expression of recombinant proteins containing the myc epitope was 
detected in Western Blot using an Anti-myc-HRP antibody (Invitrogen). Membranes were 
blocked in 5% nonfat, dry milk and 0.1% Tween-20 in phosphate-buffered saline (PBS) for 
one hour at room temperature or o.n. at 4°C, incubated with the primary antibody (α-CK8/18 
1:2000 and α-TGF-α 1:20) in blocking solution for one hour at room temperature or 
overnight at 4°C, washed three times for 10 minutes in PBS-Tween-20, and incubated with a 
1:10000 dilution of a horseradish peroxidase-labeled secondary antibody (anti-guinea pig IgG 
(Sigma, Seelze, Germany)) or anti-mouse IgG (H+L) (Promega, Mannheim, Germany) in 
10% blocking solution for 1 hour. After three 10-minute washes in PBS-T, binding of 
antibody was visualized with enhanced chemiluminescence reagent (Amersham, 
Braunschweig, Germany). 
 
 
2.5 Preparation of RNA and reverse transcription (RT PCR) 
 
Total cellular RNA was isolated from 1 x 107 mPAC or control cell lines using RNeasy Kit 
(Qiagen, Hilden, Germany) according to standard protocols. Residual chromosomal DNA was 
digested with DNAse I (Live technologies, Karlsruhe, Germany). First strand cDNA was 
synthesized from total RNA (2µg) in a 20 µl reaction using Oligo(dT) primer and the enzyme 
SuperscriptTMII (Live Technologies, Karlsruhe, Germany) according to manufacturer`s 
recommendations. One µl of the primer was mixed with 2 µg total RNA, and sterile double 
distilled water was added to a total volume of 12 µl. The mixture was incubated at 70°C for 
10 min and quickly chilled on ice. After a centifugation step 4µl of 5 x first strand buffer, 2 µl 
of 0,1 M DTT and 1 µl of 10 mM dNTP-mix were added. The contents were gently mixed 
and incubated at 42°C for 2 min, 1 µl SuperscriptTMII was added. The reaction was continued 
for 50 min at 42°C followed by inactivation of reverse transcriptases. PCR was initiated at 
95°C for 15 min (Hot Star Taq). The synthesized cDNA was analyzed using primers specific 
for Cytokeratin 18: 5`CK18 (5`-TGGTACTCTCTTCAATCTGCTG-3`) and 3`CK18 (5`-
CTCTGGATTGACTGTGGAAGTG-3`) and Cytokeratin 19: 5`CK19 (5`-CATGGTTCT 
TCTTCAGGTAGGC-3`) and 3`CK19 (5`-GCTGCAGATGACTTCAGAACC`-3) (174 bp). 
The PCR was performed for 30 cycles according to the following program: 94°C for 15 s, 
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54°C for 30 s, 72°C for 30 s. A 158 bp fragment of TGF-α  was amplified using the following 
primers: 5`TGF-α (5`-GTGGTGTCTCACTTCAACAAG-3`) and 3`TGF-α (5`-TGCCAG 
GAGATCTGCATGCTC-3`). Conditions were: 94°C for 30 s, 60°C for 1 min, 72°C for 1 
min; 30 cycles, and for human Growth Hormone: 5`hGH (5`-CCGACACCC 
TCCAACAGGGA-3`) and 3`hGH (5`-CCTTGTCCATGTCCTTCCTG-3`) (Raccurt et al., 
2002) the PCR conditions were: 94°C for 30 s, 58°C for 1 min, 72°C for 1 min; 35-40 cycles. 
  
 
2.6 Tumor transplantation 
 
To analyse the in vivo growth of the generated cell lines derived from TGF-α/Trp53-/- mice, 1 
x 107 mPAC were injected subcutaneously (s.c.) in 200 µl sterile PBS in the hind flank of 
mice. For re-challenge experiments, 1-10 x 106 mPAC were injected in the opposite flank. 
Tumor development was monitored every other day by measuring the tumor with the metric 
caliper. For ethical reasons, animals were sacrificed when tumors reached a diameter greater 
than 15 mm.  
 
 
2.7 Preparation of single cell suspensions 
 
Single cell suspensions were obtained by flushing spleens with DMEM complete medium 
followed by red blood cell lysis using erythrocyte lysis buffer (Qiagen) or by disaggregation 
of mesenteric and inguinal lymph nodes by using the back of a syringe`s plunger. Cells were 
passed through a mesh with a 100 µm pore size and were washed with DMEM complete 
medium. Blood obtained from the tail artery or by cardiac puncture was collected in PBS 
containing Heparin (50 U/ml) followed by separation on ficoll gradients. Single cell 
suspension of tumors were prepared by mechanical dissociation and collagenase/dispase 
treatment for 45-60 min at 37°C (200 U/ml collagenase (Sigma) /0,7 U/ml dispase (Roche 
Diagnostics)). Cell-cell interactions were disrupted by adding EDTA (0,1 M) during the last 5 
min of incubation, cells were washed and passed through a mesh. 
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2.8 Antibodies and flow cytometry 
 
The monoclonal antibodies (mAb) against H-2Kb (AF6-88.5), I-A/I-E (M5/114.15.2), CD3 
(145-2C11), CD4 (L3T4) (GK1.5 and RM4-4), CD8a (Ly-2) (53-6.7), CD11b (M1/70), 
CD11c (HL3), CD19 (1D3), CD25 (7D4), CD45R/B220 (RA3-6B2), CD49b/Pan-NK Cells 
(DX5), NK1.1 (PK136), used as biotin, fluorescein (FITC), phycoerythrin (PE), 
allophycocyanin (APC) or peridinin chlorophyll protein (PerCP) conjugates, were obtained 
from BD PharMingen (Heidelberg, Germany). Biotinylated antibodies were revealed by PE-
streptavidin- or APC-streptavidin- conjugates (BD PharMingen). Flow cytometry was carried 
out using a FACSCalibur and CellQuest software (Becton Dickinson). 
For in vivo depletions, antibodies were produced in serum free medium from hybridoma 
culture supernatants using the IntegraTM cell line CL1000 system (Integra Bioscience, Chur, 
Switzerland), precipitated with ammonium sulfate and dialyzed against PBS. 
 
 
2.9 Depletions of cell subsets in vivo 
 
Mice were injected intraperitoneally (i.p.) with either 100 µg of purified rat monoclonal 
antibody GK1.5 (anti-CD4), 2.43 (anti-CD8), or 1 mg PC61 (anti-CD25) with a one-day 
interval. Injection of monoclonal antibodies was started at day 3 prior to the injection of 
tumor cells and then continued every other day. Depletion of the different subsets was 
confirmed by FACS-analysis by using the RM4-4 (CD4), 53-6.7 (CD8), and 7D4 (CD25) 
antibodies (BD PharMingen), which do not compete with the depleting antibodies for binding 
to the different cell subsets. Depletion was maintained by continuing the antibody injections 
twice weekly for the duration of the tumor challenge experiments. 
 
 
2.10 Serology 
 
To determine mPAC-specific serum immunoglobulin (Ig)G titers, mPAC-6, mPAC-2ivp and 
irrelevant tumor cell lines were stained using serum (1:50 dilution) taken of mPAC bearing 
mice as primary antibody. A FITC conjugated goat anti-mouse pan IgG secondary antibody 
(Southern Biotec, Birmingham, AL, USA) was used to detect bound serum IgG. 
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2.11 Assessment of MHC I expression on tumors 
 
To evaluate the status of MHC I expression on mPAC grown in vivo after s.c. injection, single 
cell suspension of tumors were prepared by mechanical dissociation and collagenase/dispase 
treatment (see above for detailed protocol). Cells were washed, passed through a mesh, 
stained for MHC I and were analyzed by FACS. 
 
 
2.11.1 Treatment of cells with Interferon-γ 
 
For analysis of induction of MHC class I expression in tumors, recombinant murine IFN-γ 
(Peprotech, London, UK) was added to tissue culture medium at a final concentration of 100 
U/ml during 24 h of culture. Induced MHC class I expression was then revealed by FACS 
analysis. 
 
 
2.12 Cytotoxicity Assay  
 
mPAC-specific cytotoxicity was assayed in a standard chromium release assay. In brief, mice 
were immunized by s.c. injection of irradiated (50 Gy) mPAC or irrelevant tumor cell line. 
After 14 days pooled mesenteric and inguinal lymph nodes and spleen cells were restimulated 
for 5 days at 4 x 106/well in a 24-well culture dish with 1 x 105 mitomycin-treated mPAC (1 
mg mitomycin/1 x 107 cells in 10 ml for 1,5 hours) in RPMI complete medium containing 50 
µM β-mercaptoethanol. 10 U/ml IL-2 was added at day 2. After 5 days the restimulated cells 
were harvested, washed and incubated at different ratios with radioactively labeled (100 µCi 
51Cr/1 x 106 cells) mPAC or irrelevant tumor cells at 5000/well in 96-well-v-bottom culture 
dishes for 4 h. 50 µl supernatant from each well mixed with 150 µl Optiphase Super-Mix 
(Wallac, Turku, Finland) was counted in the gamma counter (Wallac). Specific lysis was 
calculated as follows: (experimental cpm – spontaneous cpm)/(maximum cpm – spontaneous 
cpm) x 100. 
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2.13 IFN-γ capture assay 
 
To detect mPAC-specific IFN-γ secretion, the Cytokine secretion assay for murine cells 
(Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to manufacturer`s 
recommendations. Briefly, 5 x 106 pooled mesenteric and inguinal lymph nodes and spleen 
cells of TGF-α/p53 deficient mice or of mice immunized with irradiated mPAC or an 
irrelevant cell line were stimulated over night (max 16 h) with 1 x 105 mitomycin treated 
mPAC in 48 well culture dishes. After washing, an IFN- γ-specific catch reagent was attached 
to the cell surface of all leukocytes. The cells were labeled for 5 min on ice, then incubated 
for 45 min at 37°C, turning the tube every 5 min to allow cytokine secretion. The secreted 
IFN- γ binds to the IFN- γ catch reagent on the positive, secreting cells. Cross-staining was 
avoided by keeping the cell density at 1 x 105 cells/ml. IFN- γ secreting cells were 
subsequently labeled with a second IFN- γ-specific antibody, the IFN- γ detection antibody 
conjugated to PE. The cells were counterstained with monoclonal antibody against CD8 
(FITC labelled CD8a, Ly-2, 53-6.7) and the frequency of IFN- γ secreting CD8+ T cells was 
determined by FACS analysis. 
 
 
2.14 Intracellular Cytokine staining 
 
Intracellular staining for IFN- γ was performed using the Cytofix/Cytoperm kit (Becton 
Dickinson) according to manufacturer`s instructions. Briefly, pooled mesenteric and inguinal 
lymph nodes and spleen cells were restimulated as described for IFN- γ capture assay and in 
the last 4h of restimulation GolgiPlug (BrefeldinA) was added to the culture. Cells were first 
stained for surface expression of CD8 (FITC labelled CD8a, Ly-2, 53-6.7) and then fixed and 
permeabelized with Cytofix/Cytoperm buffers. Intracellular IFN- γ was detected using an 
anti- IFN- γ−PE antibody ( XMG1.2, BD PharMingen). The frequency of IFN- γ positive CD8 
T cells was determined by FACS analysis. 
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2.15 Cytokine ELISA 
 
To evaluate the cytokine secretion of TILs, tumors were explanted at different time points 
after s.c. injection. 30-100 mg tumors were reduced to small pieces using scalpel and forceps 
and incubated o.n. in 0,5-2 ml (depending on the size of the tumor) DMEM complete medium 
at 37°C, 5% CO2 in 24-well-plates. 
Cytokine secretion of TILs or of restimulated lymphocyte cultures was determined using 
DuoSet ELISA (R&D) specific for IFN-γ, IL-2 or IL-4, ELISA Kits from BioSource 
(Camarillo, CA, USA) specific for IL-10 or IL-12 and an ELISA KIT from Promega specific 
for TGF-β. All ELISA were performed according to manufacturer`s recommendations. 
Briefly, Maxisorb plates were coated over night with a cytokine-specific antibody, or 
precoated plates were used (BioSource). The next day, ELISA was performed following the 
manufacturer`s protocol. All ELISA performed in this study were sandwich ELISA using 
HRP-conjugates for detection. Binding of HRP conjugates was visualized with TMB solution 
(BioRad). The optical density was determined by using a microplate reader set to 450 nm. 
 
 
 
2.16 Cytometric Bead Array (CBA) 
 
Cytokine production detected in ELISA was confirmed and additional cytokines were 
detected by using the mouse inflammatory CBA kit (Becton Dickinson) that can 
simultaneously and quantitatively measure 6 different cytokines (IL-6, IL-10, IL-12, IFN-γ, 
monocyte chemoattractant protein-1 [MCP-1] and tumor necrosis factor-α [TNF-α]) in a 
single sample. Different CBA beads are stably labeled with a fluorescent dye whose emission 
is read at ~ 650 nm (FL 3). Each different group of beads is labeled with a discrete level of 
fluorescent dye so that it can be distinguished by its mean fluorescent intensity upon FACS 
analysis. In addition, the beads have been covalently coupled with capture antibodies specific 
for the different cytokines. 
CBA was performed following the manufacturer`s recommendations. In brief, the CBA 
capture beads are mixed with PE coupled detection antibodies (specific for the definite 
cytokine) and standards, controls, or test samples, to form sandwich complexes. The mixture 
was incubated for 2 hours at room temperature. Unbound detector antibody-PE reagent was 
removed by a single washing step before data acquisition was performed by flow cytometry 
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using a FACSCalibur. Acquired data were analysed using the Becton Dickinson Cytometric 
Bead Array software. 
 
 
2.17 Histology 
 
Tumors were immersion fixed in buffered formalin, embedded in paraffin, sectioned at 4 µm 
thickness and stained with hematoxilin and eosin (H&E). 
Freshly excised tumors were snap frozen in liquid nitrogen. Sections (6 µm) of frozen tissues 
were fixed in methanol/acetone and stained with purified anti-CD4, anti CD8 or antibodies 
(GK1.5, 53-6.72, BD PharMingen), followed by incubation with rabbit anti-rat IgG 
(DakoCytomation, Copenhagen, Denmark) and visualized using the APAAP system 
(DakoCytomation). Sections were counterstained with hemalaun. Mean values of tumor 
infiltrating lymphocytes were calculated from several vision fields on three different sections. 
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3.1 Development of pancreatic tumors in TGF-α p53-/- mice on C57Bl/6 
background 
 
For immunological studies it is essential to work with mice on a defined genetic background. 
Therefore, TGF- α transgenic mice on C57Bl/6 background were mated to p53 deficient mice 
on C57Bl/6 background. In the F2 generation 100% of TGF-α p53-/- mice developed 
malignant tumors within 124 days after birth (Fig. 3.1). Some TGF-α p53-/- mice (4 of 13) 
developed pancreatic tumors already after 68-93 days, but the majority (9 of 13) of TGF-α 
p53-/- mice did not show obvious signs of wasting disease before day 100. Heterozygous 
littermates did not develop tumors within this period of time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Cumulative tumor incidence in TGF-α p53-/- mice on C57Bl/6 background (n=13). Mice were 
sacrificed at depicted time points with obvious signs of wasting disease.  
 
 
 
Histological analysis of the pancreatic tumors explanted from TGF-α p53-/- mice on C57Bl/6 
background revealed the typical structures of ductal pancreatic adenocarcinoma with irregular 
cellular morphology compared to the normal pancreas of a wildtype C57Bl/6 mouse (Fig. 
3.2). This includes pleomorphic nuclei with abnormal chromatin patterns and frequent mitotic 
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figures in ductal structures. Macroscopic examination of pancreatic tumors revealed a 
papillary to cystic phenotype (Fig. 3.2 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Histological analysis of a representative pancreatic tumor of a TGF-α p53-/- mouse on C57Bl/6 
background (A) compared to a wildtype pancreas (B). Note the histological appearance of the pancreatic 
tumor with ductal structures and irregular cellular morphology. Tissues (8 µm) were stained with hematoxilin 
and eosin (original magnification 100x). (C) Macroscopic examination of a pancreatic tumor (bar, 10 mm). 
 
 
3.1.1 Establishment of murine pancreatic adenocarcinoma cell lines (mPAC) 
 
25 pancreatic tumor cell lines were generated from pancreatic tumors of 6 different TGF-
α/p53-/- mice. Established primary cultures have been maintained in culture for more than 20 
passages. To control fibroblast overgrowth during the early phase of establishing these 
pancreatic cell lines, the fibroblasts were repeatedly differentially trypsinized while the 
malignant cells stayed attached to the tissue culture flask. Established primary cultures grew 
in monolayers (Fig. 3.3 A). Established mPAC were characterized and analysed in vitro and 
in vivo.  
 
To confirm, that the established mPAC derived from malignant epithelial tumors, mPAC were 
analysed for Cytokeratin 8/18 expression (Fig. 3.3 B). Cytokeratin 18 expression was 
confirmed by RT PCR (data not shown). Some Cytokeratin 8/18 positive mPAC were further 
analysed for Cytokeratin 19 expression detected by RT-PCR (174 bp), indicating a ductal 
A B
C
BA
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origin of mPAC (Fig. 3.3 B). Table 3.1 shows the results confirming the epithelial origin of 
mPAC-1, mPAC-1A, mPAC-2, mPAC-2A, mPAC-5, mPAC-5A, mPAC-6, mPAC-6A, 
mPAC-7, mPAC-18 and mPAC-25 and ductal origin of mPAC-6 and mPAC-25, and Figure 
3.3 shows the phenotypical characterization of representative mPAC. 
 
 
 
 
Figure 3.3. Phenotypical characterization of a murine pancreatic adenocarcinoma cell line, mPAC derived 
from a ductal adenocarcinoma of a TGF-α p53-/- mouse. (A) Phase-contrast microscopy of mPAC. 
(B) Cytokeratin 19 expression (174 bp) of mPAC was analysed by RT-PCR and Cytokeratin 8/18 (52,5 kDa and 
45,5kDa) expression by Western Blot. 
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Table 3.1. Summary of Western Blot and RT-PCR analysis on Cytokeratin 8/18, 18 and 19 expression by 
different mPAC. (+) indicates weak signal for CK8/18 expression detected in Western Blot. 
 
 
 
TGF-α transgenic mice express TGF-α under the regulation of the Elastase promotor to 
ensure that TGF-α overexpression is restricted to pancreatic acinar cells (Sandgren et al., 
1990). To show that mPAC express the transgene TGF-α, a TGF-α-specific RT-PCR was 
performed (Fig. 3.4 A). The 158 bp product specific for TGF-α was detected in all mPAC 
tested. In Western Blotting, TGF-α expression (18 kDa) could only be detected in lysates of 
pancreata of TGF-α transgenic mice (Fig. 3.4 B) but not in mPAC.  
CELL LINE CK 8/18 
(WESTERN BLOT) 
mPAC-1 (+) 
mPAC-1A + 
mPAC-2A (+) 
mPAC-2 + 
mPAC-3 - 
mPAC-4 - 
mPAC-5 (+) 
mPAC-5A + 
mPAC-6 + 
mPAC-6A + 
mPAC-7 (+) 
mPAC-7A - 
mPAC-8 - 
mPAC-9 - 
mPAC-10 - 
mPAC-11 - 
mPAC-12 - 
mPAC-13 - 
mPAC-18 (+) 
mPAC-25 (+) 
mPAC-2ivp + 
CELL LINE CK 18 
(RT-PCR) 
mPAC-6 + 
mPAC-25 + 
mPAC-2ivp + 
CELL LINE CK 19 
(RT-PCR) 
mPAC-6 + 
mPAC-25 + 
mPAC-2ivp + 
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To confirm that the TGF-α identified by RT-PCR is the overexpressed transgene, a second 
RT-PCR specific for the human Growth hormone (hGH), which is fused to the TGF-α 
transgene-construct, was performed (Fig 1.4 C). The 342 bp product specific for hGH could 
only be found in mPAC but in none of the irrelevant cell lines, such as Hepa1-6, RMA and 
NIH3T3, as tested by RT PCR. 
 
                                      A                                                     B 
 
 
 
                                  
                                     C 
 
 
 
 
 
 
Figure 3.4. RT PCR/Western blot evaluation of transgene expression in mPAC. (A) TGF-α expression (158 
bp) in mPAC was detected by RT PCR. (B) Western Blotting revealed a 18 kDa product for TGF-α expression 
only in pancreas of transgenic but not of non-transgenic wildtype littermates (wt). (C) RT-PCR showed 
expression of the human Growth Hormone (hGH: 342 bp), which is fused to the EL-TGF-α construct to produce 
TGF-α transgenic mice, in mPAC.  
 
 
As shown in Fig. 3.5, FACS analysis using anti-H-2Kb and anti-I-A/I-E antibodies was 
performed to investigate MHC class I and class II expression on established tumor cell lines. 
All mPACs analysed expressed MHC class I but not class II. Individual mPAC showed 
variable levels of MHC class I expression, ranging from almost negative (mPAC-13) to 
highly positive (mPAC-6) cells.  
 
mPAC that showed the best in vitro growth kinetics (data not shown) and were positive for 
Cytokeratin 8/18, Cytokeratin 19 and the trangene TGF-α were subjected to in vivo 
experiments. 
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Figure 3.5. MHC expression of mPAC. mPAC showed diverse patterns of MHC class I expression. None of 
the cell lines tested showed expression of MHC class II. mPAC were analysed by FACS for surface protein 
expression using antibodies against MHC class I (anti-H2-Kb) and against MHC class II (anti-I-A/I-E). The filled 
histograms represent staining of mPAC with the appropriate isotype controls. 
 
 
3.1.1.1 Tumor rejection after inoculation of mPAC  
 
To analyse in vivo growth kinetics, mPAC derived from 3 different pancreatic tumors were 
subcutaneously injected into C57Bl/6 wildtype mice. After subcutaneous inoculation of 1 x 
107 mPAC in C57Bl/6 wildtype mice, the tumor first started to grow during the first ten days 
but then regressed. 21 days after tumor injection no more tumor growth could be detected 
(Fig. 3.6). This reproducible regression of mPAC in immune competent mice was observed 
independently of the stage of MHC class I expression of the inoculated mPAC. In order to 
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look at the growth kinetics of mPAC in immunedeficient mice and to evaluate the immune 
mediation of this response, mPAC-2, mPAC-2A, mPAC-6, mPAC-6B were injected into 
RAG1-/- and nu/nu mice. Injection of mPAC in immune incompetent RAG1-/-mice resulted in 
a slow but progressive outgrowth of the tumor. In RAG1-/- mice, there was also a slight 
regression in tumor growth observed between day 10-20 after mPAC inoculation, but the 
tumor was still detectable (2-3 mm tumor diameter). The reproducible outgrowth of different 
mPAC after this kind of growth stagnation in immune incompetent RAG1-/- mice versus 
complete regression after three weeks in immune competent wildtype mice clearly indicates, 
that the regression of mPAC was an immune regulated phenomenon. This immune dependent 
regression was further defined by the difference seen in the growth kinetics of mPAC in nu/nu 
mice compared to RAG1-/- mice (Fig. 3.6). In nu/nu mice, mPAC derived tumors regressed 
and stagnated until day 40, but then restarted to grow progressively to form lethal tumors as in 
RAG1-/- mice. However, compared to RAG1-/- mice, in nu/nu mice a more delayed tumor 
progression could be observed. RAG1-/- mice lack different lymphocyte populations that are 
important for tumor rejection than nu/nu mice. Thus, these data clearly indicate that the 
regression of mPAC derived tumors is T cell dependent, although a contribution of B cells 
and NKT cells could not be ruled out by these experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. In vivo growth kinetics of mPAC. After s.c. inoculation into immune competent C57Bl/6 mice 
(circles), mPAC derived tumors grew during the first 10 days and then started to regress. 21 days after injection 
no more tumor growth was detectable in C57Bl/6 mice. Injection into immune deficient RAG1-/- (squares) and 
nu/nu (triangles) mice resulted in lagged but progressive outgrowth of the tumor. mPAC derived tumors grew 
faster in RAG1-/- (squares) than nu/nu (triangles) mice. 
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3.1.2 Cytotoxic activity of lymphocytes after immunization with mPAC 
 
To further evaluate the immunogenicity of mPAC, C57Bl/6 mice were inoculated with 
irradiated mPAC. Immunization with mPAC but not with an irrelevant cell line (e.g. RMA) 
induced a strong cytotoxic T cell response against mPAC used as targets in CTL assay (Fig. 
3.7 A). Two weeks after immunization, pooled splenocytes and lymph node cells from 
C57Bl/6 mice were analysed in CTL using MHC class I positive and MHC class I negative 
mPAC as targets at the effector to target (E:T) ratios indicated. In these CTL assays only 
MHC class I positive targets were lysed, which indicates that the detected cytotoxic response 
is CD8+ T cell and not NK cell dependent (Fig. 3.7 B). Lymphocytes derived from mice 
immunized with RMA or from naïve control mice did not show mPAC-specific lysis. 
Furthermore, mPAC-specific lysis could also be observed analysing splenocytes and lymph 
node cells of mPAC derived tumor bearing mice, i.e. in mice in which the mPAC derived 
tumor already regressed (data not shown).  
 
To analyse, whether TGF-α might be the possible antigen recognized by the cytotoxic T cells 
after immunization with mPAC derived from mice overexpressing TGF-α, MHC class I 
positive target cells were transiently transfected with TGF-α-encoding plasmid DNA. No 
specific CTL response could be detected using B78H1KbDb/TGF-α or Hepa1-6/TGF-α as 
targets (Fig. 3.7 C). B78H1KbDb and Hepa1-6 transfected with a plasmid encoding an 
irrelevant antigen (GFP) served as controls. TGF-α expression of the target cells Hepa1-
6/TGF-α and B78H1KbDb/TGF-α was confirmed in Western Blot (Fig. 3.7 D).  
 
A second set of experiments was performed to rule out the possibility that TGF-α was the 
antigen: mPAC were injected into TGF-α transgenic mice, because these mice might exhibit 
tolerance against the potential antigen, since the antigen is expressed by mPAC. However, 
mPAC showed the same growth kinetics in TGF-α transgenic mice as in normal wildtype 
mice: The mPAC derived tumors grew and regressed within three weeks after tumor 
inoculation (data not shown). 
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Figure 3.7. Cytotoxic activity in splenocytes and lymph node cells after immunization with mPAC. 
C57Bl/6 mice were immunized with irradiated mPAC or RMA cells. Two weeks after immunization pooled 
splenocytes and lymph node cells were restimulated in vitro for five days with mPAC and were subsequently 
analysed in standard 51Cr CTL assays. (A) mPAC-specific lysis could only be observed after immunization with 
mPAC but not after immunization with irradiated RMA or in naïve mice. (B) Only MHC class I positive but not 
MHC class I negative mPAC-targets (T) were recognized in CTL. (C) No mPAC-specific cytotoxic activity was 
detected using TGF-α expressing B78H1KbDb or Hepa1-6 as targets (T). (D) TGF-α expression (15kDa) of 
B78H1KbDb and Hepa1-6 transiently transfected with TGF-α encoding plasmid DNA was verified by Western 
Blot. 
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3.1.2.1 mPAC-specific IFN-γ secretion in immunized mice 
 
To further evaluate the observed mPAC-specific CTL response, the ability of CD8+ T cells to 
secrete IFN-γ was analysed. Two weeks after immunization of C57Bl/6 mice with mPAC, 
splenocytes and lymph node cells were isolated, pooled and restimulated in vitro with mPAC. 
After restimulation, IFN-γ secretion was analysed performing IFN-γ capture assay. Using this 
method, the secreted IFN-γ is captured on the viable cells and subsequently labeled with a 
second IFN-γ specific antibody. FACS analysis of the cells counterstained with an anti-CD8 
antibody revealed a significant IFN-γ secretion only in CD8+ T cells derived from mice 
immunized with mPAC but not with control cell lines (e.g. RMA). After immunization with 
mPAC 4% of CD8+ T cells secreted IFN-γ compared to 0,3% IFN-γ positive CD8+ T cells 
after immunization with RMA (Fig. 3.8 A) or in naïve mice (data not shown). The detection 
of IFN-γ-secreting CD8+ T cells supports the assumption that mPAC induced cytotoxicity is 
CD8+ T cell dependent. Furthermore, this strong IFN-γ production detected by IFN-γ capture 
assay was confirmed in an independent experiment by intracellular cytokine staining (Fig. 3.8 
B). Intracellular IFN-γ staining revealed a significant percentage of IFN-γ secreting CD8+ 
cells after immunization with mPAC (0,6% ) compared to 0,3% IFN-γ secreting CD8+ cells 
after immunization with the control cell line RMA. These data show that the secreted IFN-γ in 
fact partly derived from CD8+ T cells, but that also CD8- cells secreted significant amounts of 
IFN-γ.  
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Figure 3.8: mPAC-specific INF-γ response. Lymphocytes from mPAC-immunized mice were in in vitro 
restimulated with mPAC and thereafter analysed for IFN-γ secretion. (A) IFN-γ capture assay revealed a strong 
IFN-γ secretion of CD8+ T cells derived from mPAC immunized mice but not from mice immunized with RMA 
cells. (B) Intracellular IFN-γ staining confirmed IFN-γ production of CD8+ T cells derived from mPAC 
immunized mice but not from mice immunized with RMA cells. 
 
 
 
3.1.3 T cell infiltration of mPAC derived tumors 
 
To investigate tumor infiltrating lymphocytes, immunohistological analysis and FACS 
analysis of mPAC derived tumors at day seven after subcutaneous tumor inoculation were 
performed. Immunohistological analysis of frozen tumor sections revealed that these tumors 
were highly infiltrated with CD4+ and CD8+ T cells. Both T cell populations could also be 
detected by FACS analysis of tumor infiltrating lymphocytes after Collagenase/Dispase 
digestion of the tumors . Significant populations of 17% CD4+ T cells and 6% CD8+ T cells 
could be detected (Fig. 3.9). 
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Figure 3.9. Tumor infiltration by T cells. Seven days after s.c. injection of mPAC immunohistological analysis 
of frozen sections revealed infiltration of CD4+ (A) and CD8+ (B) T cells (bar, 100 µm). (C) FACS analysis of 
tumor infiltrating lymphocytes at day seven after mPAC injection confirmed the tumor infiltration with CD4+ 
(6% ) and CD8+ (19% ) T cells. These results are representative for two independent experiments. 
 
 
 
3.1.4 Induction of mPAC-specific humoral responses  
 
To examine the contribution of B cells in the rejection of mPAC derived tumors, three weeks 
after subcutaneous inoculation of mPAC, sera (1:50 dilution) from C57Bl/6 mice were 
analysed for mPAC-specific antibodies. FACS analysis of the sera revealed that C57Bl/6 
mice bearing mPAC derived tumors exhibit a humoral response against mPAC, but not 
CD8
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against a control cell line (Fig. 3.10). Sera taken from mice before mPAC inoculation served 
as control (filled histograms). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. mPAC induced humoral response after s.c. injection into C57-Bl/6 mice. Three weeks after 
injection of mPAC, antibodies against mPAC but not against a control cell line could be identified in sera of 
mice (1:50 dilution) as shown in histogram overlay. Filled histogram represents analysis of sera taken before 
injection of mPAC.  
 
 
3.1.5 Histological analysis of pancreatic tumors of TGF-α Trp53-/- mice at different 
time points 
 
Histological analysis of pancreatic tumors of TGF-α Trp53-/- mice at different time points 
revealed that at 6 weeks of age the pancreas was already highly enlarged, but showed to a 
large extend a normal morphology. The majority of the tissue was not yet highly proliferating, 
however hypertrophic acini, which sometimes showed a pleomorphic phenotype, could 
already be observed. Some areas of proliferating cells showed irregular outlines but with 
“pushing margins” towards the adjacent parenchyma. In these areas the cellular morphology 
was altered insofar as they had hyperchromatic nuclei and exhibited a loss of nuclear polarity. 
Mitosis, necrosis and apoptosis were rare, but mitosis were not atypical (Fig. 3.11 A-C). 
In 9-week-old mice the acinar structure of the pancreas was already lost in most of the 
lesions. The cells started to grow in layers (“budding off”). They were characterized by an 
increase in the nucleus-to-cytoplasm ratio. Bizarre giant nuclei and severe dysplasia were 
found. The number of areas with proliferating cells was higher and in contrast to 6-week-old 
mice there was also an increase of proliferation (increased mitosis index) and more interstitial 
fibrosis (data not shown). 
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In 12-week-old TGF-α Trp53-/- mice, the regular acinus structures were mostly lost. The 
tissue was replaced by highly proliferating trabecular and tubular structures showing vesicular 
nuclei and in part prominent nuclei. Multiple mitoses were present, many of them atypical. 
Moreover, there was a marked increase of apoptotic bodies. In some areas, microcystic 
transformation occured. The histomorphological picture corresponded to a highly 
differentiated carcinoma (Fig. 3.11 D-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Histological analysis of representative pancreatic tumors of TGF-α Trp53-/- mice of different 
ages. The pancreas of 6-week-old TGF-α Trp53-/- mice showed to a large extent a normal morphology (A). Only 
in some irregularly proliferating areas with “pushing margins” the acinar morphology was already altered (B,C). 
The pancreas of 12-week-old TGF-α Trp53-/- mice showed the morphological character of a highly differentiated 
carcinoma with lost acinar structure and formation of duct-like tubular complexes and vesicular nuclei (D-F). 
Each tissue was stained with hematoxilin and eosin (original magnification 100x [A,D] and 400x [B,C,E,F] ). 
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3.1.6 Normal distribution of lymphocyte populations in TGF-α Trp53-/- mice 
 
To evaluate whether TGF-α Trp53-/- mice develop a normal immune system, lymphocyte 
populations of TGF-α Trp53-/- mice were analysed in comparison to non-transgenic littermate 
control mice. The percentage of NK cells, Dendritic cells, Macrophages and B and T cells 
were evaluated in TGF-α Trp53-/- mice and in non-transgenic littermates. FACS analysis 
revealed that TGF-α Trp53-/- mice have normal numbers of DX5+ NK cells (2,5% compared 
to 2,5%), CD11c+MHC class II+ Dendritic cells (2,5% compared to 2,1%), CD11b+MHC 
class II+ Macrophages (2,9% compared to 2,6%), CD19+B220+ B cells (61,7% compared to 
56,2%), CD8+ (8,6% compared to 10%) and CD4+ T cells (30,5% compared to 33,2%) and  
 
Figure 3.12. Analysis of lymphocyte populations in TGF-α Trp53-/- mice. Lymphocytes from TGF-α Trp53-/- 
and non-transgenic littermate control mice were isolated and single cell suspensions were stained for the distinct 
lymphocyte populations and analysed by FACS. No significant difference concerning the distribution of the 
specific lymphocyte populations could be seen comparing transgenic (TGF-a Trp53-/-) and non-tansgenic mice. 
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CD4+CD25+ regulatory T cells (4,8% compared to 4,0%). These data indicate that TGF-α 
Trp53-/- mice exhibited a normal development and distribution of the distinct lymphocyte 
populations compared to non-transgenic littermate control mice. 
 
 
 
3.1.7 Analysis of immune responses in TGF-α Trp53-/- mice 
 
All experiments described above demonstrated that mPAC were highly immunogenic tumors, 
inducing tumor-specific humoral and cellular immune responses in wildtype mice. However, 
in the past it has been shown that tumors can impair immune responses. In addition, not all 
tumors induce specific immune responses, but rather tumor specific tolerance. Therefore, we 
next analysed tumor specific immune responses in TGF-α Trp53-/- mice. Additionally, we 
tested mice with premalignant lesions. 
 
Analysis of a detectable immune response in TGF-α Trp53-/- mice against the highly 
immunogenic cell line mPAC revealed an IFN-γ response only in tumor bearing TGF-α 
Trp53-/- mice (Fig. 3.13). Pooled splenocytes and lymph node cells of pancreatic tumor 
bearing 12-week-old TGF-α Trp53-/- mice, their age-matched heterozygous littermate control 
mice and of 6-week-old TGF-α Trp53-/- mice and their age-matched heterozygous littermate 
control mice were restimulated in vitro with mPAC and subsequently analysed for IFN-
γ secretion. FACS analysis of IFN-γ capture assay revealed a reproducible significant number 
of IFN-γ secreting CD8+ T (1%) cells only in 12-week-old TGF-α Trp53-/- mice, which 
already developed malignant tumors, but neither in 6-week-old TGF-α Trp53-/- mice (0,2%), 
which did not yet develop tumors, nor in heterozygous littermates (0,2%). These data clearly 
indicate that the induction of a CD8+ T cell response against the highly immunogenic cell line 
mPAC occurs only in association with the malignant pancreatic tumors. The immune 
response is not induced before the tumor arises. Additionally, this CD8+ dependent IFN-γ 
secretion was also confirmed in an independent experiment by intracellular staining for IFN-γ 
(data not shown). 
 
A CTL response against mPAC or target cells transfected with TGF-α encoding plasmid 
DNA could not be observed in naive TGF-α Trp53-/- mice of any age (data not shown), 
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indicating that the CD8+ T cells in TGF-α Trp53-/- mice were only partially activated to 
secrete IFN-γ, but not to lyse the target cells. However, independent of their age, TGF-α 
Trp53-/- mice were able to reject transplanted mPAC derived tumors in the same manner as 
non-transgenic wildtype mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Analysis of IFN-γ secretion of CD8+ T cells. Pooled splenocytes and lymph node cells of 12-
week-old TGF-α Trp53-/- and TGF-α Trp53+/- mice and of 6-week-old TGF-α Trp53-/- and TGF-α Trp53+/- mice 
were restimulated in vitro with mPAC and analysed by IFN-γ capure assay. FACS analysis revealed that only 
mice that already bear pancreatic tumors show IFN-γ secretion of CD8+ T cells. 
 
 
To analyse the tumors for the presence of inflammatory cytokines, pancreatic tumors of TGF-
α Trp53-/- mice at different ages (6 and 12 weeks) and mPAC derived tumors (d 7 after s.c. 
inoculation into C57Bl/6 wildtype mice) were explanted, cut into small pieces and incubated 
in vitro. After over night incubation, culture supernatants were harvested and analysed for 
several cytokines in Cytometric Bead Array (CBA) and ELISA (Fig. 3.14).  
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Analysis of the tumor derived supernatants by CBA revealed no IFN-γ in any of the 
autochthonous tumors analysed, but a significant IFN-γ production in explanted mPAC 
derived tumors. These results were confirmed by ELISA specific for IFN-γ (data not shown).  
TNF-α was only found in very low amounts in the supernatants of tumors derived from 6-
week-old TGF-α Trp53-/- mice, but at six-fold higher levels in the supernatants of mPAC 
derived tumors. 
Consistent with this inflammatory phenotype, also IL-12 was detected in the supernatant of 
mPAC derived tumors. Slight levels of IL-12 could also be detected in the culture 
supernatants derived from the autochthonous pancreatic tumors. None of the analysed tumor 
derived supernatants was positive for the inhibitory cytokine IL-10. 
Similarly to these results, no tumor infiltrating lymphocytes could be detected in histological 
analysis of pancreatic tumors of TGF-α Trp53-/- mice at any stage of tumor development.  
 
Figure 3.14. Cytokine profiles of pancreatic 
tumors compared to mPAC derived tumors. 
Explanted tumors were cut into small pieces and 
incubated in vitro. Culture supernatants of mPAC 
derived tumors (mPAC, black bars) and of 
autochthonous pancreatic tumors of 6-week-old 
[Tg(6w), light grey bars] and 12-week-old 
[Tg(12w), dark grey bars] TGF-α Trp53-/- mice 
were analysed for several cytokines using the 
cytokine bead array from BD. Cytokine quantities 
are depicted as pg/100mg of the corresponding 
tumor. 
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To further evaluate the tumor-specific immune response in TGF-α Trp53-/- mice, sera of 6-
week-old and 12-week-old mice and their age-matched heterozygous littermates were 
analysed for mPAC-specific antibodies. A humoral response against mPAC, but not against a 
control cell line in the sera of four of nine 12-week-old and a weaker response in the sera of 
three of seven 6-week-old TGF-α Trp53-/- mice could be detected (Fig. 3.15). No antibody 
response could be detected in the sera of heterozygous littermate control mice (0 of 4). 
Increased levels of anti-mPAC antibodies in the sera of TGF-α Trp53-/- mice as tumor 
progresses corresponded to the increased levels of IFN-γ secretion detected by IFN-γ capture 
assay . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. Humoral responses against mPAC in TGF-α Trp53-/- mice. Antibodies against mPAC but not 
against a control cell line could be identified in sera of tumor bearing 12-week-old TGF-α Trp53-/- mice (1:50 
dilution) as shown in histogram overlay. 6-week-old TGF-α Trp53-/- mice exhibit only very slight antibody 
responses against mPAC. 
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3.2 Selection of tumor escape variants mPACivp 
 
Murine pancreatic adenocarcinoma cell lines originated from pancreatic tumors of TGF-α 
Trp53-/- mice on C57Bl/6 background did not grow progressively when inoculated 
subcutaneously into syngenic immune competent mice. The tumors grew progressively, even 
though with a short delay, when injected into nu/nu and RAG1-/- mice, proving the malignant 
potential of these cell lines. 
After injection into immune competent mice, mPAC derived tumors regressed after 21 days, 
but in a minority of the mice, progressively growing tumors were observed 2-4 months after 
inoculation. These rare progressor tumors were isolated from normal C57Bl/6 mice when they 
had grown to a size of 10-15 mm in diameter, homogenized and taken into culture. Cell lines 
were established from these tumors and were named mPACivp (in vivo passaged). Injection 
of 1x107 mPAC-2ivp cells produced progressively growing tumors in 100% of the immune 
competent syngenic mice (Fig. 3.16), thereby demonstrating the heritable nature of the 
progressive growth behaviour of the newly isolated tumor mPAC-2ivp. 
However, injection of the escape variant mPAC-2ivp into nu/nu mice did not result in faster 
outgrowth of the tumors compared to immune competent mice (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. mPAC-2ivp grew out to form lethal tumors. After reisolation and establishment of this rare new 
cell line, s.c. injection of mPAC-2ivp resulted in progressive tumor growth in 100% of immune competent 
C57Bl/6 mice. 
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To prove that mPAC-2ivp and the highly immunogenic mPAC-6 derived from the same 
pancreatic tumor of a TGF-α Trp53-/- mouse, the genes coding for the human growth hormone 
(hGH) and for p53 were used as lineage-specific markers. Isolation of genomic DNA and 
subsequent analysis by PCR revealed the presence of the TGF-α/hGH fusion gene and the 
absence (disruption) of the p53 gene in the original mPAC-6 as well as in the variant mPAC-
2ivp (Fig. 3.17).  
 
Further analysis showed that mPAC-2ivp expresses Cytokeratins 8/18 and 19 as markers for 
epithelial and ductal origin and the transgene TGF-α and hGH, respectively (Fig.3.3 and 
Fig.3.4). These data clearly indicate, that mPAC-2ivp and mPAC-6 have the same origin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. mPAC-2ivp exhibited the same lineage markers as its original cell line mPAC-6. Analysis of 
genomic DNA by PCR detected the hGH gene but not the by the insertion of neo disrupted p53 gene in mPAC-
2ivp and in mPAC-6. These results matched with the genotype of TGF-α Trp53-/- mice the cell lines derived of. 
 
 
3.2.1 MHC class I expression and tumor progression 
 
Analysis of MHC class I expression by FACS showed that mPAC-2ivp has very low MHC 
class I expression, compared to the original mPAC (Fig. 3.18 A and Fig. 3.5). Induction of 
MHC class I expression by addition of IFN-γ to the cell culture medium revealed that mPAC-
2ivp has not lost but down-regulated MHC class I expression, because after incubation with 
IFN-γ 100% of the cells were highly positive for MHC class I expression. (Fig.3.18 A).  
To analyse, whether down-regulation of MHC class I expression might be the reason for the 
escape of immune destruction, a MHC class I positive clone of mPAC-2ivp was used for 
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further experiments. This clone exhibited stable MHC class I expression in vitro (Fig. 3.18 B) 
without addition of IFN-γ and showed similar in vivo growth kinetics as mPAC-2ivpMHC I- 
after s.c. inoculation into C57Bl/6 mice (Fig.3.18 C). The tumors were isolated, 
collagenase/dispase digested and the cells were subsequently analysed by FACS for MHC 
class I expression. “Ex vivo” FACS analysis of mPAC-2ivpMHC I+ and mPAC-2ivpMHC I- 
demonstrated that the MHC class I positive clone mPACivpMHC I+ did not down-regulate 
MHC class I expression in vivo (Fig. 3.18 B). These data support the idea that the in vivo 
tumor progression of mPAC-2ivp is independent of MHC class I expression.  
 
 
Figure 3.18. Progressive in vivo growth of mPAC-2ivp was independent of MHC class I expression. (A) 
FACS analysis of mPAC-2ivp for surface expression of MHC class I revealed that MHC I down-regulation 
could be reversed by addition of IFN-γ to the cell culture medium (100U/ml for 24h). (B) Cloning of mPAC-
2ivp under limiting dilution conditions results in the generation of the clone mPAC-2ivpMHC I+ that exhibited a 
stable and high expression MHC class I in vitro and ex vivo after tumor explantion. Dotted lines represent 
isotype control. (C) Progressive in vivo growth of mPACivp was independent of MHC class I expression. 
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3.2.2 Injection of mPAC-6 and mPAC-2ivp into the same mouse to evaluate cross-
protection 
 
To find out, whether mPAC-6 and mPAC-2ivp are immunologically related, mPAC-6 and 
mPAC-2ivp were injected s.c. into the same C57Bl/6 mouse (Fig. 3.19). If the mice were 
rechallenged after 10 days with mPAC-6, the mice were protected against growth of the 
second challenge with mPAC-6 (Fig. 3.19 A). This is another indication for the immunogenic 
phenotype of mPAC-6. Challenge of the mice with mPAC-2ivp after previous injection of 
mPAC-6 did not impair the progressive outgrowth of mPAC-2ivp (Fig. 3.19 B). In addition, 
to analyse whether previous injection of mPAC-2ivp facilitates the growth of mPAC-6 as 
progressive tumor, the reverse experiment was done. However, challenging C57Bl/6 mice 
with mPAC-6 after previous injection of mPAC-2ivp resulted in the same growth kinetics of 
mPAC-6 as seen in untreated mice: The mPAC-6 derived tumor grew during the first ten days 
and then started to regress (Fig. 3.19 C).  
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Figure 3.19. Inoculation of mPAC-6 and mPAC-2ivp into the same mouse. (A) Repeated injection of mPAC-
6 after 10 days into the opposite hind flank of the same mouse immunized the mouse against the second 
challenge. (B) Preinjection with the immunogenic mPAC-6 did not prevent the progressive growth of mPAC-
2ivp. (C) mPAC-2ivp tumor bearing mice were not tolerant to the outgrowth of mPAC-6.  
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3.2.3 Immune responses against mPAC-6 and mPAC-2ivp 
 
3.2.3.1 mPAC-6- and mPAC-2ivp-specific cytotoxicity in immunized mice 
 
To further investigate whether mPAC-6 and mPAC-2ivp share similar T cell antigens, CTL 
assays using both variants were performed. Two weeks after immunization with irradiated 
mPAC-6 or mPAC-2ivp, splenocytes and lymph node cells from C57Bl/6 mice were isolated, 
pooled and restimulated in vitro either with mPAC-6 or with mPAC-2ivp MHC I+. After five 
days of in vitro restimulation, mPAC-6- and mPAC-2ivp-specific lysis was analysed in 
standard 51Cr CTL assays. The assays were performed using the cell line mPAC-2ivpMHC I+ 
(MHC class I was up-regulated by adding IFN-γ to the cell culture medium) as restimulator 
and target and not the MHC I+ clone to ensure the availability of all possible antigens. A 
diagram of the experimental procedure is depicted below (Fig. 3.20). 
 
 
 
 
 
 
 
 
 
Figure 3.20: Experimental set up for the 
performance of CTL assays. 
 
 
CTL assays performed with mPAC-6 or mPAC-2ivp as restimulators and targets revealed 
cross-reactivity of the two variants. A mutual and clearly MHC class I dependent cytotoxic 
activity could be shown for almost all conditions analysed. To exclude that the observed 
mutual CTL lysis was an in vitro artefact, lymphocytes of mice immunized with an irrelevant 
tumor cell line, RMA, served as control. The results of the performed CTL assays indicate 
that mPAC and mPACivp share similar T cell antigens. Mice could be immunized with 
mPAC-6 and cross-restimulation of lymphocytes derived from these mice with mPAC-2ivp 
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resulted in subsequent lysis of mPAC-2ivp (mPAC-2ivp → mPAC-2ivp) or mPAC-6 (mPAC-
2ivp → mPAC-6), furthermore they can be restimulated with mPAC-6 to subsequently lyse 
mPAC-2ivp (mPAC-6 → mPAC-2ivp).  
Lymphocytes isolated from mice immunized with mPAC-2ivp could be restimulated with 
mPAC-2ivp to lyse mPAC-2ivp (mPAC-2ivp → mPAC-2ivp) and also to lyse mPAC-6 
(mPAC-2ivp → mPAC-6), but cross-restimulation with mPAC-6 did only result in weak lysis 
of mPAC-6 (mPAC-6 → mPAC-6) and in no significant lysis of mPAC-2ivp (mPAC-6 → 
mPAC-2ivp) compared to control mice (Fig. 3.21 and Tab. 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. Performance of CTL assays showed mutual CTL lysis after immunization with mPAC-6 or 
with mPAC-2ivp. C57Bl/6 mice were immunized with irradiated mPAC-6 (filled circles), mPAC-2ivp (open 
triangles) or with control RMA (filled squares). Isolated lymphocytes were in vitro restimulated with mPAC-6 or 
mPAC-2ivp and tested in CTL against mPAC-6 or mPAC-2ivp used as targets. The results obtained after 
restimualtion with mPAC-6 and using mPAC-6 as a target (mPAC-6 → mPAC-6), restimulation with mPAC-
2ivp and using mPAC-2ivp as target (mPAC-2ivp → mPAC-2ivp), restimulation with mPAC-6 and using 
mPAC-2ivp as target (mPAC-6→ mPAC-2ivp) and restimulation with mPAC-2ivp and using mPAC-6 as target 
(mPAC-2ivp → mPAC-6) are summarized in Table 3.2.  
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INJECTION RESTIMULATION CTL TARGET LYSIS 
mPAC-6 + mPAC-6 
mPAC-2ivp + 
mPAC-6 + 
mPAC-6 
mPAC-2ivp 
mPAC-2ivp + 
mPAC-6 +/- mPAC-6 
mPAC-2ivp - 
mPAC-6 + 
mPAC-2ivp 
mPAC-2ivp 
mPAC-2ivp + 
 
Table 3.2: Summary of CTL Assay results.  
 
 
 
3.2.3.2 mPAC-6- and mPAC-2ivp-specific IFN-γ secretion in immunized mice 
 
In order to support results obtained by cytotoxicity assays, we also performed IFN-γ-specific 
ELISA after 48h of restimulation. Comparable to the CTL results, significant amounts of 
IFN-γ could only be detected in supernatants of lymphocytes derived from C57Bl/6 mice 
immunized with mPAC-6 or mPAC-2ivp but not in those supernatants of lymphocytes 
derived from control mice.  
 
 
 
Figure 3.22. IFN-γ detection in 
supernatants of restimulated 
lymphocytes. CTL culture supernatants 
were analysed after 48h for IFN-γ 
production by ELISA. IFN-γ could only be 
detected in culture supernatants of 
lymphocytes derived from mice immunized 
with mPAC-6 and mPAC-2ivp restimulated 
with one another. 
 
 
 
restim. mPACivp    restim. mPAC
pg
/m
l
0
100
200
300
400
500
600
imm. mPAC-2ivp 
imm.mPAC-6 
imm. RMA 
RESULTS  65 
 
 
When mice were immunized with mPAC-6 or mPAC-2ivp and restimulated with mPAC-2ivp, 
there was at least 3 times more IFN-γ secretion compared to control mice immunized with 
RMA. When mice were immunized with mPAC-6 or mPAC-2ivp and restimulated with 
mPAC-6, there was 4 to 5 times more IFN-γ secretion compared to control mice immunized 
with RMA. 
 
To corroborate these results, a third assay was performed: the same experimental settings 
were used to analyse IFN-γ secreting lymphocytes by IFN-γ capture assay: After restimulation 
of lymphocytes the secreted IFN-γ was captured on the cells and subsequently labeled with a 
second IFN-γ specific antibody. FACS analysis of the cells counterstained with an anti-CD8+ 
antibody revealed IFN-γ secretion only of CD8+ T cells derived from mice immunized with 
mPAC-6 or mPAC-2ivp but not with control cell lines (e.g. RMA). Immunization with 
mPAC-6 resulted in 4% IFN-γ secreting CD8+ T cells after restimulation with mPAC-6 
compared to 0,9% IFN-γ positive CD8+ T cells after restimulation with mPAC-2ivp. Similar 
results were obtained after immunization with mPAC-2ivp: restimulation with mPAC-6 
resulted in 9% IFN-γ secreting CD8+ T cells and restimulation with mPAC-2ivp in 0,95%. In 
contrast to that, no significant numbers of IFN-γ secreting lymphocytes could be detected 
after immunization with RMA (Fig. 3.23 A). 
Furthermore, the IFN-γ production detected by IFN-γ capture assay was confirmed in an 
independent experiment by intracellular cytokine staining, whereby only IFN-γ produced 
inside the CD8+ T cells is detected. This explains the quantitative differences in IFN-γ 
detection between the two methods. Intracellular cytokine staining revealed after 
immunization with mPAC-6 0,6% IFN-γ secreting CD8+ T cells after restimulation with 
mPAC-6 compared to 0,3% IFN-γ positive CD8+ T cells after restimulation with mPAC-2ivp. 
Immunization with mPAC-2ivp resulted in 3% IFN-γ secreting CD8+ T cells after 
restimulation with mPAC-6 compared to 0,5% IFN-γ positive CD8+ T cells after restimulation 
with mPAC-2ivp. Lymphocytes derived from RMA-immunized control mice exhibited no 
significant IFN-γ secretion (Fig. 3.23 B). Looking at these data, it is quite obvious that the 
original mPAC is not only highly immunogenic in vivo, but acts also in vitro as the better 
stimulator compared to mPACivp. In summary, using three different experimental set ups, it 
can be suggested that mPAC and mPACivp share the same antigens. 
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Figure 3.23. Detection of mPAC-6/mPAC2-ivp specific IFN-γ secreting CD8+ T cell by IFN-γ capture assay 
(A) and by intracellular IFN-γ staining (B). Lymphocytes from mPAC-6 and mPAC-2ivp immunized mice 
were in in vitro restimulated with mPAC-6 or mPAC-2ivp and thereafter analysed for IFN-γ secretion. (A) IFN-
γ capture assay revealed a strong IFN-γ secretion of CD8+ T cells derived from mPAC-6 and mPAC-2ivp 
immunized mice but not from mice immunized with RMA cells. (B) Intracellular IFN-γ staining confirmed IFN-
γ production of CD8+ T cells derived from mPAC-6 and mPAC-2ivp immunized mice but not from mice 
immunized with RMA cells. 
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3.2.4 T cell infiltration in mPAC-6 and mPAC-2ivp derived tumors  
 
To examine, whether mPAC-2ivp- and mPAC-6 derived tumors were infiltrated with T cells, 
tumors were explanted at day seven after subcutaneous inoculation. Neither 
immunohistological nor FACS analysis of tumor infiltrating lymphocytes revealed significant 
differences concerning tumor infiltrating T cells. In both, the regressing and the progressing 
tumors, infiltration of CD4+ and CD8+ T cells was found, even though twice as much 
infiltrating CD8+ cells were identified in mPAC-6 as in mPAC-2ivp derived tumors (6% to 
3%) by FACS analysis after Collagenase/Dispase digestion of the tumors (Fig.3.24). 
 
 
 
Figure 3.24. mPAC-6- and mPAC-2ivp derived tumors were infiltrated with T cells. Day seven after 
injection of mPAC-6 and mPAC-2ivp, respectively, tumors were explanted, homogenized and digested and 
analysed by FACS for CD4+ and CD8+ T cells. 
 
 
3.2.4.1 Distinct cytokine patterns in mPAC-6 and mPAC-2ivp derived tumors 
 
Since both, mPAC-6 and mPAC-2ivp derived tumors were infiltrated with CD4+ and CD8+ T 
cells, we wanted to find out, whether the tumor infiltrating lymphocytes in their distinct 
surroundings exhibit the same functions. Tumors were explanted at day seven after injection, 
cut into small pieces and cultured over night. Culture supernatants were harvested and 
analysed for cytokines using ELISA and Cytometric Bead Array (CBA) (Fig. 3.25). CBA 
revealed that IFN-γ could only be detected in the supernatant of tumors derived from mPAC-6 
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but in none of the mPAC-2ivp derived tumors. Similarly, also no IL-12 was detected in 
mPAC-2ivp tumors. On the other hand, TNF-α was found in mPAC-6 as well as in mPAC-
2ivp derived tumors at comparable levels. [MCP-I and IL-6 were over detection limit 
(>5000pg/ml) in all samples tested.] Additional analyses of the supernatants by ELISA 
confirmed the CBA results for IFN-γ and furthermore revealed similar IL-4 levels in mPAC-6 
and mPAC-2ivp derived tumors, but a significant difference in the detected levels of IL-2. 
Supernatants of explanted mPAC-2ivp derived tumors exhibit on average sixfold higher 
levels of IL-2 than supernatants of explanted mPAC-6 derived tumors. Furthermore, 
transforming growth factor (TGF)-β and IL-10, both cytokines which can act as inhibitory 
cytokines by suppressing anti-tumor immune responses were tested in the supernatants of the 
tumors by ELISA (TGF-β) and by CBA (IL-10). Neither TGF-β nor IL-10 could be detected  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25. Cytokine profiles of mPAC-6 derived compared to mPAC-2ivp derived tumors. Explanted 
tumors were cut into small pieces and incubated in vitro. Culture supernatants of mPAC-6 derived tumors 
(mPAC, black bars) and of mPAC-2ivp derived tumors (mPACivp, grey bars) were analysed for several 
cytokines using the cytokine bead array from BD and ELISA. Cytokine quantities are depicted as pg/100mg of 
the corresponding tumor. 
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in any of the samples analysed. These data indicate, that the cytokines detected in the 
supernatant of the immunogenic mPAC-6 reflect mainly an inflammatory milieu. Analysis of 
an earlier time point after tumor injection (d 5) revealed no IFN-γ production before day 
seven, but comparable amounts of IL-12 and TNF-α. 
 
 
 
3.3 In vivo CD25+CD4+ T cell depletion  
 
To evaluate, whether regulatory CD25+CD4+ T cells were involved in dampening tumor-
specific immune responses against the escape variant mPAC-2ivp, FACS analysis of 
lymphocytes derived from draining (inguinal) lymph nodes as well as from the spleen of 
mPAC-6 or mPAC-2ivp tumor bearing mice for CD25+CD4+ T cells were performed. 
C57Bl/6 mice with progressively growing mPAC-2ivp derived tumors did not exhibit 
elevated numbers of CD25+CD4+ T cells compared to mice with regressing mPAC-6 derived 
tumors (Fig. 3.26). 
 
 
 
 
Figure 3.26. Analysis of draining lymphnodes of mPAC-6 and mPAC-2ivp derived tumors for CD25+CD4+ 
T cells. Lymphocytes from mPAC-2ivp or mPAC-6 derived tumor bearing mice were isolated and single cell 
suspensions were stained for the CD25+CD4+ T cells and were analysed by FACS.  
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In vivo depletion of CD25+CD4+ T cells before and after mPAC-2ivp inoculation did 
effectively remove the CD25+CD4+ T cell subset (Fig. 3.27), but had no influence on the 
progressive growth of mPAC-2ivp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27. In vivo depletion of CD25+CD4+ T cells. CD25+CD4+ T cells of mPAC-2ivp tumor bearing mice 
were in vivo depleted by the injection of PC61 (for detailed protocol see Material & Methods). Lymphocytes out 
of whole blood of mice were continuously analysed by FACS for CD25+CD4+ T cells using an antibody that 
does not compete with the depleting antibody for binding to CD25+CD4+ T cells.  
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3.4 Analysis of the contribution of different components of the immune 
system to tumor regression 
 
Because mPAC exhibited a regressive phenotype in immune competent wildtype mice but 
grew progressively to form lethal tumors in RAG1-/- mice, which are deficient of T, B and 
NKT cells, and with a lag phase also in athymic nu/nu mice, different components of the 
immune system were analysed. 
 
One possibility to further prove the involvement of T cells in the regression of mPAC-6 
derived tumors is to deplete the distinct T cell subsets in immune competent mice in vivo. 
Unfortunately, first experiments to in vivo deplete CD8+ and CD4+ T cells did not lead to 
conclusive results. Although the depletion-antibodies were repeatedly injected according to 
established, published protocols and T cell depletion was observed in the beginning 
(Fig.3.28), low numbers of T cells were recovered after tumor inoculation. This was true for 
both depletion approaches of CD4+ and CD8+ T cells. Due to this, it could not be evaluated 
whether the tumors regression was due to complete T cell depletion or not a complete 
depletion. 
 
Figure 3.28. In vivo 
depletion of CD4+ and 
CD8+ T cells. After 
injection of CD4+- or CD8+-
depletion antibody (for 
detailed protocol see 
Materials & Methods) 
splenocytes or lymphocytes 
out of whole blood were 
analysed by FACS using 
antibodies that do not 
compete with the distinct 
depletion antibody for 
binding to CD4+ and CD8+ 
T cell, respectively.  
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To check the contribution of NKT cells to mPAC-6 regression, mPAC-6 were s.c. inoculated 
into CD1-/- mice, which do not have CD1 dependent NKT cells. mPAC showed the same 
growth kinetics in CD1-/- as in immune competent wildtype mice: The tumor grew during the 
first ten days and then started to regress. After approximately three weeks no more tumor was 
palpable. These data suggest that  NKT cells were of minor importance in this experimental 
system. 
 
IFN-γ, as an inflammatory cytokine might play a key role in mPAC regression (Fig. 3.25). For 
that reason mPAC-6 were injected s.c. into IFN-γ-/- mice. Preliminary data indicate that 
mPAC-6 exhibited similar growth kinetics in IFN-γ-/- as in nu/nu mice: after a short growth 
stagnation the tumor progressed to form lethal tumors after 70 days, leading to the suggestion 
that IFN-γ plays an important role in the regression of mPAC-6. 
 
The different growth kinetics of mPAC-6 in RAG1-/- compared to nu/nu mice (Fig.3.6) 
indicate that B cells might also be possible candidates for participating in mPAC regression. 
Therefore, sera from mPAC tumor bearing immune competent wildtype mice were analysed  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29. mPAC-6 but not mPAC-2ivp induced humoral responses after s.c. injection into C57-Bl/6 
mice. Three weeks after injection of mPAC-6, antibodies against mPAC-6 but not against mPAC-2ivp could be 
identified in sera of mice (1:50 dilution) as shown in histogram overlay. Filled histogram represents analysis of 
sera taken before injection of mPAC. 
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for mPAC-specific antibodies. FACS analysis revealed that mPAC-6 induced humoral 
responses against mPAC-6 but not against mPAC-2ivp, while no antibody response was 
induced in mPAC-2ivp bearing mice (Fig.3.29). Sera of mice were analysed for mPAC-
specific antibodies by FACS analysis. 
 
 
Analysis of the transplantable mPAC tumor model suggests that tumor growth and regression 
underlie mechanisms involving T and B cells (and IFN-γ as important inflammatory mediator) 
that resulted in the selection of an escape variant by decreasing the expression of (an) immune 
dominant antigen(s) recognized by T and/or B cells. 
 
 
 
3.5 Generation of a GM-CSF Vaccine 
 
With the objective of developing a potent vaccine against the progressively growing mPAC-
2ivp derived tumors and to further study the possibility that mPAC-6 and the variant mPAC-
2ivp share the same antigens, a GM-CSF-expressing variant of mPAC-2ivp was generated. 
For that purpose, mPAC-2ivp was transduced with supernatant of GM-CSF-retrovirus 
(CMMP GM-CSF/IRES/GFP) producing cells. Subsequent fluorescence microscopy and 
FACS analysis revealed GFP expression of mPAC-2ivp/GM-CSF. Analysis of culture 
supernatants by ELISA showed that mPAC-2ivp/GM-CSF was secreting 2300 ng/1 x 106 
cells/24h GM-CSF (data not shown). In first vaccination studies, C57Bl/6 mice were 
immunized with irradiated mPAC-2ivp/GM-CSF and challenged after two weeks with 
mPAC-2ivp or mPAC-2ivpMHC I+. These studies showed that the mice were not protected 
from the outgrowth of mPAC-2ivp by vaccination with mPAC-2ivp/GM-CSF. Control mice 
and vaccinated mice developed tumors after injection of mPAC-2ivpMHC I- within the same 
period of time (45 days) (Fig. 3.30 A). However, the immunization with mPAC-2ivp/GM-
CSF resulted in delayed growth of the MHC class I + clone of mPAC-2ivp. Non-immunized 
control mice developed tumors with 4 mm in diameter already after 10 to 18 days and had to 
be sacrificed after 45 days, whereas GM-CSF vaccinated mice developed tumors of this size 
not before day 35 and survived until day 60 (Fig. 3.30 B). 
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Figure 3.30. Delayed outgrowth of mPAC-2ivp MHC I+ after vaccination with mPAC-2ivp/GM-CSF. Two 
weeks after immunization with mPAC-2ivp/GM-CSF mice were challenged with mPAC-2ivp MHC I+ or 
mPAC-2ivp MHC I- and the tumor growth was monitored. 
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4.1 TGF- α Trp53-/- mice as a model for immunological studies on 
pancreatic cancer 
 
Cancer is a multistep disease involving histological and genetical changes. The extensive 
studies of the genetic and molecular changes in human tumors provide the basis to understand 
how a given genetic lesion, or combination of mutations governs specific biological features 
of the disease during its evolution. Genetically engineered mouse models have contributed 
extensively to the systematic dissection of these and related issues for a number of cancer 
types (Macleod and Jacks, 1999; Van Dyke and Jacks, 2002). In contrast to transplantable 
tumor mouse models, the development of spontaneous tumors in transgenic mouse models is 
organ specific and the host is conditioned by the physiological events of neoplastic 
progression and tumorgenesis through various developmental stages. For that reasons 
information gained from studies using genetically engineered mice that develop 
autochthonous tumors are more likely transferable to the human settings. 
 
Pancreatic cancer in humans has one of the worst prognosis of all of the gastrointestinal 
cancers due to late diagnosis and lack of effective treatments. In the case of modelling cancer 
of the exocrine pancreas, transgenic mouse lines targeting a series of oncogenes to the acinar 
cell compartment have predominantly produced acinar carcinomas, mixed acinar-ductal 
tumors, or cystic tumors (Quaife et al., 1987; Ornitz et al., 1987; Sandgren et al., 1991; 
Grippo et al., 2003; Glasner et al., 1992; Mukherjee et al., 2000; Tevethia et al., 1997; 
Bardeesy et al., 2002) i.e. most of these models do not reproduce the ductal phenotype of the 
human disease. 
 
The first described murine tumor progression model for ductal pancreatic cancer that 
recapitulates the cellular differentiation, the growth characteristics, and the genetic alterations 
of the human disease is the TGF-α transgenic mouse. In this model, pancreatic cancer 
develops from premalignant lesions in TGF- α transgenic mice (Sandgren et al., 1990). 
Overexpression of TGF- α in the pancreas causes a progressive fibrosis and structural 
transition from acinar cells to tubular complexes (Sandgren et al., 1990; Jhappan et al., 1990; 
Bockman and Merlino, 1992). After a latency period for more than one year, TGF-α 
transgenic mice develop malignant pancreatic tumors with a duct-like phenotype. This is 
further characterized by a loss of acinar markers associated with a gain of duct-specific 
markers (Wagner et al., 1998). Crossbreeding these mice to p53-deficient mice accelerates 
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formation of invasive pancreatic carcinoma. Similar to the human disease, genetic events in 
tumor formation include loss of the wildtype p53 allele in heterozygous p53-deficient mice 
and inactivation of p16Ink4A. Furthermore, constitutive activation of the cyclin-D1-Cdk4 
complex and overexpression of EGFR, which induces the Ras/ERK pathway, have been 
shown (Wagner et al., 2001; Schreiner et al., 2003b; Schreiner et al., 2003a). 
 
Concerning histological and genetical correlations to the human disease, the TGF- α Trp53 
deficient mouse has been shown to be an informative animal model for ductal pancreatic 
cancer and should therefore be useful for immunological studies. Therefore, TGF-α and 
Trp53-/- mice were bred and crossed on a defined syngenic C57Bl/6 background. In the F2 
generation 100% of TGF-α Trp53-/- mice on C57Bl/6 background developed malignant 
pancreatic tumors within 124 days after birth (Fig. 3.1, 3.2). These results correspond to the 
results of Wagner et al., who performed their studies with TGF-α Trp53-/- mice on a mixed 
C57Bl/6 x BALB/c background. They showed that all TGF-α Trp53-/- on a mixed C57Bl/6 x 
BALB/c background developed pancreatic tumors within a comparable period of time (120d) 
(Wagner et al., 2001). The development of pancreatic tumors in 100% of TGF-a Trp53-/- 
mice within 124 days makes this tumor model highly feasible for laboratory investigations. 
The aim of this study was to immunologically characterize these TGF-α Trp53-/- mice to 
provide a basis for evaluating immunotherapeutic approaches against the autochthonous 
tumors. 
 
 
 
4.2 mPAC induce a strong tumor specific immune response 
 
A cell line derived from the pancreatic tumor of a TGF-α Trp53-/- mouse and thus expressing 
all potential tumor antigens provides an appropriate tool to perform immunological studies. 
Although several established murine pancreatic adenocarcinoma cell lines (mPAC) grew 
progressively in vitro, they unexpectedly showed a regressive phenotype after injection into 
syngenic immune competent C57Bl/6 mice (Fig 3.6). To rule out that the regression of mPAC 
is due to partial histoincompatibility, mPAC was injected s.c. into the F1 generation of TGF-α 
x Trp53+/- mice. In these mice mPAC exhibited the same kinetics of initial growth and 
subsequent regression as observed in C57Bl/6 wildtype mice (data not shown). For that 
reason, major and minor histocompatibility differences as cause for regression could be 
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excluded. The spontaneous regression of transplanted syngenic tumors has already been 
described for several tumor cell lines isolated from spontaneous tumors. In most of the studies 
this regression has been shown to be T cell dependent, because the tumors grew progressively 
in nu/nu mice (Gross, 1943; Old et al., 1962; Kripke, 1974; Urban et al., 1982; Martin et al., 
1983). 
Consistently, we showed that the regression of mPAC-derived tumors in C57Bl/6 mice is an 
immune regulated phenomenon. This was further defined by the differences seen in growth 
kinetics of mPAC in nu/nu mice and RAG1-/- mice (Fig. 3.6). In both immune deficient mouse 
strains mPAC derived tumors grew progressively. But compared to RAG1-/- mice a more 
delayed tumor growth could be observed in nu/nu mice. Athymic nu/nu mice still produce 
low but detectable numbers of αβ T cells (Hunig and Bevan, 1980; Ikehara et al., 1984; 
Maleckar and Sherman, 1987). Therefore, they still can manifest at least some degree of 
adaptive immunity. Furthermore, in nu/nu mice there are other lymphocyte populations such 
as NK cells, which are not thymus dependent, as well as γδ T cells and NKT cells that 
represent two subtypes of T cells, which may develop extrathymically (Hayday, 2000; Kikly 
and Dennert, 1992; Makino et al., 1993). Gene targeted mice that lack the recombinase 
activating gene RAG-1 do not have any T, B or NKT cells and exhibit no “leakiness” 
concerning their T cell deficiency. These data indicate that the regression of mPAC-derived 
tumors is T cell dependent, but a contribution of other components of the immune system 
cannot be excluded. For in vivo injection those mPAC, which showed the best in vitro growth 
kinetics compared to other murine tumor cell lines such as B16 were chosen (mPAC and B16 
showed a comparable in vitro growth rate of ∼ 1,5 in 24 h). However, the progression of 
mPAC-derived tumors stagnated shortly after injection into in nu/nu and RAG1-/- mice. 
Possible reasons for this initial growth lag of the tumors might be interactions of the tumors 
with the surrounding extracellular matrix leading to inefficient adherence of the tumor cells 
(Martin et al., 1996).  
 
The involvement of T cells in the rejection of mPAC could be further demonstrated by the 
detection of T cell responses in immune competent C57Bl/6 mice after inoculation of 
irradiated mPAC. The induction of cytotoxic responses (Fig. 3.7 A, B) and the observed IFN-
γ secretion by CD8+ T cells (Fig. 3.8) lead to the assumption that mPAC express a strong 
antigen on their surface that is recognized by CD8+ T cells. However, measurement of IFN-γ  
by intracellular cytokine staining and IFN-γ capture assay has shown that the detected IFN-γ 
was not only secreted by CD8+ T cells, but in significant amounts by other lymphocytes that 
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still need to be identified. On the one hand, components of the innate immune system, such as 
NK and NKT cells can produce IFN-γ and are known to act as effectors in anti-tumor immune 
responses (Smyth et al., 2000). On the other hand CD4+ TH1 cells, that provide critical help 
in priming CD8+ cells and are essential in the maintenance of CD8+ T cell effector functions, 
secrete cytokines such as IL-2 and IFN-γ. Furthermore, some studies have shown that CD4+ T 
cells are capable of eradication of tumors independently of CD8+ T cells (Greenberg, 1991; 
Wang, 2001) (Mumberg et al., 1999). Since mPAC do not express MHC class II the direct 
lysis of mPAC by CD4+ T cells can be excluded in our model, but a significant involvement 
of CD4 T cells in the regression of mPAC could be suggested. The CD8+ T cell dependency 
of the cytotoxic response could be further evaluated by using MHC class I positive and MHC 
class I negative mPAC as targets for CTL assay. NK cells display a subset of inhibitory 
receptors (e.g. KIR and Ly49) on their surface, which are specific for MHC class I (Colonna 
and Samaridis, 1995; Mason et al., 1995; Stoneman et al., 1995) and consequently 
spontaneously kill MHC class I deficient cells. Due to the observed MHC class I dependent 
lysis of the targets, NK cell as effectors are not very likely.  
 
Most of the transgenic mouse models for cancer overexpress a defined human antigen such as 
HER-2/neu, CEA or MUC1 (Muller et al., 1988; Eades-Perner et al., 1994; Rowse et al., 
1998). Since in our mouse model, TGF-α is overexpressed, TGF-α was suggested to be the 
potential antigen expressed by mPAC and recognized by CD8+ T cells. For that reason, 
cytotoxic T cell assays using TGF- α expressing MHC class I + targets were performed, but 
revealed no TGF-α specific lysis (Fig. 3.7 C). In addition, to rule out a possible tolerance of 
TGF-α transgenic mice towards mPAC expressing the potential antigen TGF-α, growth 
kinetics of mPAC after s.c. injection into TGF-α transgenic mice were analysed, mPAC 
derived tumors show the same regressive phenotype in TGF-α transgenic mice as in non-
transgenic wildtype control mice. These data suggest, that TGF-α can be excluded as the 
potential antigen. 
 
To determine whether existing CTLs can successfully access the mPAC derived tumors, 
tumor sections were stained for infiltrating lymphocytes and in addition, the tumor infiltrating 
lymphocytes were analysed by FACS. mPAC derived tumors were highly infiltrated by CD4+ 
and CD8+ T cells (Fig. 3.9). This was accompanied by the secretion of IFN-γ, IL-12 and TNF-
α detected in culture supernatants of the explanted tumors (Fig. 3.14). The detected cytokine 
profile underlines the inflammatory response induced by mPAC inoculation. In addition to the 
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disitinct T cell responses induced by mPAC, peripheral humoral responses against mPAC was 
found in the sera of immune competent mice after regression of mPAC derived tumors. Thus 
far our data suggest, that the highly immunogenic cell line mPAC represents a powerful tool 
to analyse immune responses in TGF-α Trp53-/- mice. 
 
 
 
4.3 Detection of mPAC specific immune responses in TGF-α Trp53-/- mice 
 
It has been shown that HER-2/neu mice are immunological tolerant against the antigen or 
against cell lines transfected with the antigen (Reilly et al., 2000). In other transgenic mouse 
lines, such as MET mice, no immunological tolerance could be observed (Mukherjee et al., 
2000). Interestingly, spontaneous immune responses could be detected in TGF-α Trp53-/- 
mice. This spontaneous immune response was characterized by CD8+ T cells that secreted 
IFN-γ after in vitro restimulation with mPAC (Fig. 3.13), but no cytotoxic activity against 
mPAC was detected. mPAC specific IFN-γ secretion could only be detected in 12-week-old 
TGF-α Trp53-/- mice but not in 6-week-old TGF-α Trp53-/- mice nor in age-matched TGF-α 
Trp53+/-control mice. These data suggest a relation between tumor progression and the 
induction of an immune response. Only those mice that already developed malignant 
pancreatic adenocarcinoma exhibited CD8+ T cell responses. Furthermore, spontaneous 
antibody responses against mPAC could be detected in sera of TGF-α Trp53-/- mice, which 
increased with progression of the autochthonous tumors (Fig. 3.15). The finding that in vitro 
restimulation of CD8+ T cells derived from 12-week-old TGFα Trp53-/- mice triggers IFN-γ 
release, but not specific lysis of the tumor cells in vitro, leads to the assumption that the CD8+ 
T cells were only partially activated. However, it was possible to induce CTL responses in 
TGFα Trp53-/- mice after vaccination, indicating that the CD8+ T cells have no general 
functional defect (data not shown). Additionally, independent of their age, TGFα Trp53-/- 
mice are able to reject transplanted mPAC derived tumors in the same manner as wildtype 
mice (data not shown). To further analyse the T cell function in TGFα Trp53-/- mice, culture 
supernatants of pancreatic tumors were analysed for cytokines. In sharp contrast to mPAC 
derived tumors, no significant levels of inflammatory cytokines could be detected in 
autochthonous tumors (Fig. 3.14). This finding was not unexpected, since tumor infiltrating 
lymphocytes were not found in autochthonous tumors at any stage of tumor development. 
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Double transgenic MET mice represent a transgenic mouse model for pancreatic cancer that 
has already been immunologically characterized. MET mice, obtained by crossing MUC1.tg 
mice with ET mice, which express a truncated form of Tag under the control of the elastase 
promotor, develop spontaneously MUC1-expressing acinar cell carcinoma in the pancreas 
(Mukherjee et al., 2000). It has been decribed that MUC1 transgenic mice develop B and T 
cell compartment tolerance and are refractory to immunization with the protein encoded by 
the trangene (Rowse et al., 1998), but non-immunized MET mice develop MUC1-specific 
CTL-precursor activity. Lysis of MUC1 expressing target cells increased with tumor 
progression. In addition, low, but detectable levels of circulating antibodies to MUC1 could 
be detected in some of the older tumor bearing mice (Mukherjee et al., 2000). These data are 
in strong correlation with the immune responses detected in TGF-α Trp53-/- mice. In both 
tumor models spontaneous cellular and humoral immune responses increasing with tumor 
burden could be observed, but although no cytotoxic lysis of mPAC could be detected in 
vitro, TGF-α Trp53-/- mice were able to reject mPAC derived tumors in vivo. 
In the MET mouse model, the adoptive transfer of CD8+ T cell lines established from MET 
mice resulted in the complete rejection of transplanted MUC1 expressing tumors in MUC1 
mice, but the direct in vivo function of these CD8+ T cells in MET mice was not shown. Thus, 
a direct comparison of the function of the tumor specific CD8+ T cells between these two 
transgenic mouse models for spontaneous pancreatic tumors is not possible. However, the 
significance of immunological studies performed with a mouse model for acinar carcinoma of 
the pancreas that does not mimic the human disease such as the MET mouse remains 
questionable. In another spontaneous tumor mouse model, the immune response against a 
transplantable tumor cell line was directly evaluated in transgenic mice bearing 
autochthonous tumors. CEA transgenic mice (tg) have been shown to be immunologically 
tolerant to CEA (Eades-Perner et al., 1994; Clarke et al., 1998). Because CEA.tg mice do not 
develop spontaneous tumors, CEA.tg mice were crossed with Apc knock out mice. The 
recently described Apc1638N/CEA mice develop spontaneous tumors expressing CEA in the 
GI tract and exhibit humoral but not T-cell tolerance to CEA. Furthermore, Apc1638N/CEA 
mice showed delayed growth of transplantable CEA-expressing tumors, as compared to 
CEA.tg mice, but the tumors grew faster in Apc1638N/CEA mice than in non-transgenic 
wildtype mice (Horig et al., 2001; Kantor et al., 1992).  
This is in contrast to the regression of mPAC in TGF-α Trp53-/- mice that we have shown to 
be comparable to the regression of mPAC in wildtype mice. The finding that TGF-α Trp53-/- 
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are able to reject the transplanted tumor cell line expressing the potential antigen might 
indicate that in this mouse model for ductal pancreatic cancer the induction of an effective 
immune response by vaccination might be more effective than in the models described above. 
 
In addition, in these spontaneous tumor models the existing CTL were unable to eradicate the 
autochthomous tumors, which resembles the situation for most cancer patients. It has been 
shown in humans and mice that immunogenic tumors can coexist with anti-tumor 
lymphocytes without any impact on tumor progression (Lee et al., 1999; Staveley-O'Carroll et 
al., 1998). Many different reports have suggested that progressing tumors have elaborated 
means of escaping an apparently effective MHC class I restricted immune response (Garrido 
et al., 1997; Algarra et al., 1997; Cabrera et al., 1996; Hicklin et al., 1998). Others have found 
that the CTL response occurs too late to be effective against the established tumor (Toes et al., 
1996). Another reason for the escape of the autochthonous tumor might be that the induced T 
cells are low avidity T cells (Kawai and Ohashi, 1995; Hausmann et al., 1999). Defective 
lymphocyte homing to the tumor could be another explanation for the failure of CTLs to 
control tumor growth (Onrust et al., 1996). Alternatively, efficient anti-tumor CTL acticity 
may initially be induced but then declines (Speiser et al., 1997). Other reports demonstrate 
tumor escape is likely due to limited degree of cross-presentation in the regional lymph nodes, 
which would result in insufficient numbers of activated tumor-specific T cells to protect the 
host from tumor growth (Nguyen et al., 2002) or due to the overwhelming ratio of antigen-
bearing tumor cells relative to tumor-specific CTL (Hanson et al., 2000; Nelson et al., 2001). 
Our data imply that the CTL do not enter the tumor matrix and are therefore not able to 
prevent tumor growth. An approach to address this issue in our tumor model is to adoptively 
transfer lymphocytes derived from mPAC primed immune competent mice into TGF-α 
Trp53-/- mice. These lymphocytes should be labelled in a way that they can be easily 
recovered in the TGF-α Trp53-/- mice to obtain conclusive results concerning failure in 
lymphocyte homing to the autochthonous tumors. However, preliminary results from one 
experiment using TGF-α Trp53-/- mice, demonstrated that the adoptively transferred 
lymphocytes did not invade into the autochthonous tumors. Further experiments are needed to 
complete these studies. Nevertheless, TGF-α Trp53-/- mice represent an excellent model to 
investigate phenomena of immune escape. 
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4.4 Selection of the variant mPAC-2ivp: insights into mechanisms of 
tumor growth and regression 
 
We have shown that when mPAC derived tumors were injected into immune competent mice, 
they regressed within 21 days after injection, but grew progressively, even though with a short 
delay, when injected into RAG1-/- mice. Therefore, these pancreatic tumor cell lines consist of 
potentially malignant cells that can be used to study the relative importance of different 
immune surveillance mechanisms that may function in immune competent animals. As a 
consequence of malignant transformation, malignant cells acquire genetic instability and 
within the tumor phenotypic variants may arise that exhibit selective growth advantages 
(Nowell, 1976). These variants can escape immunological or other homeostatic control 
mechanisms of the host and become the precursors of a newly emerging subpoplation that 
now become dominant (Urban et al., 1982). The tumor variant mPAC-2ivp did arise 
spontaneously in a normal immune competent C57Bl/6 mouse from the regressive growing 
pancreatic adenocarcinoma cell line mPAC. Injection of mPAC-2ivp cells produced 
progressively growing tumors in 100% of the immune competent syngenic mice (Fig. 3.16), 
thereby demonstrating the heritable nature of the progressive growth of the newly isolated 
tumor mPAC-2ivp. The establishment of the new cell line mPAC-2ivp provides the 
opportunity to analyse possible escape mechanism of solid tumors in a fast growing 
transplantation tumor model. 
 
The first issue to address was to analyse the influence of MHC class expression on 
progressive tumor growth of mPAC-2ivp. The MHC class I – cell line mPAC-2ivp and its 
MHC class I + clone exhibited comparable in vivo growth kinetics after s.c. injection into 
normal mice (Fig. 3.18). Independent of their status of MHC class I expression, all tumors 
grew progressively to form lethal tumors, indicating that loss or down-regulation of MHC 
class I seems not to be the mechanism that led to the immune escape of mPAC-2ivp.  
 
To examine whether mPAC-6 and the variant mPAC-2ivp share the same potent CTL antigen, 
in vivo and in vitro experiments were performed. Triggering the immune system of C57Bl/6 
mice by the s.c. inoculation of mPAC-6 did lead to impaired growth of a second challenge 
with mPAC-6 (Fig. 3.19 A), emphasizing once again the immunogenic phenotype of the 
original cell line mPAC-6, but did not prevent the progressive growth of the variant mPAC-
2ivp (Fig.3.19 B). This immunological unresponsiveness of the mPAC-6-primed mice 
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towards challenge with mPAC-2ivp suggests that mPAC-6 and mPAC-2ivp do not express 
the same antigens on their surface. Moreover, mice already bearing the progressive growing 
variant mPAC-2ivp did not tolerate the growth of mPAC-6 (Fig. 3.19 C). Other studies have 
shown with comparable experiments that their regressive and progressive variants of the same 
tumor are immunologically related (Caignard et al., 1985).  
 
Analysing the induction of immune responses after inoculation of mPAC-6 or mPAC-2ivp led 
to different results. CTL assays performed with mPAC-6 or mPAC-2ivp as restimulators and 
targets revealed cross-reactivity of the two variants. A mutual and clearly MHC class I 
dependent cytotoxic activity could be shown for almost all conditions analysed (Fig. 3.21, 
Tab. 3.2). The analysis of CTL supernatants showed that only lymphocytes derived from mice 
immunized with mPAC-6 or mPAC-2ivp and not with irrelevant tumor cell lines secrete IFN-
γ upon restimulation with one of the variants (Fig. 3.22). Measurement of IFN-γ either by 
intracellular cytokine staining or by capture assay have shown that a significant amount of 
IFN-γ is secreted by CD8+ T cells (Fig. 3.23). This indicates that mPAC-6 and the variant 
mPAC-2ivp can induce in vivo cellular responses against the same antigens. Both, mPAC-6 
and mPAC-2ivp could be used as mutual restimulators and targets in CTL. The regressive 
phenotype of mPAC-6 in immune competent mice showed that mPAC-6 is highly 
immunogenic in vivo. This is supported by the CTL data, showing that in mice immunized 
with mPAC-6 stronger immune responses are induced as in those mice immunized with 
mPAC-2ivp. Furthermore, the three different ways of analysing IFN-γ secretion (ELISA, IFN-
γ capture assay, intracellular staining) all reveal that mPAC-6 acts also as the better stimulator 
in vitro. These results suggest that the escape variant mPAC-2ivp has not lost but down-
regulated the expression of the immune dominant antigen, otherwise lymphocytes derived 
from mice immunized with mPAC-2ivp would not recognize mPAC-6 in vitro. In human 
cancers decreased expression of tumor antigens have also been described to be associated 
with disease progression (de Vries et al., 1997). A decreased expression of the potential 
antigen in mPAC-2ivp might not be sufficient for tumor recognition and subsequent rejection 
but the antigen could be effectively cross-presented to CD8+ T cells by APCs to induce the 
immune response detected in CTL and IFN-γ assays. This could also explain the results of the 
injection of mPAC-6 and mPAC-2ivp into the same animal (Fig. 3.19). However, the data 
cannot rule out the possibility that the antigen recognized in CTL on mPAC-2ivp is not the 
same as the potential immunodominant antigen that is recognized in vivo and leads to the 
rejection of mPAC-6. It has been shown in the extensive studies by Schreiber et al. that 
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progressively growing variants can lose their original tumor-specific transplantation antigen 
but can thereby retain their sensitivity to cross-reactive CTL-mediated killing in vitro, 
implicating that the CTL-recognized antigens detected in vitro are not necessarily the targets 
for rejection in vivo (Urban et al., 1982; Ward et al., 1990; Mumberg et al., 1996). It has been 
also reported that lack of cross-protection is not necessarily due to lack of a shared tumor 
antigen (Ramarathinam et al., 1995). More detailed studies are required to address this issue. 
 
To examine, whether the induction of CTLs by the original mPAC-6 and the escape variant 
mPAC-2ivp leads to infiltration of T cells into tumors, immunohistological and FACS 
analysis of tumor infiltrating lymphocytes were performed. Surprisingly, infiltration of CD4+ 
and CD8+ T cells was found in mPAC-6 as well as in mPAC-2ivp derived tumors, even 
though twice as much infiltrating CD8+ cells were identified in mPAC-6 as in mPAC-2ivp 
derived tumors (6% to 3% [Fig. 3.24]). Tumors can be infiltrated by T cells but the T cells in 
the tumor might be impaired in their function as effector cells. Therefore, supernatants of 
explanted mPAC-2ivp derived tumors were analysed in comparison to mPAC-6 derived 
tumors for cytokine secretion. Looking at the cytokine profile of the distinct tumors revealed 
a significant difference: One of the most important mediators for inflammation, IFN-γ could 
only be detected in the supernatants of mPAC-6 derived tumors and in none of the 
progressive growing mPAC-2ivp derived tumors. In accordance with this, IL-12, known to 
induce IFN-γ secretion, could also only be detected in mPAC-6 tumors. However, TNF-α and 
IL-4 were found in both tumor types at comparable levels. The only cytokine detected at 
significant higher levels in mPAc-2ivp derived tumors was IL-2 (Fig. 3.25).  
 
Mice deficient for IFN-γ or IFN-γ receptor have been shown to be more susceptible to the 
formation of tumors (Kaplan et al., 1998; Street et al., 2002; Qin et al., 2003; Nakajima et al., 
2001). Because significant levels of IFN-γ were detected in mPAC-6 derived tumors but not 
in the progressive mPAC-2ivp derived or autochthonous tumors, mPAC-6 was injected into 
IFN-γ-/- mice. Preliminary experiments point out that IFN-γ plays an important role in the 
regression of mPAC-6, because in IFN-γ-/- mice mPAC-6 derived tumors showed progressive 
growth kinetics comparable to nu/nu mice. 
 
The prevalence of IL-2 in mPAC-2ivp derived tumors might be an evidence for the 
involvement of CD25+CD4+ regulatory T cells in dampening tumor-specific immune 
responses against the escape variant mPAC-2ivp (Liyanage et al., 2002; Woo et al., 2001; 
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Woo et al., 2002). Compared to mPAC-6 tumor bearing mice, mPAC-2ivp tumor bearing 
mice did not exhibit elevated numbers of CD25+CD4+ regulatory T cells (Fig. 3.26). To 
evaluate a possible functional difference between the CD25+CD4+ regulatory T cells 
populations in the distinct mice, CD25+CD4+ regulatory T cells were depleted in mPAC-2ivp 
tumor bearing mice (Fig. 3.27), but did not result in spontaneous tumor-specific CTL and NK 
cell cytotoxicity and subsequent tumor eradication as it has been shown for other tumor 
models (Shimizu et al., 1999; Onizuka et al., 1999). The production of inhibitory cytokines as 
mechanism for tumor escape from immunologic destruction could be excluded, because 
neither TGF-β nor IL-10 could be detected in the supernatant of tumors isolated from mPAC-
2ivp bearing mice.  
 
In summary, the loss of immunogenicity of the variant mPAC-2ivp most likely seems be the 
result of decreased expression of the immune dominant antigen. This idea was strongly 
supported by the fact that only mPAC-6 could induce humoral responses against mPAC-6 but 
not against mPAC-2ivp, while no antibody response at all is induced in mPAC-2ivp bearing 
mice (Fig. 3.29). That antibodies specific for mPAC-6 did not bind to mPAC-2ivp leads to the 
suggestion that mPAC-2ivp has lost the expression of a certain surface antigen. This appears 
to be constistent with the different growth kinetics of mPAC-6 seen in RAG1-/- compared to 
nu/nu mice (Fig. 3.6), indicating that B cells might also be possible candidates for 
participating in mPAC regression and emphasizing once again the role of CD4 cells in this 
model. 
 
Antibody-induced down-modulation of the target antigen has been reported for a number of 
cell surface receptors and represents a relatively rapid event occurring immediately after 
antibody exposure (Sorkin and Waters, 1993). Vesicles internalising the receptors fuse with 
lysosomes, which results in increased degradation and reduced steady state levels of the 
receptor. This has already been shown in a number of studies on the human epidermal growth 
factor receptor HER-2/neu or ErbB-2. The loss of HER-2/neu expression by down-
modulation significantly inhibits growth and causes reversal of the transformed phenotype of 
the tumor (Drebin et al., 1985; Klapper et al., 1997; Baselga, 2001). It has been shown in 
TGF-α transgenic mice that overexpression of TGF-α results in up-regulation of its receptor 
EGFR (Wagner et al., 1998). Activation of epidermal growth factor receptor results in potent 
signals of cell proliferation, survival, invasion, and angiogenisis (Olayioye et al., 2000). 
Considering the hypothesis that mPAC regresses because of antibody-induced down-
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modulation of EGFR it would not explain why the variant mPAC-2ivp that potentially has 
lost the surface expression of EGFR is still surviving and progressively growing.  
 
Another reason why mPAC regression cannot solely be dependent on B cells is the 
progressive growth of mPAC derived tumors in nu/nu mice that are described to exhibit 
significant B cell function. Thus, the regression of mPAC and moreover the escape of mPAC-
2ivp are more likely due to a interaction of B and T cells. Similar to that, in transgenic mouse 
models for mammary adenocarcinoma overexpressing HER-2/neu conflicting results exists 
with regard to the role of antibodies/B cell versus T cells in tumor rejection in HER-2/neu 
based vaccination approaches. On the one hand, the need for cooperation between humoral 
and cellular immunity was reported, on the other hand specific antibodies generated by 
different vaccination protocols were found to correlate with immunity against spontaneous 
tumors (Reilly et al., 2001; Wolpoe et al., 2003; Nanni et al., 2001; De Giovanni et al., 2004). 
 
To further evaluate the mechanisms leading to growth and regression of mPAC-2ivp and 
mPAC, respectively, different components of the innate immune system were analysed. 
Therefore, mPAC-6 was injected into NKT cell deficient CD1-/- mice. mPAC-6 showed the 
same regressive phenotype in CD1-/- mice as observed in immune competent wildtype mice 
(data not shown). For that reason, NKT cells seem not to be the key component of the 
immune system leading to the regression of mPAC. As an important actor in antibody-
dependent cell mediated cytotoxicity (ADCC), NK cells recognize IgG antibody coated cells 
via their FcγRIII receptor (Ravetch and Perussia, 1989; Lanier et al., 1989; Perussia et al., 
1984). Compared to RAG1-/- mice a more delayed tumor growth could be observed in nu/nu 
mice after injection of the original mPAC (Fig 3.6). Nu/nu exhibit significant B cell functions 
and also NK cells are unaffected in nu/nu mice. To rule out, whether ADCC might contribute 
to the regression of mPAC and therefore might explain the difference seen between the 
growth of mPAC in nu/nu compared to RAG1-/- mice, mPAC was injected into SCID.beige 
mice that lack T, B, NKT and NK cells. mPAC showed comparable growth kinetics in 
SCID.beige mice as in RAG1-/- mice, indicating that NK cells seem not to be very likely the 
main components of the immune system leading to the regression of mPAC. In vivo depletion 
of NK cells should be performed to further evaluate the contribution of NK cells to tumor 
regression. 
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In conclusion, analysis of the transplantable mPAC tumor model suggests that tumor growth 
and regression underlie mechanisms involving T and B cells (and IFN-γ as important 
inflammatory mediator). These mechanisms are suggested to result in the selection of an 
escape variant by decreasing the expression of (an) immune dominant antigen(s) recognized 
by T and/or B cells. Further studies should help to clarify the role of the distinct lymphocyte 
populations. In vivo depletion of single or combined lymphocyte subsets represent one 
possible route. Another approach to identify the potential immunodominant antigen might be 
searching for decreased expressed gene products in mPACivp compared with mPAC by gene 
expression profiling. 
 
 
The results obtained from our extensive study on mPAC-6 and the variant mPAC-2ivp should 
be conclusive to understand the mechanisms leading to the escape of the autochthonous 
tumors in TGF-α Trp53-/- mice from immune destruction. Decreased antigen expression 
might also be the mechanism leading to the escape of the solid pancreatic tumors as proposed 
for tumors derived from the progressively growing variant mPAC-2ivp. The production of 
inhibitory cytokines such as IL-10 could be excluded for the transplanted as well as for the 
autochthonous tumors as a possible mechanism, but in contrast to tumors derived from 
mPAC-2ivp, the autochthonous tumors were not infiltrated by neither CD4+ nor CD8+ T cells. 
This observation suggests that the tumor stroma and the lymphocytes in the TGF-α Trp53-/- 
mice need to be further investigated (see paragraph 4.3). In addition, we did not find 
quantitative differences concerning CD25+CD4+ T cell populations in TGF-α Trp53-/- mice 
compared to wildtype littermate control mice. In vivo depletion of this lymphocyte subset 
should give us further information, whether in this mouse model for pancreatic 
adenocarcinoma CD25+CD4+ T cells play an important role in suppression of an effective 
anti-tumor response.  
 
Furthermore, immunotherapy approaches could be established and primarily evaluated in the 
transplantable tumor model before they would be transferred to the spontaneous tumor model. 
Studies in other spontaneous tumor models have shown that in most models only a very 
extensive immunization protocol led to reduced tumor burden and significantly improved 
long term survival. Recently published promising approaches include combination of a 
poxvirus-based vaccine with a triad of costimulatory molecules (TRICOM) + GM-CSF or in 
combination with an anti-inflammatory drug in CEA.Tg/min mice (Greiner et al., 2002; 
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Zeytin et al., 2004), vaccination with dendritic cells fused with tumor cells in MTT mice (Xia 
et al., 2003; Chen et al., 2003) and in APC mice (Iinuma et al., 2004), combination of T-cell 
therapy and irradiation or protein vaccination with CpG-ODN as adjuvant in RIP1-Tag5 mice 
(Ganss et al., 2002; Garbi et al., 2004) and IL-12-engineered allogenic cell vaccines in HER-
2/neu.tg mice (De Giovanni et al., 2004). 
 
Our data provide the first insights into tumor specific cellular and humoral immune responses 
induced in a novel murine model for ductal pancreatic adenocarcinoma. The careful 
evaluation of the different vaccination studies mentioned above should help us to develop 
suitable immune therapeutic approaches against the autochthonous tumors in TGF-α Trp53-/- 
mice. 
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Pancreatic adenocarcinoma is a fatal disease. Immunotherapy could prove to be a valuable 
therapeutic option, however, until today no appropriate animal model has been available to 
test this. TGF-α Trp53-/- mice develop pancreatic adenocarcinoma within 124 days after birth. 
Histological examination of these tumors reveal typical structures of ductal pancreatic 
adenocarcinoma with irregular cellular morphology mimicking the human disease. In this 
study, TGF-α Trp53-/- mice were crossed on C57Bl/6 background and it was demonstrated 
that these mice provide a suitable model to test immunotherapeutic approaches against ductal 
pancreatic adenocarcinoma.  
 
Several murine pancreatic adenocarcinoma cell lines (mPAC) derived from tumors of TGF-α 
Trp53-/- mice were generated. These cell lines showed a regressive phenotype after injection 
into C57Bl/6 mice. The regression was immune mediated, since after subcutaneous 
inoculation into immune deficient mice, mPAC grew slow but progressively to form lethal 
tumors. The more delayed growth of mPAC-6 in nu/nu mice compared to the growth in 
RAG1-/- indicates the contribution of T and B cells to tumor regression. Further studies 
demonstrated that inoculation of immune competent C57Bl/6 mice with mPAC-6 induced 
tumor-specific humoral and CTL responses. The shown cytotoxic responses were consistent 
with the detected IFN-γ secretion of CD8+ T cells.  
 
TGF-α Trp53-/- mice with sponataneous ductal pancreatic adenocarcinoma were also 
analysed. These mice developed tumor-specific cellular and humoral immune responses 
which were only found in tumor bearing mice but not in mice with premalignant lesions. 
Despite the spontaneous tumor-specific immune responses, no tumor infiltrating lymphocytes 
could be detected at any stage of tumor development in TGF-α Trp53-/- mice.  
 
Finally, an in vivo passaged variant mPAC-2ivp was generated, which showed reproducible 
progressive in vivo growth in immune competent C57Bl/6 mice. Although mPAC-2ivp 
induced no humoral tumor-specific responses, a cross-reactive cytotoxicity with mPAC-6 
could be detected, indicating that the escape variant mPAC-2ivp has not lost but might exhibit 
decreased expression of immune dominant antigen(s). Furthermore, our data suggest that 
neither loss of MHC class I expression, nor the secretion of inhibitory cytokines or the 
presence of regulatory T cells are the mechanisms that have led to the escape of mPAC-2ivp.  
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These extensive studies on mice with spontaneously developing pancreatic adenocarcinoma, 
on the spontaneous tumor-specific immune responses as well as on the transplantable mPAC 
tumor model provide a powerful tool to characterize the mechanisms leading to the escape of 
the autochthonous tumors and furthermore to develop suitable immunotherapeutic approaches 
in TGF-α Trp53-/- mice against murine pancreatic adenocarcinoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
6 REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES  91 
 
 
 
Acres,B., Apostolopoulos,V., Balloul,J.M., Wreschner,D., Xing,P.X., Ali-Hadji,D., Bizouarne,N., Kieny,M.P., 
and McKenzie,I.F. (2000). MUC1-specific immune responses in human MUC1 transgenic mice immunized with 
various human MUC1 vaccines. Cancer Immunol. Immunother. 48, 588-594. 
Adams,T.E., Alpert,S., and Hanahan,D. (1987). Non-tolerance and autoantibodies to a transgenic self antigen 
expressed in pancreatic beta cells. Nature 325, 223-228. 
Aguirre,A.J., Bardeesy,N., Sinha,M., Lopez,L., Tuveson,D.A., Horner,J., Redston,M.S., and DePinho,R.A. 
(2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal 
adenocarcinoma. Genes Dev. 17, 3112-3126. 
Ahrendt,S.A. and Pitt,H.A. (2002). Surgical management of pancreatic cancer. Oncology (Huntingt) 16, 725-734. 
Alarcon-Vargas,D. and Ronai,Z. (2002). p53-Mdm2--the affair that never ends. Carcinogenesis 23, 541-547. 
Albert,M.L., Sauter,B., and Bhardwaj,N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce 
class I-restricted CTLs. Nature 392, 86-89. 
Algarra,I., Collado,A., and Garrido,F. (1997). Altered MHC class I antigens in tumors. Int. J. Clin. Lab Res. 27, 
95-102. 
Antonia,S.J., Seigne,J., Diaz,J., Muro-Cacho,C., Extermann,M., Farmelo,M.J., Friberg,M., Alsarraj,M., 
Mahany,J.J., Pow-Sang,J., Cantor,A., and Janssen,W. (2002). Phase I trial of a B7-1 (CD80) gene modified 
autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell 
carcinoma. J. Urol. 167, 1995-2000. 
Asher,A.L., Mule,J.J., Kasid,A., Restifo,N.P., Salo,J.C., Reichert,C.M., Jaffe,G., Fendly,B., Kriegler,M., and 
Rosenberg,S.A. (1991). Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence 
for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227-3234. 
Ashley,D.M., Faiola,B., Nair,S., Hale,L.P., Bigner,D.D., and Gilboa,E. (1997). Bone marrow-generated dendritic 
cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system 
tumors. J. Exp. Med. 186, 1177-1182. 
Azuma,M., Cayabyab,M., Phillips,J.H., and Lanier,L.L. (1993). Requirements for CD28-dependent T cell-
mediated cytotoxicity. Journal of Immunology 150, 2091-101. 
Bachelier,R., Xu,X., Wang,X., Li,W., Naramura,M., Gu,H., and Deng,C.X. (2003). Normal lymphocyte 
development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene 22, 528-537. 
Bakker,A.B., Schreurs,M.W., de Boer,A.J., Kawakami,Y., Rosenberg,S.A., Adema,G.J., and Figdor,C.G. (1994). 
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. 
Exp. Med. 179, 1005-1009. 
Baldwin,R.W. (1955). Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and 
regression of the implanted tumours. Br. J. Cancer 9, 652-657. 
Banchereau,J., Palucka,A.K., Dhodapkar,M., Burkeholder,S., Taquet,N., Rolland,A., Taquet,S., Coquery,S., 
Wittkowski,K.M., Bhardwaj,N., Pineiro,L., Steinman,R., and Fay,J. (2001). Immune and clinical responses in 
patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-
6458. 
Banchereau,J. and Steinman,R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252. 
Bardeesy,N. and DePinho,R.A. (2002). Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909. 
Bardeesy,N., Morgan,J., Sinha,M., Signoretti,S., Srivastava,S., Loda,M., Merlino,G., and DePinho,R.A. (2002). 
Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol. Cell 
Biol. 22, 635-643. 
REFERENCES  92 
 
 
Baselga,J. (2001). Clinical trials of Herceptin(R) (trastuzumab). Eur. J. Cancer 37 Suppl 1, 18-24. 
Baskar,S., Nabavi,N., Glimcher,L.H., and Ostrand-Rosenberg,S. (1993). Tumor cells expressing major 
histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. 
Immunother. 14, 209-215. 
Basombrio,M.A. (1970). Search for common antigenicities among twenty-five sarcomas induced by 
methylcholanthrene. Cancer Res. 30, 2458-2462. 
Basombrio,M.A. and Prehn,R.T. (1972). Studies on the basis for diversity and time of appearance of antigens in 
chemically induced tumors. Natl. Cancer Inst. Monogr 35, 117-124. 
Baumel,H., Huguier,M., Manderscheid,J.C., Fabre,J.M., Houry,S., and Fagot,H. (1994). Results of resection for 
cancer of the exocrine pancreas: a study from the French Association of Surgery. Br. J. Surg. 81, 102-107. 
Belli,F., Testori,A., Rivoltini,L., Maio,M., Andreola,G., Sertoli,M.R., Gallino,G., Piris,A., Cattelan,A., Lazzari,I., 
Carrabba,M., Scita,G., Santantonio,C., Pilla,L., Tragni,G., Lombardo,C., Arienti,F., Marchiano,A., Queirolo,P., 
Bertolini,F., Cova,A., Lamaj,E., Ascani,L., Camerini,R., Corsi,M., Cascinelli,N., Lewis,J.J., Srivastava,P., and 
Parmiani,G. (2002). Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock 
protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180. 
Bennett,S.R., Carbone,F.R., Karamalis,F., Flavell,R.A., Miller,J.F., and Heath,W.R. (1998). Help for cytotoxic-
T-cell responses is mediated by CD40 signalling. Nature 393, 478-480. 
Blachere,N.E., Li,Z., Chandawarkar,R.Y., Suto,R., Jaikaria,N.S., Basu,S., Udono,H., and Srivastava,P.K. (1997). 
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte 
response and tumor immunity. J. Exp. Med. 186, 1315-1322. 
Blankenstein,T., Qin,Z.H., Uberla,K., Muller,W., Rosen,H., Volk,H.D., and Diamantstein,T. (1991). Tumor 
suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 173, 1047-1052. 
Blasband,A.J., Rogers,K.T., Chen,X.R., Azizkhan,J.C., and Lee,D.C. (1990). Characterization of the rat 
transforming growth factor alpha gene and identification of promoter sequences. Mol. Cell Biol. 10, 2111-2121. 
Bockman,D.E. and Merlino,G. (1992). Cytological changes in the pancreas of transgenic mice overexpressing 
transforming growth factor alpha. Gastroenterology 103, 1883-1892. 
Boon,T. (1993). Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific 
immunotherapy. Int. J. Cancer 54, 177-180. 
Boon,T., Coulie,P.G., and Van den,E.B. (1997). Tumor antigens recognized by T cells. Immunol. Today 18, 267-
268. 
Brichard,V., Van Pel,A., Wolfel,T., Wolfel,C., De Plaen,E., Lethe,B., Coulie,P., and Boon,T. (1993). The 
tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. 
J. Exp. Med. 178, 489-495. 
Bringman,T.S., Lindquist,P.B., and Derynck,R. (1987). Different transforming growth factor-alpha species are 
derived from a glycosylated and palmitoylated transmembrane precursor. Cell 48, 429-440. 
Brunner,C., Seiderer,J., Schlamp,A., Bidlingmaier,M., Eigler,A., Haimerl,W., Lehr,H.A., Krieg,A.M., 
Hartmann,G., and Endres,S. (2000). Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-
guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. 
Immunol. 165, 6278-6286. 
Bruns,C.J., Harbison,M.T., Davis,D.W., Portera,C.A., Tsan,R., McConkey,D.J., Evans,D.B., Abbruzzese,J.L., 
Hicklin,D.J., and Radinsky,R. (2000). Epidermal growth factor receptor blockade with C225 plus gemcitabine 
results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic 
mechanisms. Clin. Cancer Res. 6, 1936-1948. 
Burnet,F.M. (1970). The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27. 
REFERENCES  93 
 
 
Cabrera,T., Angustias,F.M., Sierra,A., Garrido,A., Herruzo,A., Escobedo,A., Fabra,A., and Garrido,F. (1996). 
High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 50, 127-134. 
Caignard,A., Martin,M.S., Michel,M.F., and Martin,F. (1985). Interaction between two cellular subpopulations of 
a rat colonic carcinoma when inoculated to the syngeneic host. Int. J. Cancer 36, 273-279. 
Carr-Brendel,V., Markovic,D., Ferrer,K., Smith,M., Taylor-Papadimitriou,J., and Cohen,E.P. (2000). Immunity 
to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice 
tolerant to human MUC-1. Cancer Res. 60, 2435-2443. 
Cayeux,S., Beck,C., Aicher,A., Dorken,B., and Blankenstein,T. (1995). Tumor cells cotransfected with 
interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong 
vaccines. Eur. J. Immunol. 25, 2325-2331. 
Cerwenka,A., Bakker,A.B., McClanahan,T., Wagner,J., Wu,J., Phillips,J.H., and Lanier,L.L. (2000). Retinoic 
acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12, 721-
727. 
Cerwenka,A., Baron,J.L., and Lanier,L.L. (2001). Ectopic expression of retinoic acid early inducible-1 gene 
(RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad 
Sci U. S. A 98, 11521-11526. 
Chang,F., Syrjanen,S., and Syrjanen,K. (1995). Implications of the p53 tumor-suppressor gene in clinical 
oncology. J. Clin. Oncol 13, 1009-1022. 
Chaux,P., Lethe,B., Van Snick,J., Corthals,J., Schultz,E.S., Cambiaso,C.L., Boon,T., and van der,B.P. (2001). A 
MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells. Eur. J. Immunol. 31, 1910-1916. 
Chaux,P., Vantomme,V., Stroobant,V., Thielemans,K., Corthals,J., Luiten,R., Eggermont,A.M., Boon,T., and van 
der,B.P. (1999). Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. 
J. Exp. Med. 189, 767-778. 
Chen,D., Xia,J., Tanaka,Y., Chen,H., Koido,S., Wernet,O., Mukherjee,P., Gendler,S.J., Kufe,D., and Gong,J. 
(2003). Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive 
carcinoma cells. Immunology 109, 300-307. 
Chen,L., Ashe,S., Brady,W.A., Hellstrom,I., HELLSTROM,K.E., Ledbetter,J.A., McGowan,P., and Linsley,P.S. 
(1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 
and CTLA-4. Cell 71, 1093-1102. 
Chen,Q., Daniel,V., Maher,D.W., and Hersey,P. (1994). Production of IL-10 by melanoma cells: examination of 
its role in immunosuppression mediated by melanoma. Int. J. Cancer 56, 755-760. 
Chen,W., Frank,M.E., Jin,W., and Wahl,S.M. (2001). TGF-beta released by apoptotic T cells contributes to an 
immunosuppressive milieu. Immunity. 14, 715-725. 
Chen,Y.T., Scanlan,M.J., Sahin,U., Tureci,O., Gure,A.O., Tsang,S., Williamson,B., Stockert,E., 
Pfreundschuh,M., and Old,L.J. (1997). A testicular antigen aberrantly expressed in human cancers detected by 
autologous antibody screening. Proc Natl Acad Sci U S A 94, 1914-8. 
Chiodoni,C., Paglia,P., Stoppacciaro,A., Rodolfo,M., Parenza,M., and Colombo,M.P. (1999). Dendritic cells 
infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 
ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T 
lymphocyte 
response. J Exp Med 190, 125-33. 
Clarke,P., Mann,J., Simpson,J.F., Rickard-Dickson,K., and Primus,F.J. (1998). Mice transgenic for human 
carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58, 1469-1477. 
Coley,W.B. (1893). The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of 
ten original cases. The American Journal of the Medical Sciences 105, 487-510. 
REFERENCES  94 
 
 
Colonna,M. and Samaridis,J. (1995). Cloning of immunoglobulin-superfamily members associated with HLA-C 
and HLA-B recognition by human natural killer cells. Science 268, 405-408. 
Condon,C., Watkins,S.C., Celluzzi,C.M., Thompson,K., and Falo,L.D., Jr. (1996). DNA-based immunization by 
in vivo transfection of dendritic cells. Nat. Med. 2, 1122-1128. 
Conry,R.M., Curiel,D.T., Strong,T.V., Moore,S.E., Allen,K.O., Barlow,D.L., Shaw,D.R., and LoBuglio,A.F. 
(2002). Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B 
surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8, 2782-2787. 
Coulie,P.G., Brichard,V., Van Pel,A., Wolfel,T., Schneider,J., Traversari,C., Mattei,S., De Plaen,E., Lurquin,C., 
Szikora,J.P., and . (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T 
lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42. 
Cox,A.L., Skipper,J., Chen,Y., Henderson,R.A., Darrow,T.L., Shabanowitz,J., Engelhard,V.H., Hunt,D.F., and 
Slingluff,C.L.Jr. (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell 
lines. Science 264, 716-719. 
Cubilla,A.L. and Fitzgerald,P.J. (1976). Morphological lesions associated with human primary invasive 
nonendocrine pancreas cancer. Cancer Res. 36, 2690-2698. 
Darlington,G.J., Tsai,C.C., Samuelson,L.C., Gumucio,D.L., and Meisler,M.H. (1986). Simultaneous expression 
of salivary and pancreatic amylase genes in cultured mouse hepatoma cells. Mol. Cell Biol. 6, 969-975. 
Darnell,R.B. and Posner,J.B. (2003). Observing the invisible: successful tumor immunity in humans. Nat. 
Immunol. 4, 201. 
Davidson,W.F., Giese,T., and Fredrickson,T.N. (1998). Spontaneous development of plasmacytoid tumors in 
mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187, 1825-1838. 
Davila,E., Kennedy,R., and Celis,E. (2003). Generation of antitumor immunity by cytotoxic T lymphocyte 
epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63, 3281-
3288. 
Day,J.D., Digiuseppe,J.A., Yeo,C., Lai-Goldman,M., Anderson,S.M., Goodman,S.N., Kern,S.E., and 
Hruban,R.H. (1996). Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma 
and pancreatic intraepithelial neoplasms. Hum. Pathol. 27, 119-124. 
De Giovanni,C., Nicoletti,G., Landuzzi,L., Astolfi,A., Croci,S., Comes,A., Ferrini,S., Meazza,R., Iezzi,M., Di 
Carlo,E., Musiani,P., Cavallo,F., Nanni,P., and Lollini,P.L. (2004). Immunoprevention of HER-2/neu transgenic 
mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 64, 4001-4009. 
De Plaen,E., Lurquin,C., Van Pel,A., Mariame,B., Szikora,J.P., Wolfel,T., Sibille,C., Chomez,P., and Boon,T. 
(1988). Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and 
identification of the tum- mutation. Proc. Natl. Acad Sci U. S. A 85, 2274-2278. 
de Vries,T.J., Fourkour,A., Wobbes,T., Verkroost,G., Ruiter,D.J., and van Muijen,G.N. (1997). Heterogeneous 
expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines 
and in human melanocytic lesions. Cancer Res. 57, 3223-3229. 
Derynck,R. (1988). Transforming growth factor alpha. Cell 54, 593-595. 
Diefenbach,A., Jamieson,A.M., Liu,S.D., Shastri,N., and Raulet,D.H. (2000). Ligands for the murine NKG2D 
receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1, 119-126. 
Diefenbach,A., Jensen,E.R., Jamieson,A.M., and Raulet,D.H. (2001). Rae1 and H60 ligands of the NKG2D 
receptor stimulate tumour immunity. Nature 413, 165-171. 
Digiuseppe,J.A., Hruban,R.H., Goodman,S.N., Polak,M., van den Berg,F.M., Allison,D.C., Cameron,J.L., and 
Offerhaus,G.J. (1994a). Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. 
101, 684-688. 
REFERENCES  95 
 
 
Digiuseppe,J.A., Hruban,R.H., Offerhaus,G.J., Clement,M.J., van den Berg,F.M., Cameron,J.L., and van 
Mansfeld,A.D. (1994b). Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient 
with a family history of pancreatic carcinoma. Am. J. Pathol. 144, 889-895. 
Disis,M.L., Bernhard,H., Shiota,F.M., Hand,S.L., Gralow,J.R., Huseby,E.S., Gillis,S., and Cheever,M.A. (1996). 
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. 
Blood 88, 202-10. 
Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J., Montgomery,C.A., Jr., Butel,J.S., and Bradley,A. 
(1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 
215-221. 
Dranoff,G. (2002). GM-CSF-based cancer vaccines. Immunol. Rev. 188, 147-154. 
Dranoff,G., Jaffee,E., Lazenby,A., Golumbek,P., Levitsky,H., Brose,K., Jackson,V., Hamada,H., Pardoll,D., and 
Mulligan,R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-
macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. 
Natl. Acad Sci U. S. A 90, 3539-3543. 
Drebin,J.A., Link,V.C., Stern,D.F., Weinberg,R.A., and Greene,M.I. (1985). Down-modulation of an oncogene 
protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706. 
Dudley,M.E., Wunderlich,J.R., Robbins,P.F., Yang,J.C., Hwu,P., Schwartzentruber,D.J., Topalian,S.L., 
Sherry,R., Restifo,N.P., Hubicki,A.M., Robinson,M.R., Raffeld,M., Duray,P., Seipp,C.A., Rogers-Freezer,L., 
Morton,K.E., Mavroukakis,S.A., White,D.E., and Rosenberg,S.A. (2002). Cancer regression and autoimmunity in 
patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854. 
Duenas-Carrera,S. (2004). DNA vaccination against hepatitis C. Curr. Opin. Mol. Ther. 6, 146-150. 
Dunn,G.P., Bruce,A.T., Ikeda,H., Old,L.J., and Schreiber,R.D. (2002). Cancer immunoediting: from 
immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998. 
Dunn,G.P., Old,L.J., and Schreiber,R.D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 
22, 329-360. 
Eades-Perner,A.M., van der,P.H., Hirth,A., Thompson,J., Neumaier,M., von Kleist,S., and Zimmermann,W. 
(1994). Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression 
pattern. Cancer Res. 54, 4169-4176. 
Ehrlich,P. (1909). Über den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5, 273-90. 
Elgert,K.D., Alleva,D.G., and Mullins,D.W. (1998). Tumor-induced immune dysfunction: the macrophage 
connection. J. Leukoc. Biol. 64, 275-290. 
Fan,Z. and Mendelsohn,J. (1998). Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. 
Oncol 10, 67-73. 
Finn,O.J., Jerome,K.R., Henderson,R.A., Pecher,G., Domenech,N., Magarian-Blander,J., and Barratt-Boyes,S.M. 
(1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61-89. 
Fisk,B., Blevins,T.L., Wharton,J.T., and Ioannides,C.G. (1995). Identification of an immunodominant peptide of 
HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 
2109-2117. 
Foley,E.J. (1953). Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. 
Cancer Res. 13, 835-837. 
Fong,L., Brockstedt,D., Benike,C., Breen,J.K., Strang,G., Ruegg,C.L., and Engleman,E.G. (2001). Dendritic cell-
based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167, 7150-7156. 
Fong,L. and Engleman,E.G. (2000). Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273. 
REFERENCES  96 
 
 
Foy,T.M., Bannink,J., Sutherland,R.A., McNeill,P.D., Moulton,G.G., Smith,J., Cheever,M.A., and Grabstein,K. 
(2001). Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing 
murine tumor. Vaccine 19, 2598-2606. 
Gansbacher,B., Bannerji,R., Daniels,B., Zier,K., Cronin,K., and Gilboa,E. (1990a). Retroviral vector-mediated 
gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer 
Res. 50, 7820-7825. 
Gansbacher,B., Zier,K., Daniels,B., Cronin,K., Bannerji,R., and Gilboa,E. (1990b). Interleukin 2 gene transfer 
into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224. 
Ganss,R. and Hanahan,D. (1998). Tumor microenvironment can restrict the effectiveness of activated antitumor 
lymphocytes. Cancer Res. 58, 4673-4681. 
Ganss,R., Ryschich,E., Klar,E., Arnold,B., and Hammerling,G.J. (2002). Combination of T-cell therapy and 
trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462-1470. 
Gao,Y., Yang,W., Pan,M., Scully,E., Girardi,M., Augenlicht,L.H., Craft,J., and Yin,Z. (2003). Gamma delta T 
cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198, 433-442. 
Garbi,N., Arnold,B., Gordon,S., Hammerling,G.J., and Ganss,R. (2004). CpG motifs as proinflammatory factors 
render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172, 5861-5869. 
Garrido,F. and Algarra,I. (2001). MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 
83, 117-158. 
Garrido,F., Ruiz-Cabello,F., Cabrera,T., Perez-Villar,J.J., Lopez-Botet,M., Duggan-Keen,M., and Stern,P.L. 
(1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. 
Today 18, 89-95. 
Gastman,B.R., Atarshi,Y., Reichert,T.E., Saito,T., Balkir,L., Rabinowich,H., and Whiteside,T.L. (1999). Fas 
ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T 
lymphocytes. Cancer Res. 59, 5356-5364. 
Gendler,S.J. and Mukherjee,P. (2001). Spontaneous adenocarcinoma mouse models for immunotherapy. Trends 
Mol. Med. 7, 471-475. 
Girardi,M., Glusac,E., Filler,R.B., Roberts,S.J., Propperova,I., Lewis,J., Tigelaar,R.E., and Hayday,A.C. (2003). 
The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different 
stages of chemically induced skin cancer. J. Exp. Med. 198, 747-755. 
Girardi,M., Oppenheim,D.E., Steele,C.R., Lewis,J.M., Glusac,E., Filler,R., Hobby,P., Sutton,B., Tigelaar,R.E., 
and Hayday,A.C. (2001). Regulation of cutaneous malignancy by gammadelta T cells. Science 294, 605-609. 
Girling,A., Bartkova,J., Burchell,J., Gendler,S., Gillett,C., and Taylor-Papadimitriou,J. (1989). A core protein 
epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in 
a range of primary carcinomas. Int. J. Cancer 43, 1072-1076. 
Gjertsen,M.K., Bakka,A., Breivik,J., Saeterdal,I., Solheim,B.G., Soreide,O., Thorsby,E., and Gaudernack,G. 
(1995). Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma 
patients carrying the corresponding RAS mutation. Lancet 346, 1399-1400. 
Gjertsen,M.K., Buanes,T., Rosseland,A.R., Bakka,A., Gladhaug,I., Soreide,O., Eriksen,J.A., Moller,M., 
Baksaas,I., Lothe,R.A., Saeterdal,I., and Gaudernack,G. (2001). Intradermal ras peptide vaccination with 
granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients 
with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450. 
Glasner,S., Memoli,V., and Longnecker,D.S. (1992). Characterization of the ELSV transgenic mouse model of 
pancreatic carcinoma. Histologic type of large and small tumors. Am. J. Pathol. 140, 1237-1245. 
REFERENCES  97 
 
 
Globerson,A. and Feldman,M. (1964). Antigenic specificity of benzo(A)pyrene-induced sarcomas. J. Natl. 
Cancer Inst. 32, 1229-1243. 
Godfrey,D.I., Hammond,K.J., Poulton,L.D., Smyth,M.J., and Baxter,A.G. (2000). NKT cells: facts, functions and 
fallacies. Immunol. Today 21, 573-583. 
Goggins,M., Hruban,R.H., and Kern,S.E. (2000). BRCA2 is inactivated late in the development of pancreatic 
intraepithelial neoplasia: evidence and implications. Am. J. Pathol. 156, 1767-1771. 
Golumbek,P.T., Lazenby,A.J., Levitsky,H.I., Jaffee,L.M., Karasuyama,H., Baker,M., and Pardoll,D.M. (1991). 
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716. 
Gong,J., Chen,D., Kashiwaba,M., and Kufe,D. (1997). Induction of antitumor activity by immunization with 
fusions of dendritic and carcinoma cells. Nat. Med. 3, 558-561. 
Gorelik,L. and Flavell,R.A. (2001). Immune-mediated eradication of tumors through the blockade of 
transforming growth factor-beta signaling in T cells. Nat. Med. 7, 1118-1122. 
Gorer,P.A. (1956). Some recent work on tumor immunity. Adv. Cancer Res. 4, 149-186. 
Goydos,J.S., Elder,E., Whiteside,T.L., Finn,O.J., and Lotze,M.T. (1996). A phase I trial of a synthetic mucin 
peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-
304. 
Graf,L.H., Jr., Kaplan,P., and Silagi,S. (1984). Efficient DNA-mediated transfer of selectable genes and 
unselected sequences into differentiated and undifferentiated mouse melanoma clones. Somat. Cell Mol. Genet. 
10, 139-151. 
Graffi,A., Pasternak,G., and Horn,K.H. (1964). The production of resistance against isologous transplants of 
ultraviolet-induced sarcomas in mice. Acta Biol. Med. Ger 12, 726-728. 
Grayson,J.M., Lanier,J.G., Altman,J.D., and Ahmed,R. (2001). The role of p53 in regulating antiviral T cell 
responses. J. Immunol. 167, 1333-1337. 
Greenberg,P.D. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and 
elimination of tumor cells. Adv. Immunol. 49, 281-355. 
Greenblatt,M.S., Bennett,W.P., Hollstein,M., and Harris,C.C. (1994). Mutations in the p53 tumor suppressor 
gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878. 
Greiner,J.W., Zeytin,H., Anver,M.R., and Schlom,J. (2002). Vaccine-based therapy directed against 
carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of 
autoimmunity. Cancer Res. 62, 6944-6951. 
Greten,T.F. and Jaffee,E.M. (1999). Cancer vaccines. J. Clin. Oncol. 17, 1047-1060. 
Grippo,P.J., Nowlin,P.S., Demeure,M.J., Longnecker,D.S., and Sandgren,E.P. (2003). Preinvasive pancreatic 
neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res. 63, 
2016-2019. 
Gross,L. (1943). Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the 
same line. Cancer Res. 3, 326-333. 
Hanahan,D. (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing 
recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122. 
Hanke,T., McMichael,A.J., Mwau,M., Wee,E.G., Ceberej,I., Patel,S., Sutton,J., Tomlinson,M., and Samuel,R.V. 
(2002). Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 20, 1995-1998. 
REFERENCES  98 
 
 
Hanson,H.L., Donermeyer,D.L., Ikeda,H., White,J.M., Shankaran,V., Old,L.J., Shiku,H., Schreiber,R.D., and 
Allen,P.M. (2000). Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13, 
265-276. 
Hartmann,G., Weeratna,R.D., Ballas,Z.K., Payette,P., Blackwell,S., Suparto,I., Rasmussen,W.L., 
Waldschmidt,M., Sajuthi,D., Purcell,R.H., Davis,H.L., and Krieg,A.M. (2000). Delineation of a CpG 
phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. 
Immunol. 164, 1617-1624. 
Hausmann,S., Martin,M., Gauthier,L., and Wucherpfennig,K.W. (1999). Structural features of autoreactive TCR 
that determine the degree of degeneracy in peptide recognition. J. Immunol. 162, 338-344. 
Hayakawa,Y., Kelly,J.M., Westwood,J.A., Darcy,P.K., Diefenbach,A., Raulet,D., and Smyth,M.J. (2002). 
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. 
Immunol. 169, 5377-5381. 
Hayday,A.C. (2000). [gamma][delta] cells: a right time and a right place for a conserved third way of protection. 
Annu. Rev. Immunol. 18, 975-1026. 
Hicklin,D.J., Wang,Z., Arienti,F., Rivoltini,L., Parmiani,G., and Ferrone,S. (1998). beta2-Microglobulin 
mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest 101, 2720-2729. 
Hock,H., Dorsch,M., Diamantstein,T., and Blankenstein,T. (1991). Interleukin 7 induces CD4+ T cell-dependent 
tumor rejection. J. Exp. Med. 174, 1291-1298. 
Hoglund,P., Ljunggren,H.G., Ohlen,C., Ahrlund-Richter,L., Scangos,G., Bieberich,C., Jay,G., KLEIN,G., and 
Karre,K. (1988). Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J. 
Exp. Med. 168, 1469-1474. 
Hollstein,M., Sidransky,D., Vogelstein,B., and Harris,C.C. (1991). p53 mutations in human cancers. Science 253, 
49-53. 
Hong,S., Wilson,M.T., Serizawa,I., Wu,L., Singh,N., Naidenko,O.V., Miura,T., Haba,T., Scherer,D.C., Wei,J., 
Kronenberg,M., Koezuka,Y., and Van Kaer,L. (2001). The natural killer T-cell ligand alpha-galactosylceramide 
prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7, 1052-1056. 
Hopert,A., Uphoff,C.C., Wirth,M., Hauser,H., and Drexler,H.G. (1993). Specificity and sensitivity of polymerase 
chain reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell 
lines. J. Immunol. Methods 164, 91-100. 
Horig,H., Wainstein,A., Long,L., Kahn,D., Soni,S., Marcus,A., Edelmann,W., Kucherlapati,R., and 
Kaufman,H.L. (2001). A new mouse model for evaluating the immunotherapy of human colorectal cancer. 
Cancer Res. 61, 8520-8526. 
Hruban,R.H., Adsay,N.V., Albores-Saavedra,J., Compton,C., Garrett,E.S., Goodman,S.N., Kern,S.E., 
Klimstra,D.S., Kloppel,G., Longnecker,D.S., Luttges,J., and Offerhaus,G.J. (2001). Pancreatic intraepithelial 
neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-
586. 
Hruban,R.H., Goggins,M., Parsons,J., and Kern,S.E. (2000). Progression model for pancreatic cancer. Clin. 
Cancer Res. 6, 2969-2972. 
Hsu,F.J., Benike,C., Fagnoni,F., Liles,T.M., Czerwinski,D., Taidi,B., Engleman,E.G., and Levy,R. (1996). 
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-
58. 
Hsueh,E.C., Gupta,R.K., Qi,K., and Morton,D.L. (1998). Correlation of specific immune responses with survival 
in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16, 
2913-2920. 
REFERENCES  99 
 
 
Huang,A.Y., Golumbek,P., Ahmadzadeh,M., Jaffee,E., Pardoll,D., and Levitsky,H. (1994). Role of bone marrow-
derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965. 
Huang,A.Y., Gulden,P.H., Woods,A.S., Thomas,M.C., Tong,C.D., Wang,W., Engelhard,V.H., Pasternack,G., 
Cotter,R., Hunt,D., Pardoll,D.M., and Jaffee,E.M. (1996). The immunodominant major histocompatibility 
complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. 
Proc Natl Acad Sci U S A 93, 9730-5. 
Hunig,T. and Bevan,M.J. (1980). Specificity of cytotoxic T cells from athymic mice. J. Exp. Med. 152, 688-702. 
Ibe,S., Qin,Z., Schuler,T., Preiss,S., and Blankenstein,T. (2001). Tumor rejection by disturbing tumor stroma cell 
interactions. J. Exp. Med. 194, 1549-1559. 
Iinuma,T., Homma,S., Noda,T., Kufe,D., Ohno,T., and Toda,G. (2004). Prevention of gastrointestinal tumors 
based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest 113, 1307-1317. 
Ikehara,S., Pahwa,R.N., Fernandes,G., Hansen,C.T., and Good,R.A. (1984). Functional T cells in athymic nude 
mice. Proc. Natl. Acad Sci U. S. A 81, 886-888. 
Inge,T.H., Hoover,S.K., Susskind,B.M., Barrett,S.K., and Bear,H.D. (1992). Inhibition of tumor-specific 
cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 52, 1386-1392. 
Irvine,K.R., McCabe,B.J., Rosenberg,S.A., and Restifo,N.P. (1995). Synthetic oligonucleotide expressed by a 
recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 154, 4651-4657. 
Jacks,T., Remington,L., Williams,B.O., Schmitt,E.M., Halachmi,S., Bronson,R.T., and Weinberg,R.A. (1994). 
Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7. 
Jaffee,E.M., Abrams,R., Cameron,J., Donehower,R., Duerr,D., Gossett,J., Greten,T., Grochow,L., Hruban,R., 
Kern,S., Lillemoe,K.D., O’Reilly,S., Pardoll,D.M., Sauter,S., Weber,C., and Yeo,Y. (1998). A Phase I Clinical 
Trial of  Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the 
Treatment of Pancreatic Adenocarcinoma. Hum. Gene Therapy 9, 1951-71. 
Jaffee,E.M., Hruban,R.H., Biedrzycki,B., Laheru,D., Schepers,K., Sauter,P.R., Goemann,M., Coleman,J., 
Grochow,L., Donehower,R.C., Lillemoe,K.D., O'Reilly,S., Abrams,R.A., Pardoll,D.M., Cameron,J.L., and 
Yeo,C.J. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for 
pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156. 
Jäger,E., Chen,Y.T., Drijfhout,J.W., Karbach,J., Ringhoffer,M., Jager,D., Arand,M., Wada,H., Noguchi,Y., 
Stockert,E., Old,L.J., and Knuth,A. (1998). Simultaneous Humoral and Cellular Immune Response Against 
Cancer-Testis Antigen Ny-Eso-1 - Definition Of Human Histocompatibility Leukocyte Antigen (HLA)-A2-
Binding Peptide Epitopes. Journal of Experimental Medicine 187, 265-270. 
Jager,E., Jager,D., Karbach,J., Chen,Y.T., Ritter,G., Nagata,Y., Gnjatic,S., Stockert,E., Arand,M., Old,L.J., and 
Knuth,A. (2000). Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-
DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. 
J. Exp. Med. 191, 625-630. 
Jager,E., Jager,D., and Knuth,A. (1999). CTL-defined cancer vaccines: perspectives for active 
immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 18, 143-150. 
Jamieson,A.M., Diefenbach,A., McMahon,C.W., Xiong,N., Carlyle,J.R., and Raulet,D.H. (2002). The role of the 
NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 17, 19-29. 
Janetzki,S., Palla,D., Rosenhauer,V., Lochs,H., Lewis,J.J., and Srivastava,P.K. (2000). Immunization of cancer 
patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer 88, 
232-238. 
Janeway,C.A. and Travers,P. (2001). Immunobiology. Garland, New York and London). 
REFERENCES  100 
 
 
Jemal,A., Murray,T., Samuels,A., Ghafoor,A., Ward,E., and Thun,M.J. (2003). Cancer statistics, 2003. CA 
Cancer J. Clin. 53, 5-26. 
Jhappan,C., Stahle,C., Harkins,R.N., Fausto,N., Smith,G.H., and Merlino,G.T. (1990). TGF alpha overexpression 
in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 
61, 1137-1146. 
Kantor,J., Irvine,K., Abrams,S., Kaufman,H., DiPietro,J., and Schlom,J. (1992). Antitumor activity and immune 
responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84, 
1084-1091. 
Kaplan,D.H., Shankaran,V., Dighe,A.S., Stockert,E., Aguet,M., Old,L.J., and Schreiber,R.D. (1998). 
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. 
Natl. Acad Sci U. S. A 95, 7556-7561. 
Karre,K., Ljunggren,H.G., Piontek,G., and Kiessling,R. (1986). Selective rejection of H-2-deficient lymphoma 
variants suggests alternative immune defence strategy. Nature 319, 675-678. 
Kass,E., Schlom,J., Thompson,J., Guadagni,F., Graziano,P., and Greiner,J.W. (1999). Induction of protective 
host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a 
recombinant vaccinia-CEA virus. Cancer Res. 59, 676-683. 
Kawai,K. and Ohashi,P.S. (1995). Immunological function of a defined T-cell population tolerized to low-affinity 
self antigens. Nature 374, 68-69. 
Kawakami,Y., Eliyahu,S., Delgado,C.H., Robbins,P.F., Rivoltini,L., Topalian,S.L., Miki,T., and Rosenberg,S.A. 
(1994a). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells 
infiltrating into tumor. Proc. Natl. Acad Sci U. S. A 91, 3515-3519. 
Kawakami,Y., Eliyahu,S., Sakaguchi,K., Robbins,P.F., Rivoltini,L., Yannelli,J.R., Appella,E., and 
Rosenberg,S.A. (1994b). Identification of the immunodominant peptides of the MART-1 human melanoma 
antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-
352. 
Kawakami,Y., Okada,T., and Akada,M. (2004). Development of immunotherapy for pancreatic cancer. Pancreas 
28, 320-325. 
Kawarada,Y., Ganss,R., Garbi,N., Sacher,T., Arnold,B., and Hammerling,G.J. (2001). NK- and CD8(+) T cell-
mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. 
Immunol. 167, 5247-5253. 
Kikly,K. and Dennert,G. (1992). Evidence for extrathymic development of TNK cells. NK1+ CD3+ cells 
responsible for acute marrow graft rejection are present in thymus-deficient mice. J. Immunol. 149, 403-412. 
Kittlesen,D.J., Thompson,L.W., Gulden,P.H., Skipper,J.C., Colella,T.A., Shabanowitz,J., Hunt,D.F., 
Engelhard,V.H., Slingluff,C.L., Jr., and Shabanowitz,J.A. (1998). Human melanoma patients recognize an HLA-
A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine 
development. J. Immunol. 160, 2099-2106. 
Klapper,L.N., Vaisman,N., Hurwitz,E., Pinkas-Kramarski,R., Yarden,Y., and Sela,M. (1997). A subclass of 
tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. 
Oncogene 14, 2099-2109. 
Klein,G., Sjogren,H.O., Klein,E., and Hellstrom,K.E. (1960). Demonstration of resistance against 
methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572. 
Ko,L.J. and Prives,C. (1996). p53: puzzle and paradigm. Genes Dev. 10, 1054-1072. 
Koido,S., Kashiwaba,M., Chen,D., Gendler,S., Kufe,D., and Gong,J. (2000). Induction of antitumor immunity by 
vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165, 5713-5719. 
REFERENCES  101 
 
 
Krackhardt,A.M., Witzens,M., Harig,S., Hodi,F.S., Zauls,A.J., Chessia,M., Barrett,P., and Gribben,J.G. (2002). 
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100, 2123-2131. 
Krieg,A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760. 
Krieg,A.M. (2003). CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9, 831-835. 
Kripke,M.L. (1974). Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 53, 
1333-1336. 
Laheru,D., Biedrzycki,B., and Jaffee,E.M. (2001). Immunologic approaches to the management of pancreatic 
cancer. Cancer J. 7, 324-337. 
Lane,D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16. 
Lanier,L.L., Cwirla,S., Yu,G., Testi,R., and Phillips,J.H. (1989). Membrane anchoring of a human IgG Fc 
receptor (CD16) determined by a single amino acid. Science 246, 1611-1613. 
Lee,D.C., Rose,T.M., Webb,N.R., and Todaro,G.J. (1985). Cloning and sequence analysis of a cDNA for rat 
transforming growth factor-alpha. Nature 313, 489-491. 
Lee,P., Wang,F., Kuniyoshi,J., Rubio,V., Stuges,T., Groshen,S., Gee,C., Lau,R., Jeffery,G., Margolin,K., 
Marty,V., and Weber,J. (2001). Effects of interleukin-12 on the immune response to a multipeptide vaccine for 
resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847. 
Lee,P.P., Yee,C., Savage,P.A., Fong,L., Brockstedt,D., Weber,J.S., Johnson,D., Swetter,S., Thompson,J., 
Greenberg,P.D., Roederer,M., and Davis,M.M. (1999). Characterization of circulating T cells specific for tumor-
associated antigens in melanoma patients. Nat. Med. 5, 677-685. 
Levitsky,H.I., Lazenby,A., Hayashi,R.J., and Pardoll,D.M. (1994). In vivo priming of two distinct antitumor 
effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224. 
Li,D., Xie,K., Wolff,R., and Abbruzzese,J.L. (2004). Pancreatic cancer. Lancet 363, 1049-1057. 
Liyanage,U.K., Moore,T.T., Joo,H.G., Tanaka,Y., Herrmann,V., Doherty,G., Drebin,J.A., Strasberg,S.M., 
Eberlein,T.J., Goedegebuure,P.S., and Linehan,D.C. (2002). Prevalence of regulatory T cells is increased in 
peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 
169, 2756-2761. 
Lollini,P.L. and Forni,G. (2002). Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. 
Immunother. 51, 409-416. 
Lurquin,C., Van Pel,A., Mariame,B., De Plaen,E., Szikora,J.P., Janssens,C., Reddehase,M.J., Lejeune,J., and 
Boon,T. (1989). Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide 
recognized with Ld by cytolytic T cells. Cell 58, 293-303. 
Mackay,C.R. (1993). Immunological memory. Adv. Immunol. 53, 217-265. 
Mackensen,A., Herbst,B., Chen,J.L., Kohler,G., Noppen,C., Herr,W., Spagnoli,G.C., Cerundolo,V., and 
Lindemann,A. (2000). Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells 
generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86, 385-392. 
Macleod,K.F. and Jacks,T. (1999). Insights into cancer from transgenic mouse models. J. Pathol. 187, 43-60. 
Maio,M., Fonsatti,E., Lamaj,E., Altomonte,M., Cattarossi,I., Santantonio,C., Melani,C., Belli,F., Arienti,F., 
Colombo,M.P., and Parmiani,G. (2002). Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-
transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. 
Cancer Immunol. Immunother. 51, 9-14. 
Makino,Y., Yamagata,N., Sasho,T., Adachi,Y., Kanno,R., Koseki,H., Kanno,M., and Taniguchi,M. (1993). 
Extrathymic development of V alpha 14-positive T cells. J. Exp. Med. 177, 1399-1408. 
REFERENCES  102 
 
 
Maleckar,J.R. and Sherman,L.A. (1987). The composition of the T cell receptor repertoire in nude mice. J. 
Immunol. 138, 3873-3876. 
Mandelboim,O., Berke,G., Fridkin,M., FELDMAN,M., Eisenstein,M., and Eisenbach,L. (1994). CTL induction 
by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67-71. 
Manici,S., Sturniolo,T., Imro,M.A., Hammer,J., Sinigaglia,F., Noppen,C., Spagnoli,G., Mazzi,B., Bellone,M., 
Dellabona,P., and Protti,M.P. (1999). Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in 
association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189, 871-876. 
Marchand,M., Punt,C.J., Aamdal,S., Escudier,B., Kruit,W.H., Keilholz,U., Hakansson,L., van Baren,N., 
Humblet,Y., Mulders,P., Avril,M.F., Eggermont,A.M., Scheibenbogen,C., Uiters,J., Wanders,J., Delire,M., 
Boon,T., and Stoter,G. (2003). Immunisation of metastatic cancer patients with MAGE-3 protein combined with 
adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39, 70-77. 
Marchand,M., Weynants,P., Rankin,E., Arienti,F., Belli,F., Parmiani,G., Cascinelli,N., Bourlond,A., 
Vanwijck,R., Humblet,Y., and . (1995). Tumor regression responses in melanoma patients treated with a peptide 
encoded by gene MAGE-3. Int. J. Cancer 63, 883-885. 
Marshall,J.L., Hoyer,R.J., Toomey,M.A., Faraguna,K., Chang,P., Richmond,E., Pedicano,J.E., Gehan,E., 
Peck,R.A., Arlen,P., Tsang,K.Y., and Schlom,J. (2000). Phase I study in advanced cancer patients of a diversified 
prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox 
virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol 18, 3964-3973. 
Martin,F., Caignard,A., Jeannin,J.F., Leclerc,A., and Martin,M. (1983). Selection by trypsin of two sublines of rat 
colon cancer cells forming progressive or regressive tumors. Int. J. Cancer 32, 623-627. 
Martin,M., Ahlen,K., Dimanche-Boitrel,M.T., Mendrick,D.L., Turner,D.C., Rubin,K., and Martin,F. (1996). 
Colon-cancer cell variants producing regressive tumors in syngeneic rats, unlike variants yielding progressive 
tumors, attach to interstitial collagens through integrin alpha2beta1. Int. J. Cancer 65, 796-804. 
Maruvada,P. and Levine,A.E. (1999). Increased transforming growth factor-alpha levels in human colon 
carcinoma cell lines over-expressing protein kinase C. Int. J. Cancer 80, 72-77. 
Marx,J. (1994). New link found between p53 and DNA repair. Science 266, 1321-1322. 
Mason,L.H., Ortaldo,J.R., Young,H.A., Kumar,V., Bennett,M., and Anderson,S.K. (1995). Cloning and 
functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2). 
J. Exp. Med. 182, 293-303. 
Matsui,Y., Halter,S.A., Holt,J.T., Hogan,B.L., and Coffey,R.J. (1990). Development of mammary hyperplasia 
and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61, 1147-1155. 
Mayordomo,J.I., Loftus,D.J., Sakamoto,H., De Cesare,C.M., Appasamy,P.M., Lotze,M.T., Storkus,W.J., 
Appella,E., and DeLeo,A.B. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-
based vaccines. J. Exp. Med. 183, 1357-1365. 
McCabe,B.J., Irvine,K.R., Nishimura,M.I., Yang,J.C., Spiess,P.J., Shulman,E.P., Rosenberg,S.A., and 
Restifo,N.P. (1995). Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor 
cytolytic T lymphocyte responses. Cancer Res. 55, 1741-1747. 
McConkey,S.J., Reece,W.H., Moorthy,V.S., Webster,D., Dunachie,S., Butcher,G., Vuola,J.M., Blanchard,T.J., 
Gothard,P., Watkins,K., Hannan,C.M., Everaere,S., Brown,K., Kester,K.E., Cummings,J., Williams,J., 
Heppner,D.G., Pathan,A., Flanagan,K., Arulanantham,N., Roberts,M.T., Roy,M., Smith,G.L., Schneider,J., 
Peto,T., Sinden,R.E., Gilbert,S.C., and Hill,A.V. (2003). Enhanced T-cell immunogenicity of plasmid DNA 
vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735. 
Meszoely,I.M., Means,A.L., Scoggins,C.R., and Leach,S.D. (2001). Developmental aspects of early pancreatic 
cancer. Cancer J. 7, 242-250. 
Mitchell,M.S. (2002). Cancer vaccines, a critical review--Part I. Curr. Opin. Investig. Drugs 3, 140-149. 
REFERENCES  103 
 
 
Miyamoto,K., Miyake,S., and Yamamura,T. (2001). A synthetic glycolipid prevents autoimmune 
encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413, 531-534. 
Mohr,S., Leikauf,G.D., Keith,G., and Rihn,B.H. (2002). Microarrays as cancer keys: an array of possibilities. J. 
Clin. Oncol. 20, 3165-3175. 
Morel,P.A. and Oriss,T.B. (1998). Crossregulation between Th1 and Th2 cells. Crit Rev. Immunol. 18, 275-303. 
Moser,A.R., Pitot,H.C., and Dove,W.F. (1990). A dominant mutation that predisposes to multiple intestinal 
neoplasia in the mouse. Science 247, 322-324. 
Moskaluk,C.A., Hruban,R.H., and Kern,S.E. (1997). p16 and K-ras gene mutations in the intraductal precursors 
of human pancreatic adenocarcinoma. Cancer Res. 57, 2140-2143. 
Mukherjee,P., Ginardi,A.R., Madsen,C.S., Sterner,C.J., Adriance,M.C., Tevethia,M.J., and Gendler,S.J. (2000). 
Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when 
adoptively transferred. J. Immunol. 165, 3451-3460. 
Muller,W.J., Sinn,E., Pattengale,P.K., Wallace,R., and Leder,P. (1988). Single-step induction of mammary 
adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115. 
Mumberg,D., Monach,P.A., Wanderling,S., Philip,M., Toledano,A.Y., Schreiber,R.D., and Schreiber,H. (1999). 
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. 
Natl. Acad Sci U. S. A 96, 8633-8638. 
Mumberg,D., Wick,M., and Schreiber,H. (1996). Unique tumor antigens redefined as mutant tumor-specific 
antigens. Semin. Immunol. 8, 289-293. 
Nakajima,C., Uekusa,Y., Iwasaki,M., Yamaguchi,N., Mukai,T., Gao,P., Tomura,M., Ono,S., Tsujimura,T., 
Fujiwara,H., and Hamaoka,T. (2001). A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with 
the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. 
Cancer Res. 61, 3399-3405. 
Nanni,P., Nicoletti,G., De Giovanni,C., Landuzzi,L., Di Carlo,E., Cavallo,F., Pupa,S.M., Rossi,I., Colombo,M.P., 
Ricci,C., Astolfi,A., Musiani,P., Forni,G., and Lollini,P.L. (2001). Combined allogeneic tumor cell vaccination 
and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 
1195-1205. 
Nelson,D.J., Mukherjee,S., Bundell,C., Fisher,S., van Hagen,D., and Robinson,B. (2001). Tumor progression 
despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. 
Immunol. 166, 5557-5566. 
Nestle,F.O., Alijagic,S., Gilliet,M., Sun,Y., Grabbe,S., Dummer,R., Burg,G., and Schadendorf,D. (1998). 
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332. 
Nestle,F.O., Banchereau,J., and Hart,D. (2001). Dendritic cells: On the move from bench to bedside. Nat. Med. 7, 
761-765. 
Nguyen,L.T., Elford,A.R., Murakami,K., Garza,K.M., Schoenberger,S.P., Odermatt,B., Speiser,D.E., and 
Ohashi,P.S. (2002). Tumor growth enhances cross-presentation leading to limited T cell activation without 
tolerance. J. Exp. Med. 195, 423-435. 
Nielsen,S.E., Zeuthen,J., Lund,B., Persson,B., Alenfall,J., and Hansen,H.H. (2000). Phase I study of single, 
escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or 
pancreatic carcinoma. J. Immunother. 23, 146-153. 
Nishihara,T., Sawada,T., Yamamoto,A., Yamashita,Y., Ho,J.J., Kim,Y.S., and Chung,K.H. (2000). Antibody-
dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for 
pancreatic cancer. Jpn. J. Cancer Res. 91, 817-824. 
Nowell,P.C. (1976). The clonal evolution of tumor cell populations. Science 194, 23-28. 
REFERENCES  104 
 
 
Ochsenbein,A.F., Klenerman,P., Karrer,U., Ludewig,B., Pericin,M., Hengartner,H., and Zinkernagel,R.M. 
(1999). Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad 
Sci U. S. A 96, 2233-2238. 
Ochsenbein,A.F., Sierro,S., Odermatt,B., Pericin,M., Karrer,U., Hermans,J., Hemmi,S., Hengartner,H., and 
Zinkernagel,R.M. (2001). Roles of tumour localization, second signals and cross priming in cytotoxic T-cell 
induction. Nature 411, 1058-1064. 
Olayioye,M.A., Neve,R.M., Lane,H.A., and Hynes,N.E. (2000). The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO J. 19, 3159-3167. 
Old,L.J., Boyse,E.A.C.D.A., and Carswell E.A. (1962). Antigenic properties of chemically-induced tumors. Ann 
NY Acad Sci 101, 80-106. 
Onizuka,S., Tawara,I., Shimizu,J., Sakaguchi,S., Fujita,T., and Nakayama,E. (1999). Tumor rejection by in vivo 
administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59, 3128-3133. 
Onrust,S.V., Hartl,P.M., Rosen,S.D., and Hanahan,D. (1996). Modulation of L-selectin ligand expression during 
an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest 97, 54-64. 
Ornitz,D.M., Hammer,R.E., Messing,A., Palmiter,R.D., and Brinster,R.L. (1987). Pancreatic neoplasia induced 
by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238, 188-193. 
Ostrand-Rosenberg,S. (2004). Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. 
Opin. Immunol. 16, 143-150. 
Overwijk,W.W., Theoret,M.R., Finkelstein,S.E., Surman,D.R., de Jong,L.A., Vyth-Dreese,F.A., Dellemijn,T.A., 
Antony,P.A., Spiess,P.J., Palmer,D.C., Heimann,D.M., Klebanoff,C.A., Yu,Z., Hwang,L.N., Feigenbaum,L., 
Kruisbeek,A.M., Rosenberg,S.A., and Restifo,N.P. (2003). Tumor regression and autoimmunity after reversal of 
a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580. 
Paglia,P., Chiodoni,C., Rodolfo,M., and Colombo,M.P. (1996). Murine dendritic cells loaded in vitro with 
soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322. 
Pardoll,D. (2003). Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839. 
Pardoll,D.M. and Topalian,S.L. (1998). The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. 
Immunol. 10, 588-594. 
PASTERNAK,G., GRAFFI,A., and HORN,K.H. (1964). [The demonstration of individual specific antigenicity in 
UV-induced mouse sarcoma]. Acta Biol. Med. Ger 13, 276-279. 
Pecher,G., Haring,A., Kaiser,L., and Thiel,E. (2002). Mucin gene (MUC1) transfected dendritic cells as vaccine: 
results of a phase I/II clinical trial. Cancer Immunol. Immunother. 51, 669-673. 
Perussia,B., Trinchieri,G., Jackson,A., Warner,N.L., Faust,J., Rumpold,H., Kraft,D., and Lanier,L.L. (1984). The 
Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with 
monoclonal antibodies. J. Immunol. 133, 180-189. 
Phan,G.Q., Yang,J.C., Sherry,R.M., Hwu,P., Topalian,S.L., Schwartzentruber,D.J., Restifo,N.P., Haworth,L.R., 
Seipp,C.A., Freezer,L.J., Morton,K.E., Mavroukakis,S.A., Duray,P.H., Steinberg,S.M., Allison,J.P., Davis,T.A., 
and Rosenberg,S.A. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated 
antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad Sci U. S. A 100, 8372-8377. 
Porgador,A., Mandelboim,O., Restifo,N.P., and Strominger,J.L. (1997). Natural killer cell lines kill autologous 
beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad Sci U. 
S. A 94, 13140-13145. 
Porgador,A., Tzehoval,E., Katz,A., Vadai,E., Revel,M., FELDMAN,M., and Eisenbach,L. (1992). Interleukin 6 
gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers 
immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686. 
REFERENCES  105 
 
 
Prehn,R.T. and MAIN,J.M. (1957). Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 
769-778. 
Qin,Z., Schwartzkopff,J., Pradera,F., Kammertoens,T., Seliger,B., Pircher,H., and Blankenstein,T. (2003). A 
critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 
63, 4095-4100. 
Quaife,C.J., Pinkert,C.A., Ornitz,D.M., Palmiter,R.D., and Brinster,R.L. (1987). Pancreatic neoplasia induced by 
ras expression in acinar cells of transgenic mice. Cell 48, 1023-1034. 
Raccurt,M., Lobie,P.E., Moudilou,E., Garcia-Caballero,T., Frappart,L., Morel,G., and Mertani,H.C. (2002). High 
stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. 
J. Endocrinol. 175, 307-318. 
Ramarathinam,L., Sarma,S., Maric,M., Zhao,M., Yang,G., Chen,L., and Liu,Y. (1995). Multiple lineages of 
tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155, 5323-5329. 
Ramshaw,I.A. and Ramsay,A.J. (2000). The prime-boost strategy: exciting prospects for improved vaccination. 
Immunol. Today 21, 163-165. 
Ravetch,J.V. and Perussia,B. (1989). Alternative membrane forms of Fc gamma RIII(CD16) on human natural 
killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide 
substitutions. J. Exp. Med. 170, 481-497. 
Reilly,R.T., Gottlieb,M.B., Ercolini,A.M., Machiels,J.P., Kane,C.E., Okoye,F.I., Muller,W.J., Dixon,K.H., and 
Jaffee,E.M. (2000). HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 
60, 3569-3576. 
Reilly,R.T., Machiels,J.P., Emens,L.A., Ercolini,A.M., Okoye,F.I., Lei,R.Y., Weintraub,D., and Jaffee,E.M. 
(2001). The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the 
complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61, 880-883. 
Restifo,N.P., Bacik,I., Irvine,K.R., Yewdell,J.W., McCabe,B.J., Anderson,R.W., Eisenlohr,L.C., Rosenberg,S.A., 
and Bennink,J.R. (1995). Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 
154, 4414-4422. 
Ridge,J.P., Fuchs,E.J., and Matzinger,P. (1996). Neonatal tolerance revisited: turning on newborn T cells with 
dendritic cells. Science 271, 1723-1726. 
Robbins,P.F., el Gamil,M., Kawakami,Y., Stevens,E., Yannelli,J.R., and Rosenberg,S.A. (1994). Recognition of 
tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54, 3124-
3126. 
Rosenberg,S.A. (1996). Development of cancer immunotherapies based on identification of the genes encoding 
cancer regression antigens. J. Natl. Cancer Inst. 88, 1635-1644. 
Rosenberg,S.A. (1999). A new era for cancer immunotherapy based on the genes that encode cancer antigens. 
Immunity. 10, 281-287. 
Rosenberg,S.A. (2004). Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350, 1461-1463. 
Rosenberg,S.A., Yang,J.C., Schwartzentruber,D.J., Hwu,P., Marincola,F.M., Topalian,S.L., Restifo,N.P., 
Dudley,M.E., Schwarz,S.L., Spiess,P.J., Wunderlich,J.R., Parkhurst,M.R., Kawakami,Y., Seipp,C.A., 
Einhorn,J.H., and White,D.E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for 
the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327. 
Rosenberg,S.A., Yannelli,J.R., Yang,J.C., Topalian,S.L., Schwartzentruber,D.J., Weber,J.S., Parkinson,D.R., 
Seipp,C.A., Einhorn,J.H., and White,D.E. (1994). Treatment of patients with metastatic melanoma with 
autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166. 
REFERENCES  106 
 
 
Rovero,S., Amici,A., Carlo,E.D., Bei,R., Nanni,P., Quaglino,E., Porcedda,P., Boggio,K., Smorlesi,A., 
Lollini,P.L., Landuzzi,L., Colombo,M.P., Giovarelli,M., Musiani,P., and Forni,G. (2000). DNA vaccination 
against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic 
BALB/c mice. J. Immunol. 165, 5133-5142. 
Rowse,G.J., Tempero,R.M., VanLith,M.L., Hollingsworth,M.A., and Gendler,S.J. (1998). Tolerance and 
immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58, 315-321. 
Rozenblum,E., Schutte,M., Goggins,M., Hahn,S.A., Panzer,S., Zahurak,M., Goodman,S.N., Sohn,T.A., 
Hruban,R.H., Yeo,C.J., and Kern,S.E. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 
57, 1731-1734. 
Sadanaga,N., Nagashima,H., Mashino,K., Tahara,K., Yamaguchi,H., Ohta,M., Fujie,T., Tanaka,F., Inoue,H., 
Takesako,K., Akiyoshi,T., and Mori,M. (2001). Dendritic cell vaccination with MAGE peptide is a novel 
therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7, 2277-2284. 
Sahin,U., Tureci,O., and Pfreundschuh,M. (1997). Serological identification of human tumor antigens. Current 
Opinion in Immunology 9, 709-716. 
Sakaguchi,S., Sakaguchi,N., Shimizu,J., Yamazaki,S., Sakihama,T., Itoh,M., Kuniyasu,Y., Nomura,T., Toda,M., 
and Takahashi,T. (2001). Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common 
role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32. 
Sakorafas,G.H., Tsiotou,A.G., and Tsiotos,G.G. (2000). Molecular biology of pancreatic cancer; oncogenes, 
tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat. Rev. 26, 
29-52. 
Salgia,R., Lynch,T., Skarin,A., Lucca,J., Lynch,C., Jung,K., Hodi,F.S., Jaklitsch,M., Mentzer,S., Swanson,S., 
Lukanich,J., Bueno,R., Wain,J., Mathisen,D., Wright,C., Fidias,P., Donahue,D., Clift,S., Hardy,S., Neuberg,D., 
Mulligan,R., Webb,I., Sugarbaker,D., Mihm,M., and Dranoff,G. (2003). Vaccination with irradiated autologous 
tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor 
immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630. 
Sandgren,E.P., Luetteke,N.C., Palmiter,R.D., Brinster,R.L., and Lee,D.C. (1990). Overexpression of TGF alpha 
in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 
61, 1121-1135. 
Sandgren,E.P., Quaife,C.J., Paulovich,A.G., Palmiter,R.D., and Brinster,R.L. (1991). Pancreatic tumor 
pathogenesis reflects the causative genetic lesion. Proc. Natl. Acad Sci U. S. A 88, 93-97. 
Sandler,A.D., Chihara,H., Kobayashi,G., Zhu,X., Miller,M.A., Scott,D.L., and Krieg,A.M. (2003). CpG 
oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-
stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 63, 394-399. 
Sato,H., Nakayama,T., Tanaka,Y., Yamashita,M., Shibata,Y., Kondo,E., Saito,Y., and Taniguchi,M. (1999). 
Induction of differentiation of pre-NKT cells to mature Valpha14 NKT cells by granulocyte/macrophage colony-
stimulating factor. Proc. Natl. Acad Sci U. S. A 96, 7439-7444. 
Schaed,S.G., Klimek,V.M., Panageas,K.S., Musselli,C.M., Butterworth,L., Hwu,W.J., Livingston,P.O., 
Williams,L., Lewis,J.J., Houghton,A.N., and Chapman,P.B. (2002). T-cell responses against tyrosinase 368-
376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's 
adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. 
Cancer Res. 8, 967-972. 
Schoenberger,S.P., Toes,R.E., van der Voort,E.I., Offringa,R., and Melief,C.J. (1998). T-cell help for cytotoxic T 
lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483. 
Schreiber,H., Wu,T.H., Nachman,J., and Kast,W.M. (2002). Immunodominance and tumor escape. Semin. 
Cancer Biol. 12, 25-31. 
REFERENCES  107 
 
 
Schreiner,B., Baur,D.M., Fingerle,A.A., Zechner,U., Greten,F.R., Adler,G., Sipos,B., Kloppel,G., Hameister,H., 
and Schmid,R.M. (2003a). Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- 
transgenic mice. Genes Chromosomes. Cancer 38, 240-248. 
Schreiner,B., Greten,F.R., Baur,D.M., Fingerle,A.A., Zechner,U., Bohm,C., Schmid,M., Hameister,H., and 
Schmid,R.M. (2003b). Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes 
with two independently amplified gene loci. Oncogene 22, 6802-6809. 
Schuler,G., Schuler-Thurner,B., and Steinman,R.M. (2003). The use of dendritic cells in cancer immunotherapy. 
Curr. Opin. Immunol. 15, 138-147. 
Schuler-Thurner,B., Schultz,E.S., Berger,T.G., Weinlich,G., Ebner,S., Woerl,P., Bender,A., Feuerstein,B., 
Fritsch,P.O., Romani,N., and Schuler,G. (2002). Rapid induction of tumor-specific type 1 T helper cells in 
metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived 
dendritic cells. J. Exp. Med. 195, 1279-1288. 
Schwartz,R.H. (1990). A cell culture model for T lymphocyte clonal anergy. Science 248, 1349-1356. 
Serrano,M., Lee,H., Chin,L., Cordon-Cardo,C., Beach,D., and DePinho,R.A. (1996). Role of the INK4a locus in 
tumor suppression and cell mortality. Cell 85, 27-37. 
Shankaran,V., Ikeda,H., Bruce,A.T., White,J.M., Swanson,P.E., Old,L.J., and Schreiber,R.D. (2001). IFNgamma 
and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-
1111. 
Sharif,S., Arreaza,G.A., Zucker,P., Mi,Q.S., Sondhi,J., Naidenko,O.V., Kronenberg,M., Koezuka,Y., 
Delovitch,T.L., Gombert,J.M., Leite-De-Moraes,M., Gouarin,C., Zhu,R., Hameg,A., Nakayama,T., 
Taniguchi,M., Lepault,F., Lehuen,A., Bach,J.F., and Herbelin,A. (2001). Activation of natural killer T cells by 
alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 
7, 1057-1062. 
Shevach,E.M. (2000). Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. 18, 423-449. 
Shimizu,J., Yamazaki,S., and Sakaguchi,S. (1999). Induction of tumor immunity by removing CD25+CD4+ T 
cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218. 
Shinkai,Y., Rathbun,G., Lam,K.P., Oltz,E.M., Stewart,V., Mendelsohn,M., Charron,J., Datta,M., Young,F., 
Stall,A.M., and . (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J 
rearrangement. Cell 68, 855-867. 
Simons,J.W., Mikhak,B., Chang,J.F., DeMarzo,A.M., Carducci,M.A., Lim,M., Weber,C.E., Baccala,A.A., 
Goemann,M.A., Clift,S.M., Ando,D.G., Levitsky,H.I., Cohen,L.K., Sanda,M.G., Mulligan,R.C., Partin,A.W., 
Carter,H.B., Piantadosi,S., Marshall,F.F., and Nelson,W.G. (1999). Induction of immunity to prostate cancer 
antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to 
secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-
5168. 
Sing,A.P., Ambinder,R.F., Hong,D.J., Jensen,M., Batten,W., Petersdorf,E., and Greenberg,P.D. (1997). Isolation 
of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for 
immune-mediated therapy of EBV+ Hodgkin's disease. Blood 89, 1978-1986. 
Singh,S., Ross,S.R., Acena,M., Rowley,D.A., and Schreiber,H. (1992). Stroma is critical for preventing or 
permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139-146. 
Smith,J.W., Walker,E.B., Fox,B.A., Haley,D., Wisner,K.P., Doran,T., Fisher,B., Justice,L., Wood,W., Vetto,J., 
Maecker,H., Dols,A., Meijer,S., Hu,H.M., Romero,P., Alvord,W.G., and Urba,W.J. (2003). Adjuvant 
immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific 
CD8+ T-cell responses. J. Clin. Oncol. 21, 1562-1573. 
Smyth,M.J., Crowe,N.Y., and Godfrey,D.I. (2001a). NK cells and NKT cells collaborate in host protection from 
methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463. 
REFERENCES  108 
 
 
Smyth,M.J., Crowe,N.Y., Hayakawa,Y., Takeda,K., Yagita,H., and Godfrey,D.I. (2002). NKT cells - conductors 
of tumor immunity? Curr. Opin. Immunol. 14, 165-171. 
Smyth,M.J., Godfrey,D.I., and Trapani,J.A. (2001b). A fresh look at tumor immunosurveillance and 
immunotherapy. Nat. Immunol. 2, 293-299. 
Smyth,M.J., Thia,K.Y., Street,S.E., Cretney,E., Trapani,J.A., Taniguchi,M., Kawano,T., Pelikan,S.B., 
Crowe,N.Y., and Godfrey,D.I. (2000). Differential tumor surveillance by natural killer (NK) and NKT cells. J. 
Exp. Med. 191, 661-668. 
Soares,M.M., Mehta,V., and Finn,O.J. (2001). Three different vaccines based on the 140-amino acid MUC1 
peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in 
wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-
6563. 
Sohn,T.A. and Yeo,C.J. (2000). The molecular genetics of pancreatic ductal carcinoma: a review. Surg. Oncol 9, 
95-101. 
Sondak,V.K., Liu,P.Y., Tuthill,R.J., Kempf,R.A., Unger,J.M., Sosman,J.A., Thompson,J.A., Weiss,G.R., 
Redman,B.G., Jakowatz,J.G., Noyes,R.D., and Flaherty,L.E. (2002). Adjuvant immunotherapy of resected, 
intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a 
randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20, 2058-2066. 
Song,W., Kong,H.L., Carpenter,H., Torii,H., Granstein,R., Rafii,S., Moore,M.A., and Crystal,R.G. (1997). 
Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce 
protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256. 
Sorkin,A. and Waters,C.M. (1993). Endocytosis of growth factor receptors. Bioessays 15, 375-382. 
Specht,J.M., Wang,G., Do,M.T., Lam,J.S., Royal,R.E., Reeves,M.E., Rosenberg,S.A., and Hwu,P. (1997). 
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established 
pulmonary metastases. J. Exp. Med. 186, 1213-1221. 
Speiser,D.E., Miranda,R., Zakarian,A., Bachmann,M.F., McKall-Faienza,K., Odermatt,B., Hanahan,D., 
Zinkernagel,R.M., and Ohashi,P.S. (1997). Self antigens expressed by solid tumors Do not efficiently stimulate 
naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645-653. 
Staib,L., Birebent,B., Somasundaram,R., Purev,E., Braumuller,H., Leeser,C., Kuttner,N., Li,W., Zhu,D., Diao,J., 
Wunner,W., Speicher,D., Beger,H.G., Song,H., and Herlyn,D. (2001). Immunogenicity of recombinant GA733-
2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int. J. Cancer 92, 
79-87. 
Staveley-O'Carroll,K., Sotomayor,E., Montgomery,J., Borrello,I., Hwang,L., Fein,S., Pardoll,D., and Levitsky,H. 
(1998). Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. 
Acad Sci U. S. A 95, 1178-1183. 
Stift,A., Friedl,J., Dubsky,P., Bachleitner-Hofmann,T., Schueller,G., Zontsich,T., Benkoe,T., Radelbauer,K., 
Brostjan,C., Jakesz,R., and Gnant,M. (2003). Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol 21, 
135-142. 
Stoneman,E.R., Bennett,M., An,J., Chesnut,K.A., Wakeland,E.K., Scheerer,J.B., Siciliano,M.J., Kumar,V., and 
Mathew,P.A. (1995). Cloning and characterization of 5E6(Ly-49C), a receptor molecule expressed on a subset of 
murine natural killer cells. J. Exp. Med. 182, 305-313. 
Strand,S., Hofmann,W.J., Hug,H., Muller,M., Otto,G., Strand,D., Mariani,S.M., Stremmel,W., Krammer,P.H., 
and Galle,P.R. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a 
mechanism of immune evasion? Nat. Med. 2, 1361-1366. 
Straus,S.E., Jaffe,E.S., Puck,J.M., Dale,J.K., Elkon,K.B., Rosen-Wolff,A., Peters,A.M., Sneller,M.C., 
Hallahan,C.W., Wang,J., Fischer,R.E., Jackson,C.M., Lin,A.Y., Baumler,C., Siegert,E., Marx,A., 
Vaishnaw,A.K., Grodzicky,T., Fleisher,T.A., and Lenardo,M.J. (2001). The development of lymphomas in 
REFERENCES  109 
 
 
families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte 
apoptosis. Blood 98, 194-200. 
Street,S.E., Cretney,E., and Smyth,M.J. (2001). Perforin and interferon-gamma activities independently control 
tumor initiation, growth, and metastasis. Blood 97, 192-197. 
Street,S.E., Trapani,J.A., MacGregor,D., and Smyth,M.J. (2002). Suppression of lymphoma and epithelial 
malignancies effected by interferon gamma. J. Exp. Med. 196, 129-134. 
Su,L.K., Kinzler,K.W., Vogelstein,B., Preisinger,A.C., Moser,A.R., Luongo,C., Gould,K.A., and Dove,W.F. 
(1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 
668-670. 
Su,Z., Dannull,J., Heiser,A., Yancey,D., Pruitt,S., Madden,J., Coleman,D., Niedzwiecki,D., Gilboa,E., and 
Vieweg,J. (2003). Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor 
RNA-transfected dendritic cells. Cancer Res. 63, 2127-2133. 
Swain,S.L., Bradley,L.M., Croft,M., Tonkonogy,S., Atkins,G., Weinberg,A.D., Duncan,D.D., Hedrick,S.M., 
Dutton,R.W., and Huston,G. (1991). Helper T-cell subsets: phenotype, function and the role of lymphokines in 
regulating their development. Immunol. Rev. 123, 115-144. 
Tada,T., Ohzeki,S., Utsumi,K., Takiuchi,H., Muramatsu,M., Li,X.F., Shimizu,J., Fujiwara,H., and Hamaoka,T. 
(1991). Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells 
of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. 
Immunol. 146, 1077-1082. 
Takeda,K., Hayakawa,Y., Smyth,M.J., Kayagaki,N., Yamaguchi,N., Kakuta,S., Iwakura,Y., Yagita,H., and 
Okumura,K. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of 
tumor metastasis by liver natural killer cells. Nat. Med. 7, 94-100. 
Takeda,K., Smyth,M.J., Cretney,E., Hayakawa,Y., Kayagaki,N., Yagita,H., and Okumura,K. (2002). Critical role 
for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. 
Exp. Med. 195, 161-169. 
Tamura,Y., Peng,P., Liu,K., Daou,M., and Srivastava,P.K. (1997). Immunotherapy of tumors with autologous 
tumor-derived heat shock protein preparations. Science 278, 117-120. 
Tang,D.C., DeVit,M., and Johnston,S.A. (1992). Genetic immunization is a simple method for eliciting an 
immune response. Nature 356, 152-154. 
Tevethia,M.J., Bonneau,R.H., Griffith,J.W., and Mylin,L. (1997). A simian virus 40 large T-antigen segment 
containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces 
pancreatic acinar carcinomas in transgenic mice. J. Virol. 71, 8157-8166. 
Theobald,M., Biggs,J., Dittmer,D., Levine,A.J., and Sherman,L.A. (1995). Targeting p53 as a general tumor 
antigen. Proc. Natl. Acad. Sci. USA 92, 11993-97. 
Thomas,A.M., Santarsiero,L.M., Lutz,E.R., Armstrong,T.D., Chen,Y.C., Huang,L.Q., Laheru,D.A., Goggins,M., 
Hruban,R.H., and Jaffee,E.M. (2004). Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo 
Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. J. Exp. Med. 200, 297-306. 
Thomas,L. (1959). Discussion of Cellular and Humoral Aspects of the Hypersensitive states. H.S.Lawrence, ed. 
(New York: Hoeber-Harper). 
Thompson,J.A., Eades-Perner,A.M., Ditter,M., Muller,W.J., and Zimmermann,W. (1997). Expression of 
transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor 
immunotherapy. Int. J. Cancer 72, 197-202. 
Timmerman,J.M., Singh,G., Hermanson,G., Hobart,P., Czerwinski,D.K., Taidi,B., Rajapaksa,R., Caspar,C.B., 
Van Beckhoven,A., and Levy,R. (2002). Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype 
in patients with B-cell lymphoma. Cancer Res. 62, 5845-5852. 
REFERENCES  110 
 
 
Toes,R.E., Blom,R.J., Offringa,R., Kast,W.M., and Melief,C.J. (1996). Enhanced tumor outgrowth after peptide 
vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to 
reject tumors. J. Immunol. 156, 3911-3918. 
Toes,R.E., Ossendorp,F., Offringa,R., and Melief,C.J. (1999). CD4 T cells and their role in antitumor immune 
responses. J. Exp. Med. 189, 753-756. 
Topalian,S.L., Gonzales,M.I., Parkhurst,M., Li,Y.F., Southwood,S., Sette,A., Rosenberg,S.A., and Robbins,P.F. 
(1996). Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. 
Med. 183, 1965-1971. 
Topalian,S.L., Rivoltini,L., Mancini,M., Markus,N.R., Robbins,P.F., Kawakami,Y., and Rosenberg,S.A. (1994). 
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase 
gene. Proc. Natl. Acad Sci U. S. A 91, 9461-9465. 
Townsend,S.E. and Allison,J.P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-
transfected melanoma cells. Science 259, 368-370. 
Ulmer,J.B., Donnelly,J.J., Parker,S.E., Rhodes,G.H., Felgner,P.L., Dwarki,V.J., Gromkowski,S.H., Deck,R.R., 
DeWitt,C.M., Friedman,A., and . (1993). Heterologous protection against influenza by injection of DNA 
encoding a viral protein. Science 259, 1745-1749. 
Uphoff,C.C., Meyer,C., and Drexler,H.G. (2002). Elimination of mycoplasma from leukemia-lymphoma cell 
lines using antibiotics. Leukemia 16, 284-288. 
Urban,J.L., Burton,R.C., Holland,J.M., Kripke,M.L., and Schreiber,H. (1982). Mechanisms of syngeneic tumor 
rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 
155, 557-573. 
Uyttenhove,C., Maryanski,J., and Boon,T. (1983). Escape of mouse mastocytoma P815 after nearly complete 
rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052. 
van der Bruggen,P., Traversari,C., Chomez,P., Lurquin,C., De Plaen,E., Van den,E.B., Knuth,A., and Boon,T. 
(1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 
1643-1647. 
van der Bruggen,P., Zhang,Y., Chaux,P., Stroobant,V., Panichelli,C., Schultz,E.S., Chapiro,J., Van den 
Eynde,B.J., Brasseur,F., and Boon,T. (2002). Tumor-specific shared antigenic peptides recognized by human T 
cells. Immunol. Rev. 188, 51-64. 
Van Dyke,T. and Jacks,T. (2002). Cancer modeling in the modern era: progress and challenges. Cell 108, 135-
144. 
van Ojik,H., Kruit,W., Portielje,J., Brichard,V., Verloes,R., Delire,M., and Stoter,G. (2002). Phase I/II study with 
CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Ann 
Oncol 13, 157-162. 
Vivier,E., Tomasello,E., and Paul,P. (2002). Lymphocyte activation via NKG2D: towards a new paradigm in 
immune recognition? Curr. Opin. Immunol. 14, 306-311. 
Wagner,M., Greten,F.R., Weber,C.K., Koschnick,S., Mattfeldt,T., Deppert,W., Kern,H., Adler,G., and 
Schmid,R.M. (2001). A murine tumor progression model for pancreatic cancer recapitulating the genetic 
alterations of the human disease. Genes Dev. 15, 286-293. 
Wagner,M., Luhrs,H., Kloppel,G., Adler,G., and Schmid,R.M. (1998). Malignant transformation of duct-like 
cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 115, 1254-1262. 
Walker,P.R., Saas,P., and Dietrich,P.Y. (1998). Tumor expression of Fas ligand (CD95L) and the consequences. 
Curr. Opin. Immunol. 10, 564-572. 
REFERENCES  111 
 
 
Wang,R.F. (2001). The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. 
Trends Immunol. 22, 269-276. 
Wang,Z., Cao,Y., Albino,A.P., Zeff,R.A., Houghton,A., and Ferrone,S. (1993). Lack of HLA class I antigen 
expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger 
RNA. J. Clin. Invest 91, 684-692. 
Ward,P.L., Koeppen,H.K., Hurteau,T., Rowley,D.A., and Schreiber,H. (1990). Major histocompatibility complex 
class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. 
Cancer Res. 50, 3851-3858. 
Warshaw,A.L. and Fernandez-del Castillo,C. (1992). Pancreatic carcinoma. N. Engl. J. Med. 326, 455-465. 
Weiner,G.J., Liu,H.M., Wooldridge,J.E., Dahle,C.E., and Krieg,A.M. (1997). Immunostimulatory 
oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen 
immunization. Proc. Natl. Acad Sci U. S. A 94, 10833-10837. 
Wen,R., Wang,D., McKay,C., Bunting,K.D., Marine,J.C., Vanin,E.F., Zambetti,G.P., Korsmeyer,S.J., Ihle,J.N., 
and Cleveland,J.L. (2001). Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. 
Mol. Cell Biol. 21, 678-689. 
Whiteside,T.L. and Herberman,R.B. (1995). The role of natural killer cells in immune surveillance of cancer. 
Curr. Opin. Immunol. 7, 704-710. 
Wilentz,R.E., Geradts,J., Maynard,R., Offerhaus,G.J., Kang,M., Goggins,M., Yeo,C.J., Kern,S.E., and 
Hruban,R.H. (1998). Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of 
intranuclear expression. Cancer Res. 58, 4740-4744. 
Wilentz,R.E., Iacobuzio-Donahue,C.A., Argani,P., McCarthy,D.M., Parsons,J.L., Yeo,C.J., Kern,S.E., and 
Hruban,R.H. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 
inactivation occurs late in neoplastic progression. Cancer Res. 60, 2002-2006. 
Wilkinson,R.W., Ross,E.L., Poulsom,R., Ilyas,M., Straub,J., Snary,D., Bodmer,W.F., and Mather,S.J. (2001). 
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors. Proc. Natl. Acad Sci 
U. S. A 98, 10256-10260. 
Wirth,M., Berthold,E., Grashoff,M., Pfutzner,H., Schubert,U., and Hauser,H. (1994). Detection of mycoplasma 
contaminations by the polymerase chain reaction. Cytotechnology 16, 67-77. 
Wolfel,T., Hauer,M., Schneider,J., Serrano,M., Wolfel,C., Klehmann-Hieb,E., De Plaen,E., Hankeln,T., Meyer 
zum Buschenfelde,K.H., and Beach,D. (1995). A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T 
lymphocytes in a human melanoma. Science 269, 1281-1284. 
Wolfel,T., Van Pel,A., Brichard,V., Schneider,J., Seliger,B., Meyer zum Buschenfelde,K.H., and Boon,T. (1994). 
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. 
Immunol. 24, 759-764. 
Wolpoe,M.E., Lutz,E.R., Ercolini,A.M., Murata,S., Ivie,S.E., Garrett,E.S., Emens,L.A., Jaffee,E.M., and 
Reilly,R.T. (2003). HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte 
macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function 
and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171, 2161-2169. 
Wong,S.T., Winchell,L.F., McCune,B.K., Earp,H.S., Teixido,J., Massague,J., Herman,B., and Lee,D.C. (1989). 
The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to 
signal transduction. Cell 56, 495-506. 
Woo,E.Y., Chu,C.S., Goletz,T.J., Schlienger,K., Yeh,H., Coukos,G., Rubin,S.C., Kaiser,L.R., and June,C.H. 
(2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer 
and late-stage ovarian cancer. Cancer Res. 61, 4766-4772. 
REFERENCES  112 
 
 
Woo,E.Y., Yeh,H., Chu,C.S., Schlienger,K., Carroll,R.G., Riley,J.L., Kaiser,L.R., and June,C.H. (2002). Cutting 
edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 
168, 4272-4276. 
Wu,T.C. (1994). Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6, 746-
754. 
Xia,J., Tanaka,Y., Koido,S., Liu,C., Mukherjee,P., Gendler,S.J., and Gong,J. (2003). Prevention of spontaneous 
breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J. Immunol. 170, 1980-1986. 
Xiang,R., Primus,F.J., Ruehlmann,J.M., Niethammer,A.G., Silletti,S., Lode,H.N., Dolman,C.S., Gillies,S.D., and 
Reisfeld,R.A. (2001). A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer 
induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. 
J. Immunol. 167, 4560-4565. 
Yee,C., Thompson,J.A., Byrd,D., Riddell,S.R., Roche,P., Celis,E., and Greenberg,P.D. (2002). Adoptive T cell 
therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo 
persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad Sci U. S. A 99, 16168-16173. 
Yeo,C.J., Cameron,J.L., Lillemoe,K.D., Sitzmann,J.V., Hruban,R.H., Goodman,S.N., Dooley,W.C., Coleman,J., 
and Pitt,H.A. (1995). Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 
221, 721-731. 
Yonish-Rouach,E., Resnitzky,D., Lotem,J., Sachs,L., Kimchi,A., and Oren,M. (1991). Wild-type p53 induces 
apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347. 
Zarour,H.M., Kirkwood,J.M., Kierstead,L.S., Herr,W., Brusic,V., Slingluff,C.L., Jr., Sidney,J., Sette,A., and 
Storkus,W.J. (2000a). Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope 
recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad Sci U. S. A 97, 400-405. 
Zarour,H.M., Maillere,B., Brusic,V., Coval,K., Williams,E., Pouvelle-Moratille,S., Castelli,F., Land,S., 
Bennouna,J., Logan,T., and Kirkwood,J.M. (2002). NY-ESO-1 119-143 is a promiscuous major 
histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T 
cells. Cancer Res. 62, 213-218. 
Zarour,H.M., Storkus,W.J., Brusic,V., Williams,E., and Kirkwood,J.M. (2000b). NY-ESO-1 encodes 
DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 60, 4946-4952. 
Zeng,G., Touloukian,C.E., Wang,X., Restifo,N.P., Rosenberg,S.A., and Wang,R.F. (2000). Identification of 
CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165, 1153-1159. 
Zeng,G., Wang,X., Robbins,P.F., Rosenberg,S.A., and Wang,R.F. (2001). CD4(+) T cell recognition of MHC 
class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-
1 antibody production. Proc. Natl. Acad Sci U. S. A 98, 3964-3969. 
Zeytin,H.E., Patel,A.C., Rogers,C.J., Canter,D., Hursting,S.D., Schlom,J., and Greiner,J.W. (2004). Combination 
of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-
term survival in CEA.Tg/MIN mice. Cancer Res. 64, 3668-3678. 
Zhou,H., Luo,Y., Mizutani,M., Mizutani,N., Becker,J.C., Primus,F.J., Xiang,R., and Reisfeld,R.A. (2004). A 
novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene 
vaccines. J. Clin. Invest 113, 1792-1798. 
Zhu,M.Z., Marshall,J., Cole,D., Schlom,J., and Tsang,K.Y. (2000). Specific cytolytic T-cell responses to human 
CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6, 24-33. 
Zitvogel,L., Mayordomo,J.I., Tjandrawan,T., DeLeo,A.B., Clarke,M.R., Lotze,M.T., and Storkus,W.J. (1996). 
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, 
and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97. 
 
 
ABBREVIATIONS 
 
 
ADCC    Antibody-dependent cell mediated cytotoxicity 
AICD    Activation-induced cell death 
APC    Antigen presenting cell 
Apc    Adenomatous polyposis coli 
bp    Base pairs 
CBA    Cytometric bead array 
CD    Cluster of differentiation  
CEA    Carcinoembryonic antigen  
CK    Cytokeratin 
CpG    Cytosine-phosphorothioate-guanine 
cpm    counts per minute 
CTL    Cytotoxic T lymphocyte  
DC    Dendritic cell 
EGF    Epidermal growth factor 
EGFR    Epidermal growth factor receptor 
EL    Elastase 
ELISA    Enzyme linked immunosorbent assay 
FACS    Fluorescence activated cell sorter 
GM-CSF                                Granulocyte-macrophage-colony stimulating factor 
GFP    Green fluorescent protein 
HER    Human epidermal growth factor receptor 
hGH    Human growth hormone 
HLA    Human leukocyte antigen 
HSP    Heat-shock protein  
IFN    Interferon 
Ig    Immunoglobulin 
IL     Interleukin 
i.p.    intraperitoneal 
ivp    in vivo passaged 
MCA    methylencholanthrene 
MHC    Major histocompatibility complex 
MMTV   Mouse mammary tumor virus 
mPAC    Murine pancreatic adenocarcinoma cell line  
MUC    Mucin 
NK    Natural killer 
OD    Optical density 
ODN    Oligodeoxynucleotides 
o.n.    Over night 
PanINs   Pancreatic intraepithelial neoplasia 
PCR    Polymerase chain reaction 
RAG    Recombinase activating gene 
RIP    Rat insulin promoter 
RT    Reverse transcription 
RT-PCR   Reverse transcription dependent polymerase chain reaction 
s.c.    subcutaneous 
SCID    Severe combined immunodeficiency 
TGF    Transforming growth factor 
TH    T helper  
TILs    Tumor infiltrating lymphocytes 
Tg    Trangene, transgenic 
TNF    Tumor necrosis factor 
Trp    Transformation related protein 
wt    wildtype 
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